

19 - Chapter 14

Prescribing psychotropics

- [01 - Working towards adherence](#)
- [02 - What is adherence](#)
- [03 - How common is non adherence](#)
- [04 - Impact of non adherence](#)
- [05 - Factors affecting adherence7,28](#)
- [06 - Assessing adherence29,30](#)
- [07 - Monitoring adherence and assessing attitudes](#)
- [08 - Enhancing medication adherence](#)
- [09 - Conclusion](#)
- [10 - References](#)
- [11 - Restarting psychotropic medications after a p](#)
- [12 - References](#)
- [13 - Relational aspects of prescribing practice](#)
- [14 - Object relations](#)
- [15 - Memory](#)
- [16 - Treatment framework](#)
- [17 - Factors that may influence the patients use o](#)
- [18 - Summary a checklist when prescribing](#)
- [19 - References](#)

- [20 - Prescribing drugs outside their licensed indi](#)
- [21 - Examples of acceptable use of drugs outside t](#)
- [22 - References](#)
- [23 - The Mental Health Act in England and Wales](#)
- [24 - Completion of forms T2 and T3](#)
- [25 - Arranging and preparing for SOAD visits](#)
- [26 - Statutory consultees](#)
- [27 - What is consent](#)
- [28 - What is capacity](#)
- [29 - Section 62 urgent treatment](#)
- [30 - Section 132 duty of managers of hospitals to](#)
- [31 - Electroconvulsive therapy \(ECT\)](#)
- [32 - Community patients](#)
- [33 - Reference](#)
- [34 - Site of administration of intramuscular injec](#)
- [35 - References](#)

01 - Working towards adherence

Working towards adherence

02 - What is adherence

What is adherence?

03 - How common is non adherence

How common is non-adherence?

The Maudsley® Prescribing Guidelines in Psychiatry, Fifteenth Edition. David M. Taylor, Thomas R. E. Barnes and Allan H. Young. © 2025 David M. Taylor. Published 2025 by John Wiley & Sons Ltd. Chapter 14 Working towards adherence What is adherence? The first clear statement about adherence comes from Hippocrates (460–377 bc), who vividly described non-adherence and linked it with poor outcomes. The World Health Organization (WHO) has described adherence as ‘the extent to which a person’s behaviour – taking medication, following a diet, and/or executing lifestyle changes – corresponds with agreed recommendations from a healthcare provider’.¹ In the UK, the National Institute for Health and Care Excellence (NICE) has, more succinctly, defined adherence as ‘the extent to which the patient’s action matches the agreed recommendations’.² The more traditional notion of the patient ‘complying’ with the doctor’s orders seems patronising and to deny the agency of the patient.³ ‘Concordance’ is another term that has been used, which seems to refer to an agreement between the patient and the doctor. This is part of the notion of informed consent and is essential for a ‘prescribing partnership’ with patients.⁴ But, as we know, agreement about a course of action does not necessarily guarantee that the action will happen. Thus ‘adherence’ will be used in this section to refer to the development of behaviours that will, it is hoped, result in better outcomes for our patients. How common is non-adherence? Large numbers of people, in most areas of medicine, do not seem to take their tablets very regularly – and so can be said to be partly or fully non-adherent. This is a phenomenon that arises in other clinical areas as well, such as psychological therapies. For people referred to psychotherapy services in the north of England, 34% did not attend for their first assessment session and, of those who did, only 57% subsequently attended the first treatment session.⁵ Prescribing psychotropics

04 - Impact of non adherence

Impact of non-adherence

928 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 14 For chronic physical and mental disorders, the picture is not much better. Although 76% of patients with several conditions reported adhering to medication, electronic monitoring suggested that, in fact, only 44% did so.⁶ Consistent with previous findings, a 2020 meta-analysis suggested that, overall, about 50% of people with mental health problems do not take their medication as prescribed.⁷ This, however, may be an oversimplification. It is probable that a small proportion of patients are fully adherent, the majority are partially adherent to varying degrees, and a few never take any medication at all (of their own volition).⁸ These findings are not only characteristic of western medical culture, they are reflected in other parts of the world.⁹ Adherence rates also vary both over time and across settings. For example, 10 days after discharge from hospital, up to 25% of patients with schizophrenia are partially or completely non-adherent with oral treatment and this figure rises to 50% at 1 year and to 75% by 2 years.¹⁰ Other studies have reported 25.8% complete discontinuation of medication within 1 year of discharge from hospital.¹¹ In some mental healthcare settings, the rate of non-adherence may be as high as 90%.¹² Diagnosis may also be significant. An Austrian study found that significantly more patients with schizophrenia (66%) did not take their medication as prescribed, compared with patients with affective disorders (47%) or those with other psychiatric diagnoses (41%).¹³ A major issue is that poor adherence almost always occurs without the knowledge of the prescriber. In one study, prescribers identified only half of those who were non-adherent.¹⁴ In another, 35% of patients referred for treatment of (apparently) refractory schizophrenia had sub-therapeutic plasma concentrations and many of them had plasma levels of zero.¹⁵ Impact of non-adherence Medicines are only effective if taken at a therapeutic dose. And they are effective. A 20-year follow-up study of 62 250 patients with schizophrenia reported a significantly lower suicide mortality during antipsychotic use compared with non-use.¹⁶ Antipsychotic use also decreased overall mortality. Poor adherence to medication is a major risk factor for worse outcomes including relapse in people with schizophrenia,¹⁷⁻¹⁹ bipolar disorder²⁰ and depression.²¹ Wider health benefits are also lost. Depressed patients who do not take an antidepressant have a 20% increased risk of an incident myocardial infarction compared with those who do.²² The serious consequences of non-adherence with medication may be mitigated by implementing routine monitoring. Data were collected as part of the National Confidential Inquiry into Suicide and Homicide by People with Mental Illness.²³ This revealed that healthcare providers who had a policy regarding how to manage patients who are not taking their medication as prescribed had 20% fewer suicides than providers who did not have such a policy.²³

Another reason that poorly adherent individuals do worse is that they may stop their medication abruptly and without monitoring (and without telling anyone). Abrupt cessation of almost all psychotropic drugs tends to worsen prognosis (see The Maudsley Deprescribing Guidelines). One of the findings that clearly illustrate the benefits of adherence is the example of depot antipsychotic medications. They do not differ pharmacologically from their oral equivalents but have consistently been shown to result in lower rates of readmission to

05 - Factors affecting
adherence7,28

Factors affecting
adherence7,28

06 - Assessing adherence^{29,30}

Assessing adherence^{29,30}

Prescribing psychotropics CHAPTER 14 hospital. The only difference is that with the depot preparations, adherence is, for a while at least, assured (and known about) – something which cannot be said for oral medications. Improving adherence offers substantial possibilities for improving the outcomes from treatments. WHO comments that ‘increasing the effectiveness of adherence interventions may have far greater impact on the health of the population than any improvements in specific medical treatments’.¹ We must also remember that medication is not the only effective treatment for psychosis. Although a meta-analysis²⁴ and systematic review²⁵ of such psychodynamic interventions (which included studies in unmedicated patients) confirmed the superiority of treatment with antipsychotics, the most recent systematic review of psychosocial interventions for psychotic patients (with no or low-dose antipsychotics) found the effect of such interventions to be equal to treatment with antipsychotics.²⁶ Cognitive behavioural therapy (CBT) for psychosis has been demonstrated to reduce certain symptoms, although its effect on quality of life does not seem to be significant.²⁷ So – we certainly need better drugs, but we need also to improve adherence. Factors affecting adherence^{7,28} Table 14.1 lists many of the factors that might affect adherence. Clearly, not all of these factors necessarily fit into a single category. For example, poor understanding by the patient can either be due to poor health literacy and/or numeracy or can be due to deficiencies in communication by the doctor. Assessing adherence^{29,30} Table 14.2 outlines methods of assessing medication adherence. For some antipsychotics such as clozapine, olanzapine, aripiprazole and risperidone, blood tests can be used to directly assess plasma levels. However, the plasma levels of these drugs attained with a fixed dose do vary, as do the therapeutic effects in individuals. It is therefore not possible to accurately determine partial non-adherence. That is to say, total non-adherence will be readily revealed (plasma level = zero) but partial and full adherence may be difficult to tell apart. Table 14.1 Factors affecting adherence. Illness-related Treatment-related Clinician-related Patient-related Environmental Lack of motivation Poor insight Grandiose delusions Cognitive deficit Thought disorder Forgetfulness Disorganisation Adverse effects Dysfunctional beliefs Inappropriate medication preparation or packaging Dosing schedules^{31,32} Poor therapeutic alliance Lack of follow-up Limited consultation time Poor provision of information and explanation Denial Poor insight Comorbidities Physical impairments Poor literacy Poor health literacy³³ Poor understanding of treatment options Disorganised environment Family’s beliefs Religious beliefs Health beliefs

930 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 14 Table 14.2 Assessing adherence.

Method	Variables measured	Advantages	Disadvantages
Direct Blood test	Drug/metabolite plasma levels	Accurate	Invasive Costly Inter-individual variations (e.g. fast and slow metabolisers) Not reliable for all drugs (see text) Only a result of zero can be definitively interpreted Information only relevant for a very limited timeframe No information about the patterns of medication-taking behaviour, levels of adherence or factors that may change adherence
Indirect Pill count	Number of missing tablets/ missed prescriptions	Simple to use (useful in clinical trials)	Labour-intensive in clinical practice Substantial evidence that pill counts underestimate levels of non-adherence
Electronic database: clinical/pharmacy records	History of non-adherence (but generally with very little detail or formal assessment)	Pharmacy dispensing and collection records (e.g. medication possession ratio – MPR)	Readily accessible Easy to identify non-adherent patients Inexpensive Non-invasive Not reliable – only provides evidence for collection and possession of medication
Self-report	Validated assessment scales (questionnaires) (e.g. Medication Adherence Rating Scale – MARS)	Easy to use Inexpensive	Subject to reporting bias Tendency to please clinicians Massively overestimates adherence
Subjective	Electronic monitoring devices (e.g. Medication Event Monitoring System – MEMS)	Number of times medication container has been opened and (assumed) percentage of doses removed	Among the most accurate methods
Objective	Provides additional information on medication-taking behaviour	Expensive Bulky containers	Not evidence for ingestion of medication – only of container opening Patient feels under surveillance

07 - Monitoring adherence and assessing attitudes

Monitoring adherence
and assessing attitudes
to medication

08 - Enhancing medication adherence

Enhancing medication adherence

Prescribing psychotropics CHAPTER 14 Monitoring adherence and assessing attitudes to medication Psychiatrists generally prefer to use direct questioning over the use of more intrusive/ objective and elaborate methods of assessing adherence. Partly as a result non-adherence may go undetected.³⁴ NICE recommends that the patient should be asked in a non- judgemental way if they have missed any doses over a specific time period such as the previous week.³⁵ Issues of forgetfulness aside, whether the patient takes medication or not will be, to a significant extent, determined by their views about medication and its perceived effect on their life and condition. Rating scales and checklists can help the clinician to guide and structure a discussion of what the patient thinks and feels about medication. The most widely used is the Drug Attitude Inventory (DAI),³⁶ which consists of a mix of positive and negative statements about medication; 30 statements in its full form and 10 in its short form. The patient completes it by simply agreeing or disagreeing with each statement. The total score is an indicator of the patient's overall perception of the balance between the benefits and harms associated with taking medication, and therefore likely adherence. Attitudes to medication as measured in this way have been shown to be a useful predictor of adherence over time.³⁷ Other checklists include the Rating of Medication Influences (ROMI) scale,³⁸ the Beliefs about Medicines Questionnaire³⁹ and the Medication Adherence Rating Scale (MARS).¹⁹ Enhancing medication adherence Adherence to medication requires collaboration between the patient and the prescriber. NICE recommends that, as long as the patient has capacity to consent, their right not to take medication should be respected. If the prescriber considers that this decision may lead to harm, the reasons for the patient's decision and the prescriber's concerns should be recorded. Adherence is a complex behaviour that is influenced by malleable underlying factors. Consequently, determinants of non-adherence can be modified through patient-specific and factor-focused interventions (Table 14.3). However, most adherence-enhancing interventions are not based on a sound theoretical framework and lack methodological rigour.⁴⁰ Low-quality studies and their outcomes are often not duplicated in different settings. This phenomenon was also highlighted by the most recent Cochrane review of adherence interventions when they reported that only 11 studies out of 182 included papers had the lowest risk of bias.⁴¹ Strategies for improving adherence Systematic reviews suggest that patient-specific interventions are more likely to enhance adherence in patients with serious mental disorders.⁴² NICE has reviewed the

evidence for adherence over a range of health conditions and concluded that no specific intervention can be recommended for all patients. Note that few studies in this area specifically recruited non-adherent patients (the refusal rate in such patients is likely to be high) and the specific barriers to adherence are rarely identified. The small effect size seen in many studies may simply be a consequence of this unfocused approach. An intervention mapping framework⁴³ provides a way to connect determinants of non-adherence to evidence-based interventions.

932 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 14 Medication-taking aids

'Compliance aids' are boxes that contain compartments that can accommodate up to four doses of multiple medicines each day. These may be helpful in patients who are clearly motivated to take medication but who are disorganised or who have cognitive deficits. But only 10% of non-adherent patients say that they simply forgot to take medication, so medication-taking aids are not a substitute for lack of insight or lack of motivation. Moreover, some medicines are unstable when removed from blister packaging and placed in a compliance aid. These include oro-dispersible formulations which are often prescribed for non-adherent patients. In addition, medication-taking aids are labour-intensive (expensive) to fill, it can be difficult to change prescriptions at short notice and the process of filling of these devices is particularly error-prone.⁴⁶ More sophisticated programmes of practical support, both electronic and in-person, have been shown to be effective.⁴⁷ Depot/long-acting antipsychotics

Meta-analyses of clinical trials have shown that the relative and absolute risks of relapse with depot maintenance treatment were 30% and 10% lower, respectively, than with oral treatment.^{48,49} NICE recommends that depots are an option in patients who are known to be non-adherent to oral treatment and/or those who prefer this method of administration. However, it is worth remembering that switching a non-adherent patient from oral antipsychotics to a long-acting injectable formulation does not address the underlying reasons driving that non-adherence. This has been highlighted by a recent systematic review that reported a rate of discontinuation of above 50% in those who had been prescribed second-generation depots.⁵⁰ So long-acting antipsychotics do not stop non-adherence but they do prevent sudden cessation of medication and its consequences (all depots provide a slow decline in plasma levels).

Table 14.3 Interventions for non-adherence.⁴⁴

Intentional non-adherence	Unintentional non-adherence
Psychoeducation is the foundation for all adherence interventions, but without behaviour-changing components it is not overwhelmingly effective. Provides both verbal and written information. Motivational interviewing for goal-setting Adherence therapy for exploring dysfunctional beliefs about medication or the illness, providing information and goal setting. It requires more time and multiple sessions. Cognitive behavioural therapy to eradicate or control the residual symptoms that prevent adherence. To address dysfunctional beliefs about treatment. Cognitive remediation to help with cognitive deficit in psychotic patients and thought disorder Mindfulness to help with symptoms Monitor adverse effects regularly and periodically Therapeutic alliance - a non-judgemental clinician allows patients to honestly disclose their thoughts and beliefs about medication Family intervention - psychoeducation and family therapy Simplify dose regimen - reduce number of medications and/or frequency of administration Dispensing interventions - medication-taking aids EAM (electronic adherence monitoring) - evidence for this is weak ⁴⁵ Pairing-up medication - taking with a daily activity (e.g. having breakfast, brushing teeth or before bedtime) Use technology - messaging service, email and telephone reminders Pharmacy interventions for those with physical impairment (e.g. opening bottles)	

Prescribing psychotropics CHAPTER 14 Their use can also provide certainty about the level of adherence (the injection is either given or it is not). Depots are probably underused, for example a US study found that depot preparations were prescribed for fewer than one in five patients with a recent episode of non-adherence.⁵¹ An alternative to depots is the use of long-acting oral antipsychotics such as penfluridol, which can be given weekly.⁵² Supervised administration obviates the need for injections but does not provide the same level of certainty over compliance given the facility that patients have demonstrated for disguising the taking of oral medication. In the USA, Abilify MyCite is approved for use.⁵³ This is a version of aripiprazole with a transmitting sensor embedded in the formulation which is able to confirm that a tablet has been taken. Evidence for its effectiveness is slim.⁵⁴

Financial incentives Controlled trials in a number of disease areas support the offer of financial incentives to enhance medication adherence. Paying people to take their medication is extremely controversial, though some clinicians have found this strategy to be effective. The effect could not be maintained in a randomised controlled trial (RCT) at 6- and 24-month follow-up after payments were stopped, and complete adherence was achieved in only 28% of patients receiving the incentives.⁵⁵ Other RCTs also have demonstrated a significant increase in adherence during the trial and a decline at follow-up when payments had stopped.⁵⁶ Offering financial incentives did not reduce patients' motivation for treatment.⁵⁷ A systematic review of acceptability of financial incentives for health-related behaviours has raised concerns about the validity and reliability of these interventions given their methodological limitations.⁵⁸

Psychological interventions In physical medicine, medication adherence has been found to be associated with health beliefs and psychological variables, such as self-efficacy and locus of control.⁵⁹ Family support is also positively related to medication adherence. It is likely to be the same in psychiatry – but what can be done? One such intervention – called, at the time, 'compliance therapy' – was evaluated at the Maudsley Hospital.⁶⁰ This was a pilot of a mixed intervention, consisting of active listening, cognitive behavioural techniques, motivational interviewing and the provision of information and explanation. This showed promising results in terms of increased adherence and reduced admission rates over the next 6 months. However, training for staff and supervision render it time-consuming. A subsequent replication did not show the same improvements,⁶¹ but also did not appear to have incorporated a training or supervisory element for those delivering the therapy. However, a trial of training in compliance therapy did seem to have an effect on the junior doctors involved, who felt that they were more aware of the drivers of non-adherence and of the importance of empathic listening and more able to understand why a patient might not take medication.⁶² One prerequisite for successful adherence to a treatment regimen should be that the patient understands the objectives of treatment, the options on offer and the rationale behind them. However, many – perhaps most – doctors have had no specific training in how to convey information and understanding to patients. Difficulties have been noted

09 - Conclusion

Conclusion

10 - References

References

934 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 14 to arise in cancer medicine regarding the benefits and risks of anti-cancer medications.⁶³ One must assume that we are likely to meet the same difficulties in psychiatry. We also need to consider that our patients may have a very different explanatory model for what is happening to them. For example, not so long ago, only just over a third of white English patients viewed schizophrenia as having a substantially biological origin.⁶⁴ So our explanations for a person's psychosis may not be as convincing to them – and their families – as we might imagine. One simple step that might help is to encourage patients with a serious medical illness to read their own notes; one study reported that this helped such patients to better understand why they were prescribed medications.⁶⁵ However, this begs the question of why they did not understand in the first place. The range of practical interventions described in Table 14.3 – and, to a great extent, the psychological interventions contained in the original model of compliance therapy – will need to be tailored to the needs of the individual patient. But this assumes that clinicians have an awareness of the issue, the requisite skills and the time available to use them. The current RCPsych curricula, although they refer to some of the psychological skills modalities mentioned, do not include the management of adherence as an issue in either the core curriculum or the general psychiatry curriculum.⁶⁶ Conclusion Establishing and maintaining adherence is a quintessentially biopsychosocial activity. It is central to the practice of medicine and, hence, to psychiatry. It demands both an awareness of the problem, a knowledge of practical strategies for its improvement and a repertoire of psychological skills. The neglect of this area of therapeutics in training should not deter prescribers from recognising non-adherence and taking active steps to manage it. An initial gambit might be, at the end of any first prescription, to ask ourselves 'What have I done to help this patient take this medication?' and to record this answer as part of the care plan, as a reminder to ourselves and our colleagues that this issue needs our conscious, structured and regular attention. References

1. World Health Organization. Adherence to long-term therapies: evidence for action. 2003; <https://apps.who.int/iris/bitstream/handle/10665/42682/9241545992.pdf>.
2. National Institute for Health and Care Excellence. Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence. Clinical guideline [CG76]. 2009 (last checked August 2023); <https://www.nice.org.uk/guidance/cg76>.
3. Piatkowska O, et al. Medication — compliance or alliance? A client-centred approach to increasing adherence. In: Kavanagh DJ, ed. Schizophrenia: An Overview and Practical Handbook. Boston, MA: Springer US; 1992:339–355.
4. Bond C, et al. Prescribing and partnership with patients. Br J Clin Pharmacol 2012; 74:581–588.

5. Sweetman J, et al. Risk factors for initial appointment non-attendance at Improving Access to Psychological Therapy (IAPT) services: a retrospective analysis. *Psychother Res* 2023; 33:535-550.
6. Foley L, et al. Prevalence and predictors of medication non-adherence among people living with multimorbidity: a systematic review and meta-analysis. *BMJ Open* 2021; 11:e0987.
7. Semahegn A, et al. Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: a systematic review and meta-analysis. *Syst Rev* 2020; 9:17.
8. Masand PS, et al. Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review. *Prim Care Companion J Clin Psychiatry* 2009; 11:147-154.
9. Alosaimi K, et al. Medication adherence among patients with chronic diseases in Saudi Arabia. *Int J Environ Res Public Health* 2022; 19:10053.
10. Leucht S, et al. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. *J Clin Psychiatry* 2006; 67 Suppl 5:3-8.

Prescribing psychotropics CHAPTER 14

11. Zhou Y, et al. Factors associated with complete discontinuation of medication among patients with schizophrenia in the year after hospital discharge. *Psychiatry Res* 2017; 250:129-135.
12. Cramer JA, et al. Compliance with medication regimens for mental and physical disorders. *Psychiatr Serv* 1998; 49:196-201.
13. Geretsegger C, et al. Non-adherence to psychotropic medication assessed by plasma level in newly admitted psychiatric patients: prevalence before acute admission. *Psychiatry Clin Neurosci* 2019; 73:175-178.
14. Remington G, et al. The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia. *Schizophr Res* 2007; 90:229-237.
15. McCutcheon R, et al. Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia. *Acta Psychiatr Scand* 2018; 137:39-46.
16. Taipale H, et al. 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). *World Psychiatry* 2020; 19:61-68.
17. Morken G, et al. Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. *BMC Psychiatry* 2008; 8:32.
18. Knapp M, et al. Non-adherence to antipsychotic medication regimens: associations with resource use and costs. *Br J Psychiatry* 2004; 184:509-516.
19. Jaeger S, et al. Adherence styles of schizophrenia patients identified by a latent class analysis of the Medication Adherence Rating Scale (MARS): a six-month follow-up study. *Psychiatry Res* 2012; 200:83-88.
20. Lang K, et al. Predictors of medication nonadherence and hospitalization in Medicaid patients with bipolar I disorder given long-acting or oral antipsychotics. *J Med Econ* 2011; 14:217-226.
21. Mitchell AJ, et al. Why don't patients take their medicine? Reasons and solutions in psychiatry. *Adv Psychiatric Treat* 2007; 13:336-346.
22. Scherrer JF, et al. Antidepressant drug compliance: reduced risk of MI and mortality in depressed patients. *Am J Med* 2011; 124:318-324.
23. Appleby L, et al. National Confidential Inquiry into Suicide and Homicide by People with Mental Illness. 2013; <http://www.bbmh.manchester.ac.uk/cmhr/research/centreforsuicideprevention/nci/>.
24. Malmberg L, et al. Individual psychodynamic psychotherapy and psychoanalysis for schizophrenia and severe mental illness. *Cochrane Database Syst Rev* 2001; 3:CD001360.
25. Mueser KT, et al. Psychodynamic treatment of schizophrenia: is there a future? *Psychol Med* 1990; 20:253-262.
26. Cooper RE, et al. Psychosocial interventions for people with schizophrenia or psychosis on minimal or no antipsychotic medication: a systematic review. *Schizophr Res* 2019;

225:15–30. 27. Health Quality Ontario. Cognitive behavioural therapy for psychosis: a health technology assessment. *Ont Health Technol Assess Ser* 2018; 18:1–141. 28. Pedley R, et al. Qualitative systematic review of barriers and facilitators to patient-involved antipsychotic prescribing. *BJPsych Open* 2018; 4:5–14. 29. Forbes CA, et al. A systematic literature review comparing methods for the measurement of patient persistence and adherence. *Curr Med Res Opin* 2018; 34:1613–1625. 30. Anghel LA, et al. An overview of the common methods used to measure treatment adherence. *Med Pharmacy Rep* 2019; 92:117–122. 31. Greenberg RN. Overview of patient compliance with medication dosing: a literature review. *Clin Ther* 1984; 6:592–599. 32. Saini SD, et al. Effect of medication dosing frequency on adherence in chronic diseases. *Am J Manag Care* 2009; 15:e22–33. 33. Miller TA. Health literacy and adherence to medical treatment in chronic and acute illness: a meta-analysis. *Patient Educ Couns* 2016; 99:1079–1086. 34. Vieta E, et al. Psychiatrists' perceptions of potential reasons for non- and partial adherence to medication: results of a survey in bipolar disorder from eight European countries. *J Affect Disord* 2012; 143:125–130. 35. National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: prevention and management. Clinical guideline [CG178]. 2014 (last checked August 2023); <https://www.nice.org.uk/guidance/cg178>. 36. Hogan TP, et al. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. *Psychol Med* 1983; 13:177–183. 37. Perkins DO. Predictors of noncompliance in patients with schizophrenia. *J Clin Psychiatry* 2002; 63:1121–1128. 38. Weiden P, et al. Rating of medication influences (ROMI) scale in schizophrenia. *Schizophr Bull* 1994; 20:297–310. 39. Horne R, et al. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. *Psychol Health* 1999; 14:1–24. 40. Zullig LL, et al. Moving from the trial to the real world: improving medication adherence using insights of implementation science. *Annu Rev Pharmacol Toxicol* 2019; 59:423–445. 41. Nieuwlaat R, et al. Interventions for enhancing medication adherence. *Cochrane Database Syst Rev* 2014; 11:CD000011. 42. Nosè M, et al. [Systemic review of clinical interventions for reducing treatment non-adherence in psychosis]. *Epidemiol Psichiatr Soc* 2003; 12:272–286. 43. Kok G, et al. A taxonomy of behaviour change methods: an intervention mapping approach. *Health Psychol Rev* 2016; 10:297–312. 44. Hartung D, et al. Interventions to improve pharmacological adherence among adults with psychotic spectrum disorders and bipolar disorder: a systematic review. *Psychosomatics* 2017; 58:101–112. 45. Chan AHY, et al. Effect of electronic adherence monitoring on adherence and outcomes in chronic conditions: a systematic review and meta-analysis. *PLoS One* 2022; 17:e0265715. 46. Barber ND, et al. Care homes' use of medicines study: prevalence, causes and potential harm of medication errors in care homes for older people. *Qual Safety Health Care* 2009; 18:341–346.

936 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 14 47. Velligan D, et al. A randomized trial comparing in person and electronic interventions for improving adherence to oral medications in schizophrenia. *Schizophr Bull* 2013; 39:999–1007. 48. Leucht C, et al. Oral versus depot antipsychotic drugs for schizophrenia – a critical systematic review and meta-analysis of randomised long-term trials. *Schizophr Res* 2011; 127:83–92. 49. Leucht S, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. *Lancet* 2012; 379:2063–2071. 50. Gentile S. Discontinuation rates during long-term, second-generation antipsychotic long-acting injection treatment: a systematic review. *Psychiatry Clin Neurosci* 2019; 73:216–230. 51. West JC, et al. Use of depot antipsychotic medications for medication nonadherence in schizophrenia. *Schizophr Bull* 2008; 34:995–1001. 52. Soares BG, et al. Penfluridol for schizophrenia. *Cochrane Database Syst Rev* 2006; 2:CD002923. 53. Otsuka

Pharmaceutical Co. Ltd. Highlights of prescribing information. Abilify Mycite (aripiprazole with sensor) for oral use 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207202lbl.pdf. 54. Cosgrove L, et al. Digital aripiprazole or digital evergreening? A systematic review of the evidence and its dissemination in the scientific literature and in the media. *BMJ Evid Based Med* 2019; 24:231–238. 55. Priebe S, et al. Financial incentives to improve adherence to antipsychotic maintenance medication in non-adherent patients: a cluster randomised controlled trial. *Health Technol Assess* 2016; 20:1–122. 56. Noordraven EL, et al. Financial incentives for improving adherence to maintenance treatment in patients with psychotic disorders (Money for Medication): a multicentre, open-label, randomised controlled trial. *Lancet Psychiatry* 2017; 4:199–207. 57. Noordraven EL, et al. The effect of financial incentives on patients' motivation for treatment: results of 'Money for Medication,' a randomised controlled trial. *BMC Psychiatry* 2018; 18:144. 58. Hoskins K, et al. Acceptability of financial incentives for health-related behavior change: an updated systematic review. *Prev Med* 2019; 126:105762. 59. Marrero RJ, et al. Psychological factors involved in psychopharmacological medication adherence in mental health patients: a systematic review. *Patient Educ Couns* 2020; 103:2116–2131. 60. Kemp R, et al. Compliance therapy in psychotic patients: randomised controlled trial. *BMJ* 1996; 312:345–349. 61. O'Donnell C, et al. Compliance therapy: a randomised controlled trial in schizophrenia. *BMJ* 2003; 327:834. 62. Surguladze S, et al. Teaching psychiatric trainees 'compliance therapy'. *Psychiatric Bull* 2002; 26:12–15. 63. Davis C, et al. Communication of anticancer drug benefits and related uncertainties to patients and clinicians: document analysis of regulated information on prescription drugs in Europe. *BMJ* 2023; 380:e073711. 64. McCabe R, et al. Explanatory models of illness in schizophrenia: comparison of four ethnic groups. *Br J Psychiatry* 2004; 185:25–30. 65. Blease C, et al. Association of patients reading clinical notes with perception of medication adherence among persons with serious mental illness. *JAMA Netw Open* 2021; 4:e212823. 66. Royal College of Psychiatrists. Curricula documents and resources. 2022; <https://www.rcpsych.ac.uk/training/curricula-and-guidance/curricula-implementation/curricula--documents-and-resources>.

11 - Restarting psychotropic medications after a p

Restarting psychotropic medications after a period of non-compliance

Prescribing psychotropics CHAPTER 14 Restarting psychotropic medications after a period of non-compliance When a patient is admitted to hospital it is often because they have been non-compliant with their medications for some time before admission. The clinical question of whether to restart the medication and at which dose is a complex one. The risk of withdrawal symptoms and relapse must be balanced against the risk of adverse drug reactions when medications are reintroduced too quickly. There is little published evidence on this area, with most guidance (often of undeclared provenance) coming from manufacturers. The guidance below should be followed with caution. Summaries of product characteristics (SPCs) and other formal, regulatory documents tend not to deal with the issue of restarting medication. Official patient information leaflets sometimes give detailed advice. These leaflets are unanimous in advising that on no account should a double dose be given to make up for a missed dose. However, the vast majority of leaflets advise only on what to do if a single dose has been missed. Some leaflets advise taking the missed dose later (providing it is not too close to the next dose), whereas others recommend skipping the missed dose altogether and starting again with the next dose. In the event that more than one dose has been missed, the first question to ask is whether or not this is the appropriate drug for a patient to be taking. Poor compliance often indicates some dissatisfaction on the part of the patient. If it is a drug with a short half-life or one that requires lengthy re-titration, it may not be appropriate to restart prescribing for a patient who is frequently non-compliant. Similarly, if a patient is intoxicated with alcohol or drugs, it may not be sensible to restart medication at that time. Efforts should be made to find out if there are any particular reasons for non-compliance. Where poor adherence is a result of factors other than tolerability, consider the use of a long-acting injection (although these are only used, officially at least, in schizophrenia and schizoaffective disorder). When considering whether to restart the drug at the same dose as before or to re-titrate from a lower dose, the time since the last dose is vitally important. If more than a week or two has passed, then all drugs will probably need to be restarted as if it is new treatment (although for

many drugs that do not require titration this might mean starting back on the same dose as before). Exceptions include long-acting depot formulations and oral drugs with long half-lives such as aripiprazole, cariprazine and penfluridol. With these, there is a need to reload if the gap in treatment is very long, although shorter gaps (<2 weeks) might be managed by giving the usual dose and then reverting to the original dosing schedule. Lamotrigine must be considered separately from all other psychotropics because it has been associated with life-threatening cutaneous reactions, especially with high initial doses. The manufacturer's product information advises that if five half-lives have elapsed since the last lamotrigine dose was given, lamotrigine should be titrated as if for the first time. The half-life in healthy subjects on no other medication is around 33 hours. This is affected by other medications and is approximately 14 hours when given with glucuronidation-inducing drugs such as carbamazepine or phenytoin. The half-life is increased to approximately 70 hours when given with valproate. This means that the time before complete re-titration is necessary varies between 3 and 7 days, depending on other drugs co-prescribed.¹ Table 14.4 summarises some very general recommendations. The drugs in the first column have specific safety issues that mean they require re-titration after the specified

12 - References

References

938 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 14 length of time. The drugs in the middle column are thought to be safe because the maximum dose is usually no higher than the highest recommended starting dose. The drugs in the right-hand column are thought to be safe to restart at the prior dose because a similar drug appears in the middle column, because clinical experience suggests they are safe or because the risks associated with giving untitrated high doses are thought to be low. Some suggestions are obtained from EU regulatory documents (SPCs),² while others are mere suggestions based on clinical experience. If the gap in oral treatment is longer than 2 weeks, start as if it is new treatment (noting the exceptions listed earlier). References

1. Aurobindo Pharma-Milpharm Ltd. Summary of product characteristics. Lamotrigine 25mg tablets. 2024 (last accessed September 2024); <https://www.medicines.org.uk/emc/product/4736/smpc>.
2. EMC. Summaries of Product Characteristics. 2024 (last accessed September 2024); <https://www.medicines.org.uk/emc/>. Table 14.4 Restarting medication up to 2 weeks after stopping oral treatment. Drugs that require re-titration Drugs that are usually safe for restarting at the previous dose Drugs that are possibly safe for restarting at the previous dose Drug Time after which re-titration must be performed Further guidance Clozapine 48 hours See section in Chapter 1 Acamprosate Asenapine Fluoxetine Haloperidol Isocarboxazid Lofepamine Methylphenidate Phenelzine Sulpiride Tranylcypromine Valproate Antipsychotics (exceptions in column 1) Carbamazepine (beware loss on enzyme induction) Cholinesterase inhibitors CNS stimulants Disulfiram Lithium (titration advised if renal function has changed) MAOIs Memantine Naltrexone Pregabalin SSRIs Lamotrigine 3-7 days See text Methadone, buprenorphine 3 days See section in Chapter 4 Paliperidone long-acting injection Depends on formulation See section in Chapter 1 Aripiprazole long-acting injection Depends on formulation See section in Chapter 1 Quetiapine Suggest 1 week Tolerance to sedative and hypotensive effects may be lost Risperidone Suggest 1 week Tolerance to hypotensive effects may be lost Tricyclics Suggest 1 week Tolerance to sedative and hypotensive effects may be lost MAOIs, monoamine oxidase inhibitors.

13 - Relational aspects of prescribing practice

Relational aspects
of prescribing practice

14 - Object relations

Object relations

15 - Memory

Memory

16 - Treatment framework

Treatment framework

Prescribing psychotropics CHAPTER 14 Relational aspects of prescribing practice This section provides clinicians with practically useful advice in the relational aspects of prescribing. Evidence exists for the importance of the doctor-patient relationship in improving treatment outcomes.¹⁻³ The key factors that help develop, maintain and deepen the relationship include instilling trust and regard.⁴ Three concepts are important here: object relations, memory and the treatment framework.

Object relations This means how the individual views themselves and others around them. This view then influences how they process incoming data (e.g. what is happening in an interaction). This view of themselves has been determined from early experience. In essence it means that the present interaction may be experienced inaccurately through the prism of the past (another way to think of this experience is that this is the transference). This has implications for both the patient and the clinician. For example, if the patient has had early experience of uncaring parents, they will have greater difficulty in trusting the clinician. In turn, if the clinician's early experience is of demanding parents who expected them to always get it right, a treatment-resistant patient may be a particular challenge for them. This object relations approach allows one to be aware of factors regarding the patient, the clinician and the clinician-patient relationship.

Memory Up to 95% of our goal-directed activities are executed unconsciously.⁵ Thus, the clinician's prescribing may be more influenced by procedural memory than their subjective view that they are using working memory (i.e. there is an illusion of the application of active thinking to solve the specificity of the present problem). By definition, procedural memory and the action flowing from this may not be best suited for a particular clinical situation. Acknowledging the unconscious influence on the present may help bring the conscious mind into play.

Treatment framework This is using knowledge of the clinician's usual way of working (e.g. following this edition of The Maudsley Prescribing Guidelines), and a knowledge of how they tend to personally apply these guidelines. Straying from the guidelines may be based on good clinical judgement but also it may indicate that there is some psychological factor influencing decision-making. Given this psychological factor may be unconscious, the ability to review 'what one usually does' is then a useful check on what may be happening in prescribing. For example, if the prescriber is able to think 'I do not usually prescribe such a high dose of antipsychotic as a starting dose' they may then be able to pose the question 'Am I feeling very anxious to satisfy the demands of this patient?' In effect they may then be able to catch themselves acting out (i.e. replacing thinking with behaviour) in the countertransference (in this case their great anxiety to satisfy the patient).

17 - Factors that may influence the patients use of

Factors that may influence the patient's use of and adherence to medication

940 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 14 Factors that may influence the patient's use of and adherence to medication How the individual views themselves, and others, will influence many aspects of a person's behaviour. These issues include their personal and cultural beliefs, readiness to change, ambivalence, expectations of treatment, attachment style and treatment preference. In addition, patients might use medication in countertherapeutic ways. We address each of these in turn in terms of their practical implications.^{6,7} Personal and cultural beliefs The religious, cultural and socioeconomic contexts shape our beliefs around concepts of illness, health and disability.⁸ Adherence to treatments is affected by the patient's subjective beliefs and averages roughly 50% in almost all conditions.⁹ Recommendation: When it comes to prescribing within a culturally diverse population, prescribers need to reflect on their own cultural biases, enquire about the patient's cultural beliefs, and work collaboratively with communities and families.¹⁰ Readiness to change Patients' motivation and readiness to change can affect treatment outcomes. Beitman et al.¹¹ examined stages of change and response to medication in patients with panic disorder and found that readiness to change was associated with better outcomes. The transtheoretical model¹² proposes that people move through different stages of change and that interventions must match the stage of readiness. This model can also be useful for the treatment of other mental health conditions including personality disorder.¹³ Recommendation: The clinician's appreciation of the stages of change, and the work involved in lasting change, can increase compassion and avoid wrongly timed interventions (including wrongly timed prescribing). A recovery-focused and patient-centred approach may help patients to understand entrenched patterns of behaviour, and to actively participate in behavioural change. Ambivalence Patients may worry about the safety of psychotropics, and mistrust clinicians. Further, symptoms may have an

adaptive and protective function thus making them harder for the patient to relinquish. For example, a patient who has elicited care might be ambivalent about getting better and losing this care. Recovery might portend, for example, confronting a difficult relationship or working through an intolerable loss.¹⁴ Recent advances in the field of neuropsychanalysis suggest that unpleasurable feelings at a biological level indicate that the patient's underlying emotional needs are not being satisfied, serving as homeostatic 'error signals'. It is not a surprise then that symptoms (associated with feelings states) can be stubbornly resistant to symptom-focused treatments when the patient's basic emotional needs continue to be unmet.¹⁵ Recommendation: Exploring patients' ambivalence towards medication and healthcare professionals, and their previous experiences of care, can deepen the therapeutic relationship and is crucial in understanding patients' concerns. Understanding the

Prescribing psychotropics CHAPTER 14 patient's (often unconscious) underlying conflicts and motivations can explain symptom perseverance despite pharmacological endeavours. Acknowledgement of the patient's ambivalence during the recovery process may help validate their experience, facilitate rapport and enable conversations that the patient might otherwise be reluctant to approach. Expectations of treatment: placebo and nocebo effect Expectations of improvement or harm when taking medication exert a significant impact on treatment responses. The powerful 'placebo' response has been well described in medicine as a genuine psychobiological event.¹⁶ Conversely, expectations of harm are associated with negative treatment outcomes known as the 'nocebo' effect. Patients often expect harm from taking antidepressants, fearing dependence and loss of control of their emotions.¹⁷ Interestingly, patients who discussed adverse effects of antidepressants with their doctors were reported less likely to discontinue therapy than patients who did not discuss them.¹⁸ Recommendation: These findings emphasise the need to use all the elements of the therapeutic relationship in the care of patients.¹⁹ Clinical management of the nocebo effect includes awareness and recognition, focusing on the treatment alliance, carefully naming and working through mistrust, and careful disclosure of potential drug-related adverse effects, while remaining honest and clear.²⁰ Attachment style Healthcare staff often represent attachment figures²¹ as they treat patients in times of need and distress. The attachment is particularly important when it comes to the management of long-term conditions. In one study, diabetic patients with dismissive attachment had significantly worse glucose control than patients with preoccupied or secure attachment style, but the effect was mitigated by improved communication between doctors and patients.^{22,23} Concerns about rejection, abandonment, control and intimacy²⁴ are likely to affect patients' use of their medication. Patients with a dismissive attachment style may fear dependence on medication and services and not adhere to the prescribed interventions. Patients with a fearful-anxious attachment might need regular reassurance, while patients with a disorganised attachment might evoke disorganised and chaotic responses from healthcare staff. Recommendation: Consider attachment patterns when prescribing. Particular attention and consistency are needed to deliver coherent and reliable care alongside pharmacological interventions. Treatment preference The chronic illness model encourages consideration of the patient's treatment preferences. Research suggests that matching treatment to preference might improve outcomes for patients with depression.²⁵ An RCT matching patients to treatment preference for major depressive disorder concluded that patients had better outcomes on their preferred treatment.²⁶ These observations might apply to other conditions.

18 - Summary a checklist when prescribing

Summary - a checklist when prescribing

942 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 14 Recommendation: Consider treatment preference as one of the decision factors when prescribing. Countertherapeutic use of medication Medication (including overdose) may be used as a way of signalling submission, anger or helplessness. This is especially true in people who lack an emotional vocabulary and secure internal representations of benign care. Medication may become a way of self-management, replacing more developmental coping strategies and relationships.

Recommendation: The clinician should consider the meaning of the emotional communication and be curious about alliance ruptures and system failures (and therefore reflect on the clinician's possible contributions to the rupture). Summary - a checklist when prescribing When faced with complex prescribing decisions, a checklist considering the discussed issues from the perspective of the patient, the clinician and the clinician-patient relationship may be helpful. The patient factor Q: 'What is my patient's story? What is my patient trying to communicate using words or, as important, through their actions in the here and now?' Recommendation: A formulation of the patient's underlying psychological difficulties may help. This may include: ■ ■Predominant relational pattern(s) - attachment style and relationship to care/ authority. ■ ■Ambivalence about symptoms - underlying psychological investment in status quo. ■ ■Meaning attached to medication and overall use of medication (including countertherapeutic use of medication). The clinician factor Q: 'How do I feel in response to my patient and how does that influence the action I am considering taking (e.g. do I feel helpless, frustrated, incompetent, guilty in the face of the patient's symptoms)? Am I prescribing to avoid unwanted feelings in my relationship with my patient?' Recommendation: 1 The first step in identifying countertransference pressure is to recognise and accept it, without always resorting to immediate action. 2 Self-review of practice. The clinician may ask: ■ ■Am I working within relevant guidelines? ■ ■Am I doing what I normally do (if not, am I being overly influenced by my countertransference)? ■ ■Do I have strong feelings about this patient? Do I have no feelings about this patient? (Which would be also worth considering.)

Prescribing psychotropics CHAPTER 14 ■ ■Are any circumstances different, for example do I have managers or other colleagues or the patient's family scrutinising me with this particular patient? 3

Seek support. Use supervision with colleagues and ask support from other members of the multidisciplinary team. It is important to work closely with colleagues (including pharmacists) to triangulate decisions when in complex prescribing dilemmas. Choosing to discuss a problem in supervision and outside of the heat of the consulting room can clarify thinking. The clinician–patient relationship Q: ‘What might prescribing a medication – or not prescribing – come to represent in my relationship with my patient?’ Limited consultation time and cancelled clinics might reinforce feelings of rejection and abandonment. Non-adherence to medication or overdose of prescribed medication might be a sign of a rupture in the clinician–patient relationship and further exploration can promote useful insights for patient and clinician. Recommendation: Consider the meaning of medication in the context of the patient, the clinician and the clinician–patient relationship. Cultivate a pharmacotherapeutic partnership and set limits:24 ■ ■Reframe prescribing as a partnership, rather than a one-directional activity of the doctor. ■ ■Provide, as much as possible, a stable and consistent consultation setting. ■ ■Set therapeutic limits, confronting unrealistic expectations of care. (This includes maintaining a realistic humility around the limitations of psychopharmacology, and psychoeducating patients regarding what medications can and cannot achieve and their place in the overall journey to recovery and development.) ■ ■Endorse a stance that can promote the pharmacotherapeutic alliance, characterised by emotional presence and warmth, good and honest communication, and support of the patient’s autonomy and agency. This includes shared decision-making and respect for the patient’s treatment preferences, when clinically indicated. ■ ■Openly discuss overall recovery goals, target symptoms, duration of treatment and potential adverse effects, and address any associated anxieties. ■ ■A clear agreement on treatment objectives, consistent with the overall care plan, and the respective responsibilities of doctor and patient can promote agency and strengthen the pharmacotherapeutic partnership. ■ ■Collaborative crisis planning should be part of this, especially when there are risk concerns.

19 - References

References

944 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 14 References

1. Olaisen RH, et al. Assessing the longitudinal impact of physician-patient relationship on functional health. *Ann Fam Med* 2020; 18:422-429.
2. McKay KM, et al. Psychiatrist effects in the psychopharmacological treatment of depression. *J Affect Disord* 2006; 92:287-290.
3. Kelley JM, et al. The influence of the patient-clinician relationship on healthcare outcomes: a systematic review and meta-analysis of randomized controlled trials. *PLoS One* 2014; 9:e94207.
4. Ridd M, et al. The patient-doctor relationship: a synthesis of the qualitative literature on patients' perspectives. *Br J Gen Pract* 2009; 59:e116-e133.
5. Bargh JA, et al. The unbearable automaticity of being. *Am Psychol* 1999; 54:462.
6. Mintz DL, et al. How (not what) to prescribe: nonpharmacologic aspects of psychopharmacology. *Psychiatr Clin North Am* 2012; 35:143-163.
7. Konstantinidou H, et al. Will this tablet make me happy again? The contribution of relational prescribing in providing a pragmatic and psychodynamic framework for prescribers. *BJPsych Advances* 2023; 29:265-273.
8. Ravindran N, et al. Cultural influences on perceptions of health, illness, and disability: a review and focus on autism. *J Child Fam Studies* 2012; 21:311-319.
9. Lam WY, et al. Medication adherence measures: an overview. *BioMed Res Int* 2015; 2015:217047.
10. Brooks LA, et al. Culturally sensitive communication in healthcare: a concept analysis. *Collegian* 2019; 26:383-391.
11. Beitman BD, et al. Patient stage of change predicts outcome in a panic disorder medication trial. *Anxiety* 1994; 1:64-69.
12. Prochaska JO, et al. Stages and processes of self-change of smoking: toward an integrative model of change. *J Consult Clin Psychol* 1983; 51:390-395.
13. Roughley M, et al. Referral of patients with emotionally unstable personality disorder for specialist psychological therapy: why, when and how? *BJPsych Bull* 2021; 45:52-58.
14. Gibbons R. The mourning process and its importance in mental illness: a psychoanalytic understanding of psychiatric diagnosis and classification. *BJPsych Advances* 2024; 30:80-88.
15. Lee T, et al. Managing the clinical encounter with patients with personality disorder in a general psychiatry setting: key contributions from neuropsychanalysis. *BJPsych Advances* 2023; doi:10.1192/bja.2023.43.

16. Finniss DG, et al. Biological, clinical, and ethical advances of placebo effects. *Lancet* 2010; 375:686–695.
17. Piguet V, et al. Patients' representations of antidepressants: a clue to nonadherence? *Clin J Pain* 2007; 23:669–675.
18. Bull SA, et al. Discontinuation of use and switching of antidepressants: influence of patient-physician communication. *JAMA* 2002; 288:1403–1409.
19. Benedetti F. Placebo and the new physiology of the doctor-patient relationship. *Physiol Rev* 2013; 93:1207–1246.
20. Data-Franco J, et al. The nocebo effect: a clinicians guide. *Aust NZ J Psychiatry* 2013; 47:617–623.
21. Adshead G. Psychiatric staff as attachment figures. Understanding management problems in psychiatric services in the light of attachment theory. *Br J Psychiatry* 1998; 172:64–69.
22. Ciechanowski PS, et al. The patient-provider relationship: attachment theory and adherence to treatment in diabetes. *Am J Psychiatry* 2001; 158:29–35.
23. Ciechanowski PS, et al. The association of patient relationship style and outcomes in collaborative care treatment for depression in patients with diabetes. *Med Care* 2006; 44:283–291.
24. Mintz D. *Psychodynamic Psychopharmacology: Caring for the Treatment-Resistant Patient*. Washington, DC: American Psychiatric Association Publishing; 2022.
25. Lin P, et al. The influence of patient preference on depression treatment in primary care. *Ann Behav Med* 2005; 30:164–173.
26. Kocsis JH, et al. Patient preference as a moderator of outcome for chronic forms of major depressive disorder treated with nefazodone, cognitive behavioral analysis system of psychotherapy, or their combination. *J Clin Psychiatry* 2009; 70:354–361.

20 - Prescribing drugs outside their licensed indications ('off-label' prescribing)

Prescribing psychotropics CHAPTER 14 Prescribing drugs outside their licensed indications ('off-label' prescribing) A Product Licence is granted when regulatory authorities are satisfied that the drug in question has proven efficacy in the treatment of a specified disorder, along with an acceptable adverse effect profile, relative to the severity of the disorder being treated and other available treatments. Licensed indications are preparation-specific, outlined in the SPCs, and may be different for branded and generic formulations of the same drug.¹ In the USA, product 'labelling' has a similar legal status to EU licensing. The decision of a manufacturer to seek a Product Licence for a given indication is essentially a commercial one. Potential sales are balanced against the cost of conducting the necessary clinical trials. Drugs may be effective outside their licensed indications for different disease states, age ranges, doses and durations. The absence of a formal Product Licence or labelling may reflect the absence of controlled trials supporting the drug's efficacy in these areas. In some cases (e.g. sertraline or quetiapine in generalised anxiety disorder [GAD]) there is sufficient evidence but a licence has not been sought by the manufacturer. Importantly, however, it is also possible that trials have been conducted but have given negative or equivocal results. Clinicians often assume that drugs with a similar mode of action will be similarly effective for a given indication. This may encourage the assumption that the official labelling for one drug indicates efficacy and safety of another, similar drug. However, apparently similar drugs may differ in respect to active metabolites and in regard to receptor affinity. Prescribing a drug within its licence or labelling does not guarantee that the patient will come to no harm. Likewise, prescribing outside a licence does not mean that the risk-benefit ratio is automatically adverse. For example, sertraline and fluoxetine are no less effective for GAD than alternative, licensed drugs.² Prescribing outside a licence, usually called 'off-label', does confer extra responsibilities on prescribers, who will be expected to be able to show that they acted in accordance with a respected body of medical opinion (the Bolam test)³ and that their action was capable of withstanding logical analysis (the Bolitho test).⁴ In the UK, both have effectively been superseded, or at least clarified, by the

Montgomery vs Lanarkshire Health Board appeal case decision⁵ which stated: An adult person of sound mind is entitled to decide which, if any, of the available forms of treatment to undergo, and her consent must be obtained before treatment interfering with her bodily integrity is undertaken. The doctor is therefore under a duty to take reasonable care to ensure that the patient is aware of any material risks involved in any recommended treatment, and of any reasonable alternative or variant treatments. The test of materiality is whether, in the circumstances of the particular case, a reasonable person in the patient's position would be likely to attach significance to the risk, or the doctor is or should reasonably be aware that the particular patient would be likely to attach significance to it. Thus, in the UK at least, the prescriber has a duty to make a patient aware of any material risks associated with the prescribing of any medicines and to outline alternatives.

946 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 14 The General Medical Council allows doctors to prescribe off-label but only where the prescriber is satisfied that there is enough evidence or experience to support efficacy and safety.⁶ In the USA, it is lawful to prescribe off-label 'within a legitimate health care practitioner-patient relationship'.⁷ Marketing of off-label use is forbidden but information may be provided following an unsolicited request.⁸ Off-label prescribing represents a significant proportion of prescribing in mental health conditions in the USA.^{9,10} A similar degree of off-label prescriptions is seen in other countries.¹¹⁻¹³ Off-label prescribing in psychiatry is less likely to be supported by a strong evidence base than off-label prescribing in other areas of medicine.¹⁴ In psychiatry, small (underpowered) studies (with wide confidence intervals) often influence practice, particularly with respect to treatment-resistant illness (a great many examples can be found in this book). When these small studies are combined in the form of a meta-analysis, considerable heterogeneity is often found, suggesting publication bias (i.e. that some negative studies are not published). Treatments may therefore become incorporated into 'routine custom and practice' in the absence of robust evidence supporting efficacy and/or tolerability, and these treatments may sometimes continue to be used despite the findings of later, larger and more definitive negative studies and meta-analyses. An example of widespread off-label prescribing of a psychotropic in non-mental health conditions is amitriptyline - 93% of UK primary care prescriptions are off-label.¹⁵ The psychopharmacology special interest group at the Royal College of Psychiatrists published a consensus statement on the use of licensed medicines for unlicensed uses.¹⁶ They noted that unlicensed use is common in general adult psychiatry, with cross-sectional studies showing that up to 50% of patients are prescribed at least one drug outside the terms of its licence. They also note that the prevalence of this type of prescribing is likely to be higher in patients under the age of 18 or over 65, in those with a learning disability, in women who are pregnant or lactating and in those patients who are cared for in forensic psychiatry settings. The main recommendations in the consensus statement are summarised in Box 14.1. Box 14.1 Recommendations before prescribing 'off-label' ■ ■ Exclude licensed alternatives (e.g. they have proved ineffective or poorly tolerated). ■ ■ Ensure familiarity with the evidence base for the intended unlicensed use. If unsure, seek advice from another clinician (and possibly a specialist pharmacist). ■ ■ Consider and document the potential risks and benefits of the proposed treatment. Share this risk assessment with the patient, and carers if applicable. Document the discussion and the patient's consent or lack of capacity to consent. ■ ■ If prescribing responsibility is to be shared with primary care, ensure that the risk assessment and consent issues are shared with the GP. ■ ■ Monitor for efficacy and adverse effects; start a low dose and increase slowly. ■ ■ Consider publishing the case to add to the body of knowledge. ■ ■ Withdraw any treatment that is ineffective or where emergent risks outweigh the benefits. The more experimental the

unlicensed use is, the more important it is to adhere to the above guidance.

21 - Examples of acceptable use of drugs outside their licences/labels

Prescribing psychotropics CHAPTER 14 The advice is largely echoed by more recent publications from the American Psychiatric Association¹⁷ (who note that off-label prescribing should be reimbursed) and the Royal Australian and New Zealand College of Psychiatrists¹⁸ who emphasise shared decision-making and the presumption of capacity. Examples of acceptable use of drugs outside their licences/labels Table 14.5 gives examples of common unlicensed uses of drugs in psychiatric practice. These examples would all fulfil the Bolam and Bolitho criteria in principle. An exhaustive list of unlicensed uses is impossible to prepare as the evidence base is constantly changing and because the expertise and experience of prescribers vary. A particular strategy may be justified in the hands of a specialist in psychopharmacology based in a tertiary referral centre but be much more difficult to justify if initiated by someone with a special interest in psychotherapy who rarely prescribes. Note that some drugs do not have a UK licence for any indication. Two commonly prescribed examples in psychiatric practice are immediate-release formulations of melatonin (used to treat insomnia in children and adolescents) and pirenzepine (used to treat clozapine-induced hypersalivation). Awareness of the evidence base and documentation of potential benefits, adverse effects and patient consent are especially important here. Table 14.5 Examples of common unlicensed uses of drugs in psychiatric practice. Drug/drug group Unlicensed use(s) Further information Second-generation antipsychotics Psychotic illness other than schizophrenia Licensed indications vary markedly, and in most cases are unlikely to reflect real differences in efficacy between drugs. Clozapine Bipolar disorder Substantial evidence to support efficacy when standard treatments have failed to control symptoms Cyproheptadine Akathisia Some evidence to support efficacy in this distressing and difficult to treat adverse effect of antipsychotics Fluoxetine/sertraline Generalised anxiety disorder Substantial supporting evidence Ketamine (racemate) Refractory depression Substantial evidence with both racemate and S-isomer Melatonin (circadin) Insomnia in children Licence covers adults >55 years only. Probably preferable to unlicensed formulations of melatonin. Naltrexone Self-injurious behaviour in people with learning

disabilities Limited evidence base Acceptable in specialist hands Sodium valproate Treatment and prophylaxis of bipolar disorder Established clinical practice Evidence from other valproate preparations

22 - References

References

948 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 14 References

1. EMC. Summary of Product Characteristics. 2024; <http://www.medicines.org.uk/emc/>.
2. Baldwin D, et al. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. *BMJ* 2011; 342:d1199.
3. Bolam v Friern Barnet Hospital Management Committee [1957] 1 WLR582.
4. Bolitho v City and Hackney Health Authority [1997] 3 WLR1151.
5. British and Irish Legal Information Institute. Montgomery (Appellant) v Lanarkshire Health Board (Respondent) (Scotland). 2015; <http://www.bailii.org/uk/cases/UKSC/2015/11.html>.
6. General Medical Council. Good practice in prescribing and managing medicines and devices. 2021 (last checked September 2024); https://www.gmc-uk.org/guidance/ethical_guidance/14316.asp.
7. Buckman Co. v. Plaintiffs' Legal Comm. 531 U.S. 341. 2001; <https://www.law.cornell.edu/supct/html/98-1768.ZO.html>.
8. FindLaw. Off-label use promotion is protected free speech. 2019 (last accessed September 2024); <https://www.findlaw.com/legalblogs/second-circuit/off-label-use-promotion-is-protected-free-speech/>.
9. Vijay A, et al. Patterns and predictors of off-label prescription of psychiatric drugs. *PLoS One* 2018; 13:e0198363.
10. Leslie DL, et al. Off-label use of antipsychotic medications in Medicaid. *Am J Manag Care* 2012; 18:e109-117.
11. Ishtiak-Ahmed K, et al. Treatment indications and potential off-label use of antidepressants among older adults: a population-based descriptive study in Denmark. *Int J Geriatr Psychiatry* 2022; 37:10.1002/gps.5841.
12. Martínez CE, et al. Antidepressant use and off-label prescribing in primary care in Spain (2013-2018). *An Pediatr (Engl Ed)* 2022; 97:237-246.
13. Hefner G, et al. Off-label use of antidepressants, antipsychotics, and mood-stabilizers in psychiatry. *J Neural Transm (Vienna)* 2022; 129:1353-1365.
14. Epstein RS, et al. The many sides of off-label prescribing. *Clin Pharmacol Ther* 2012; 91:755-758.
15. Wong J, et al. Off-label indications for antidepressants in primary care: descriptive study of prescriptions from an indication based electronic prescribing system. *BMJ* 2017; 356:j603.
16. Royal College of Psychiatrists. Use of licensed medicines for unlicensed applications in psychiatric practice (2nd edition) (CR210 Dec 2017). 2017 (last accessed September 2024); <https://www.rcpsych.ac.uk/improving-care/campaigning-for-better-mental-health-policy/college-reports/2017-college-reports/use-of-licensed-medicines-for-unlicensed->

applications-in-psychiatric-practice-2nd-edition-cr210-dec-2017.

17. American Psychiatric Association. APA official actions: position statement on off-label treatments. 2021 (last accessed September 2024);

<https://www.psychiatry.org/getattachment/053eae03-9e23-422f-ab75--2ea052eb6c81/Position-Off-Label-Treatments.pdf>.

18. Royal Australian New Zealand College of Psychiatrists (RANZCP). 'Off-label' prescribing in psychiatry. Professional Practice Guideline 4. 2023 (last accessed September 2024);

<https://www.ranzcp.org/getmedia/edc66b1d-005b-411d-b277-5c7fddc71ba2/ppg-4-off--label-prescribing-december-2023.pdf>.

23 - The Mental Health Act in England and Wales

The Mental Health Act in England and Wales

Prescribing psychotropics CHAPTER 14 The Mental Health Act in England and Wales The 1983 Mental Health Act (MHA) as amended by the 2007 MHA is the legislation within England and Wales that provides the framework for detaining and treating people with mental disorder in hospital. It also allows for the supervision of people in the community. Mental health law as it pertains to other countries is not covered in this book. The guidance here provides a quick summary of the sections that prescribers are likely to come across in their day-to-day work (Box 14.2). It is not an exhaustive list. The Act has a statutory Code of Practice for practitioners and Chapter 25 of the Code provides detailed guidance on the treatment rules of the Act.¹ The MHA can be accessed at www.legislation.gov.uk. The power to treat under S58 is only for treatment of mental disorder. Physical treatment (generally) is governed by the normal rules of consent or, if the person lacks capacity, the authority of the Mental Capacity Act. The Responsible Clinician (RC) is usually the patient's consultant. For the first 3 months of detention, the RC may give medication with or without consent to a person under one of the detention sections named for the treatment of their mental disorder. Thereafter, the patient's consent or a second opinion must be sought. The 3 months' countdown starts when medication for mental disorder is first administered while the patient is detained. This includes a patient detained under S2 who is then, without a break, detained under S3. For practical purposes the 3-month rule is usually calculated from the date of first detention. Box 14.2 Civil and forensic detention sections Section 2 Admission for assessment which lasts for up to 28 days Section 3 Admission for treatment which may last up to 6 months and is renewable Section 36 Remand to hospital for treatment Section 37 Hospital Order made by the courts (runs like an S3) Notional 37 Treat as if subject to S37. This term is used informally under a number of different circumstances. One example is where a patient was previously detained under S47/49 and their restriction order expires. Section 38 Interim Hospital Order Section 41 Restriction order: an order made by the Crown Court restricting discharge. Accompanies S37 and is written as S37/41. Section 47 Transfer to hospital of prisoners Section 49 A restriction order which usually accompanies S47 (written as S47/49) Section 48 Applies to unsentenced prisoners in need of urgent treatment and is accompanied by S49 (written as S48/49) Section 58 Treatment requiring consent or a second opinion Please note in law it is the Responsible Clinician (RC) who is accountable for the operation of S58

24 - Completion of forms T2
and T3

Completion of \hat{A} forms T2
and \hat{A} T3

25 - Arranging and preparing
for SOAD visits

Arranging and preparing
for SOAD visits

26 - Statutory consultees

Statutory consultees

950 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 14 If a patient consents to treatment, the RC completes a form T2. If a patient has not given consent or has not got the capacity to consent, a Second Opinion Appointed Doctor (SOAD) is called. The SOAD then completes a form T3. A copy of the forms T2 and T3 should be kept with the patient's medication chart as recommended in paragraph 25.75 of the Code of Practice.¹ Completion of forms T2 and T3

The following should be stated on the forms: ■ ■The name of the drug or the class of drug. ■ ■If the class of drug is stated, the number of drugs allowed at any one time. ■ ■The route of administration. ■ ■The maximum dosage with reference to BNF guidance. For example: Antipsychotic, second generation 1 oral within B () × NF maximum dose limits. For a patient who has capacity and is consenting to treatment and is only willing to take a particular drug, it is appropriate for the RC to write the name of the drug instead of the name of the class of drug on the T2. For example: Olanzapine tablets only(oral)within BNF maximum dose limits. Psychotropics not found in the BNF may be written on a T2 or T3 with their indication. For example: Melperone tablets oral up to a maximum of 25mg dai ()

ly for the treatment of schizophrenia.

Non-psychotropics used for the treatment of mental disorder should be included on the T2 and T3, for example omega-3 fatty acids (fish oils) in schizophrenia. Antimuscarinics used to treat hypersalivation and the extrapyramidal side effects of antipsychotics should be included too.

Arranging and preparing for SOAD visits The Code of Practice 25.51 states: 'Clinicians should consider seeking a review by a specialist mental health pharmacist before seeking a SOAD certificate, particularly if the patient's medication regime is complex or unusual.' Statutory consultees The SOAD should consult with two people before issuing a T3. One must be a nurse. The other must not be a nurse or a doctor. Both must have been involved with the patient's treatment. These two people are known as statutory consultees. Mental health pharmacists can perform this role where they have been involved in any recent review of a patient's medication.

27 - What is consent

What is consent?

28 - What is capacity

What is capacity?

Prescribing psychotropics CHAPTER 14 The Code of Practice 25.56 states: Statutory consultees may expect to have a private discussion with the SOAD and to be listened to with consideration. Issues that the consultees may be asked about include, but are not limited to: ■ ■the proposed treatment and the patient's ability to consent to it; ■ ■their understanding of the past and present views and wishes of the patient; ■ ■other treatment options and the way in which the decision on the treatment proposal was arrived at; ■ ■the patient's progress and the views of the patient's carers; and ■ ■where relevant, the implications of imposing treatment on a patient who does not want it and the reasons why the patient is refusing treatment. What is consent? The Code of Practice 24.34 defines consent as: ... the voluntary and continuing permission of a patient to be given a particular treatment, based on a sufficient knowledge of the purpose, nature, likely effects and risks of that treatment, including the likelihood of its success and any alternatives to it. Permission given under any unfair or undue pressure is not consent. For a patient to consent formally they must have the 'capacity' to make a decision. What is capacity? The Mental Capacity Act 2005 states that: ■ ■People must be assumed to have capacity unless it is established that they lack capacity. ■ ■People are not to be treated as unable to make a decision unless all practicable steps to help them do so have been taken without success. ■ ■People are not to be treated as unable to make a decision merely because they make an unwise decision. A patient is deemed to lack capacity if they cannot: ■ ■Understand relevant information about the decision to be made; or ■ ■Retain that information in their mind; or ■ ■Use or weigh that information as part of the decision-making process; or ■ ■Communicate their decision (by talking, using sign language or any other means). The patient needs to fail on only one of the four points above to be deemed not to have capacity. Capacity may change over time so reassessment is important. A person may lack capacity about one decision but not about another.

29 - Section 62 urgent
treatment

Section 62 urgent
treatment

30 - Section 132 duty of
managers of hospitals to

Section 132 duty

of managers of hospitals

to give information

to detained patients

31 - Electroconvulsive therapy (ECT)

Electroconvulsive therapy (ECT)

952 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 14 Section 62 urgent treatment
If after 3 months medication is needed urgently to treat a patient's mental disorder and it is not covered by a T2 or T3, S62 may be applied. The Code of Practice 25.38 states: This applies only if the treatment in question is immediately necessary to: ■ ■save the patient's life; ■ ■prevent a serious deterioration of the patient's condition, and the treatment does not have unfavourable physical or psychological consequences which cannot be reversed; ■ ■alleviate serious suffering by the patient, and the treatment does not have unfavourable physical or psychological consequences which cannot be reversed and does not entail significant physical hazard; or ■ ■prevent patients behaving violently or being a danger to themselves or others, and the treatment represents the minimum interference necessary for that purpose, does not have unfavourable physical or psychological consequences which cannot be reversed and does not entail significant physical hazard. Each Trust should design a form for the clinician in charge of treatment (usually the consultant) to state what the treatment is, why it is immediately necessary and the length of treatment. Section 132 duty of managers of hospitals to give information to detained patients With regard to S132 and consent to treatment the Code of Practice 4.20 states: Patients must be told what the Act says about treatment for their mental disorder. In particular they must be told: ■ ■the circumstances (if any) in which they can be treated without their consent - and the circumstances in which they have the right to refuse treatment; ■ ■the role of second opinion appointed doctors (SOADs) and the circumstances in which they may be involved; and ■ ■(where relevant) the rules on electroconvulsive therapy (ECT) and medication administered as part of ECT. Electroconvulsive therapy (ECT) Section 58a deals with ECT. Treatment for ECT is authorised on forms: T4 For consenting adults 18 and over, may be written by the RC or SOAD T5 For consenting patients under 18, to be written by SOAD only T6 For patients who lack capacity, to be written by SOAD only

32 - Community patients

Community patients

33 - Reference

Reference

Prescribing psychotropics CHAPTER 14 All patients under the age of 18 who are to receive ECT, whether or not they are detained under the MHA, must have treatment authorised on a T5 or T6. Patients who have the capacity to consent must not receive ECT unless they do consent (in emergencies this can, however, be over-ridden under S62 of the Act). There is no 3-month rule with regard to ECT and this also applies to medication given as part of ECT. Hence a form for ECT must always be in place regardless of the first date of detention. The forms should indicate the maximum number of treatments the patient is to receive (Code of Practice paragraph 25.23). Community patients Patients on a Community Treatment Order (CTO) should have treatment authorised on one of the following forms: CTO11 Written by SOAD, after 1 month on a CTO, when the patient lacks capacity CTO12 Written by the RC when the patient has capacity and is consenting to treatment, after 1 month on a CTO There is no legal authority to give patients medication in the community if they refuse it. Reference

1. Gov.UK. Code of practice: Mental Health Act 1983. 2017 (last accessed August 2024); <https://www.gov.uk/government/publications/code-of-practice-mental-health-act-1983#history>.

34 - Site of administration of intramuscular injections

Site of administration of intramuscular injections

954 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 14 Site of administration of intramuscular injections Table 14.6 gives the sites of administration formally permitted in the individual product's EU licence. Other routes and sites may be possible but pharmacokinetic analysis of administration via these sites is generally not available. Table 14.6 Sites of administration of intramuscular injections. Antipsychotic generic name and formulation Licensed site(s) of administration Typical antipsychotic (FGA) depots Bromperidol decanoate in sesame oil (available in Belgium, Germany, Italy, Luxembourg and the Netherlands^{1,2}) Deep intramuscular injection into the gluteal muscle. SPCs in some countries recommend to alternate injections into the left and right sides to prevent pain at the injection site.³ Flupentixol decanoate in thin vegetable oil derived from coconuts Deep intramuscular injection into the upper outer buttock (dorsogluteal) or lateral thigh (vastus lateralis).⁴ As with all oil-based injections it is important to ensure, by aspiration before injection, that inadvertent intravascular entry does not occur.⁵ This probably applies to dorsogluteal injections only; for all other sites where there are no major blood vessels close to the injection site, this is unnecessary.⁴ Fluphenazine decanoate in sesame oil Deep intramuscular injection into the gluteal region.⁴ Has also been administered into the lateral surface of the thigh muscle but this is unlicensed. Administration into the deltoid is not recommended by manufacturer.⁶ In the USA, licensed to be used 'intramuscularly or subcutaneously'. The site of administration is not specified. Drug leakage appears to be lower after SC injection than after intramuscular administration.⁷ Fluspirilene in vegetable oil⁸ (available in some EU countries, Canada, Argentina and Israel⁹) Deep intramuscular injection into the gluteal muscle (intragluteal). Because of its microcrystalline form, irritation and inflammation symptoms may occur at the injection site. Manufacturer recommends to alternate between left and right gluteal muscles.^{3,10} Haloperidol decanoate in sesame oil Deep intramuscular injection into the gluteal region.⁴ It is recommended to alternate between the two gluteal muscles.¹¹ As the administration of volumes greater than 3mL is uncomfortable for the patient, such large volumes are not recommended.^{11,12} Can also be administered into the deltoid muscle according to the manufacturer.¹³ Although this is an unlicensed use, one trial suggests it is safe and effective.¹⁴ Perphenazine decanoate in sesame oil (used in the Nordic countries, Belgium, Portugal and the Netherlands¹⁵) Deep intramuscular injection.^{15,16} No other information available.

Table 14.6 (Continued) Antipsychotic generic name and formulation Licensed site(s) of administration Perphenazine enanthate in sesame oil (in clinical use in the Nordic countries, Belgium, Portugal and the Netherlands¹⁵) Pipotiazine palmitate in sesame oil⁴ (variable availability) Zuclopenthixol decanoate in thin vegetable oil derived from coconuts Atypical antipsychotic (SGA) depots Gluteal muscle administration⁴ Aripiprazole Prefilled syringe for prolonged-release suspension Aripiprazole lauroxil Prefilled syringe for extended-release suspension Aripiprazole lauroxil nanocrystal dispersion Prefilled syringe for extended-release suspension Olanzapine pamoate monohydrate Powder and vehicle for prolonged-release suspension Paliperidone palmitate 1-monthly Prolonged-release suspension for injection every month Prescribing psychotropics Deep intramuscular injection into the gluteal region.^{15,17} Administration should be by deep intramuscular injection into the gluteal region.¹⁸ Deep intramuscular injection into the upper outer buttock (dorsogluteal) or lateral thigh (vastus lateralis).⁴ As with all oil-based injections it is important to ensure, by aspiration before injection, that inadvertent intravascular entry does not occur.¹⁹ Gluteal injections should be alternated between the two gluteal muscles. Deltoid muscle administration^{4,20} Deltoid injections should be alternated between the two deltoid muscles.²⁰ The powder and vehicle vials and the prefilled syringe are for single use only.⁴ Intramuscular administration into the deltoid or gluteal (441mg dose only) muscle.^{4,21} CHAPTER 14 Intramuscular injection into the deltoid or gluteal muscle.²² Not intended for repeat dosing. Given as a single dose to initiate treatment with aripiprazole lauroxil.²² Olanzapine pamoate monohydrate should only be administered by deep intramuscular gluteal injection by a healthcare professional trained in the appropriate injection technique and in locations where post-injection observation and access to appropriate medical care in the case of overdose can be assured.²³ Injected slowly, deep into the deltoid or dorsogluteal muscle (the two initial loading doses should be administered in the deltoid muscle so as to attain therapeutic concentrations rapidly).^{4,24} Following the second initiation dose, monthly maintenance doses can be administered in either the deltoid or gluteal muscle. Administration should be in a single injection. The dose should not be given in divided injections.²⁴ (Continued)

956 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 14 Table 14.6 (Continued) Antipsychotic generic name and formulation Licensed site(s) of administration Paliperidone palmitate 3-monthly Prolonged-release suspension for injection every 3 months Deltoid muscle administration²⁵ The specified needle for administration of Trevicta into the deltoid muscle is determined by the patient's weight (see manufacturer's advice). It should be administered into the centre of the deltoid muscle. Deltoid injections should be alternated between the two deltoid muscles. Gluteal muscle administration²⁵ To be administered into the upper outer quadrant of the gluteal muscle. Gluteal injections should be alternated between the two gluteal muscles. Paliperidone palmitate 6-monthly Prolonged-release suspension for injection every 6 months Byanli is for gluteal intramuscular use only. It must not be administered by any other route. Each injection must be administered only by a healthcare professional giving the full dose in a single injection. It should be injected slowly, deep into the upper outer quadrant of the gluteal muscle. A switch between the two gluteal muscles should be considered for future injections in the event of injection site discomfort. Needles from the 3-monthly or 1-monthly paliperidone palmitate injectable pack or other commercially available needles must not be used when administering Byanli.²⁶ Risperidone microspheres (Consta) Powder and vehicle for prolonged-release suspension Following reconstitution, administer via deep intramuscular deltoid or gluteal injection.²⁷ Risperidone ISM (Okedi) Powder and solvent for extended-release suspension After

reconstitution, administer by deep intramuscular deltoid or gluteal injection.²⁸ Risperidone 2-weekly injection (Rykindo) Prefilled syringe and powder vial for prolonged-release suspension After reconstitution, administer via intramuscular injection into the gluteal muscle.²⁹ Risperidone subcutaneous long-acting injections (Perseris [RBP-7000], Uzedy [TV-46000]) Extended-release suspension Subcutaneous administration in the abdomen or upper arm.^{30,31} Prior to administration of Perseris (RBP-7000), the liquid and powder syringes need to be mixed by passing the contents back and forth between the syringes. Intramuscular injections for rapid tranquilisation

Aripiprazole Solution for injection To enhance absorption and minimise variability, injection into the deltoid or deep within the gluteus maximus muscle, avoiding adipose regions, is recommended.³²

Haloperidol Solution for injection Intramuscular administration.³³ Preferably, the gluteal muscle is selected when the dosage volume is high. The deltoid muscle is preferred for low doses of the injection. However, there is no information on the dosage limit for these specific muscle groups. Choice of site is at the discretion of the prescriber according to the manufacturer.³⁴

35 - References

References

Prescribing psychotropics CHAPTER 14 Table 14.6 (Continued) Antipsychotic generic name and formulation Licensed site(s) of administration Lorazepam Solution for injection Intramuscular administration. Can be administered into the gluteal, deltoid or frontal thigh area according to the manufacturer.³⁵ A 1:1 dilution of Ativan injection with normal saline or Sterile Water for Injection BP is recommended in order to facilitate intramuscular administration and absorption.¹⁸ Olanzapine Powder for solution for injection Inject slowly, deep into the muscle mass. The exact site of administration is not specified and choice of muscle site should be a clinical decision according to the manufacturer.³⁶ Not to be used intravenously* or subcutaneously. Use the solution immediately within 1 hour of reconstitution.³⁷ *Intravenous use has been reported^{38,39} but is off-licence/label. Promethazine hydrochloride Solution for injection By deep intramuscular injection into a large muscle.⁴⁰ Can be administered into the thigh, upper arm or gluteal region. Ensure muscle mass is sufficient for the volume being injected.⁶ Other intramuscular injections Clotiapine 40mg/4mL injection (available in Argentina, Belgium, Israel, Italy, Luxembourg, South Africa, Spain, Switzerland and Taiwan⁴¹) By intramuscular injection.⁴¹ No other information available. Clozapine intramuscular injection 25mg/mL (unlicensed)^{42,43} Only for deep intramuscular administration into the gluteal muscle. 25mg IM clozapine = 50mg oral. The maximum volume that can be injected into each site is 4mL (100mg). For doses greater than 100mg daily, the dose may be divided and administered into two sites. (Injection sites should be rotated as per usual IM practice.) Administration into the lateral thigh and deltoid muscles has been used in one case series.⁴² FGA, first-generation antipsychotic; ISM, in situ microparticles; SC, subcutaneous; SGA, second-generation antipsychotic; SPC, summary of product characteristics. References

1. Purgato M, et al. Bromperidol decanoate (depot) for schizophrenia. Cochrane Database Syst Rev 2012; 11:CD001719.
2. Riboldi I, et al. Practical guidance for the use of long-acting injectable antipsychotics in the treatment of schizophrenia. Psychol Res Behav Manag 2022; 15:3915–3929.
3. Eumedita. Medical Information Department – written communication, 2020.
4. Janssen UK. Guidance on the Administration to Adults of Oil-Based Depot and Other Long-Acting Intramuscular Antipsychotic Injections, 7th edn. 2022 (last accessed August 2024); <https://www.hpft.nhs.uk/media/6180/guidance-on-im-administration-of-oil-based-depots--and- other-long-acting-antipsychotic-injections-7th-edition.pdf>.
5. Lundbeck Ltd. Summary of product characteristics. Depixol 20mg/ml solution for injection (flupentixol decanoate). 2021 (last accessed August 2024); <https://www.medicines.org.uk/emc/product/995/smpc>.
6. Sanofi. Medical Information Department – verbal and written communication, 2017.

7. Glazer WM, et al. Injection site leakage of depot neuroleptics: intramuscular versus subcutaneous injection. *J Clin Psychiatry* 1987; 48:237-239.
8. Spanarello S, et al. The pharmacokinetics of long-acting antipsychotic medications. *Curr Clin Pharmacol* 2014; 9:310-317.
9. Abhijnhan A, et al. Depot fluspirilene for schizophrenia. *Cochrane Database Syst Rev* 2007; 2007:CD001718.
10. iMedikament.de. IMAP. 2024 (last accessed August 2024); <https://imedikament.de/imap>.

958 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 14 11. Essential Pharma Ltd. Medical Information Department – written communication, 2024. 12. Essential Pharma Ltd (Malta). Summary of product characteristics. HALDOL Decanoate (haloperidol decanoate) 100mg/ml solution for injection. 2023 (last checked August 2024); <https://www.medicines.org.uk/emc/product/15246/smpc#gref>. 13. Janssen. Medical Information Department – verbal and written communication, 2024. 14. McEvoy JP, et al. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. *JAMA* 2014; 311:1978-1987. 15. Quraishi S, et al. Depot perphenazine decanoate and enanthate for schizophrenia. *Cochrane Database Syst Rev* 2000; 2:CD001717. 16. Laakeinfo.fi. PERATSIN DECANOATE solution for injection 108mg/ml (perphenazine decanoate). 2023 (last accessed August 2024); <https://laakeinfo.fi/Medicine.aspx?m=2333>. 17. Starmark JE, et al. Abscesses following prolonged intramuscular administration of perphenazine enantate. *Acta Psychiatr Scand* 1980; 62:154-157. 18. myHealthbox 2012-2024. Summary of Product Characteristics. 2024 (last accessed August 2024); <https://myhealthbox.eu/en/>. 19. Lundbeck Ltd. Summary of product characteristics. Clopixol 200mg/ml solution for injection (zuclopenthixol decanoate). 2022 (last accessed August 2024); <https://www.medicines.org.uk/emc/product/6414/smpc>. 20. Otsuka Pharmaceuticals (UK) Ltd. Summary of product characteristics. Abilify Maintena 300mg powder and solvent for prolonged--release suspension for injection in pre-filled syringe (aripiprazole). 2024 (last accessed August 2024); <https://www.medicines.org.uk/emc/product/12955/smpc%202022>. 21. Alkermes Inc. Highlights of prescribing information. ARISTADA® (aripiprazole lauroxil) extended-release injectable suspension for intramuscular use. 2018 (last accessed August 2024); https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207533s013lbl.pdf. 22. Alkermes Inc. Highlights of prescribing information. ARISTADA INITIO® (aripiprazole lauroxil) extended-release injectable suspension, for intramuscular use. 2023; <https://www.aristada.com/downloadables/ARISTADA-INITIO-PI.pdf>. 23. Eli Lilly and Company Ltd. Summary of product characteristics. Zypadhera (olanzapine pamoate monohydrate) 210mg powder and solvent for prolonged release suspension for injection. 2023 (last assessed August 2024); <https://www.medicines.org.uk/emc/product/6429/smpc>. 24. Janssen-Cilag Ltd. Summary of product characteristics. Xeplion (paliperidone) 25mg, 50mg, 75mg, 100mg, and 150mg prolonged--release suspension for injection. 2023 (last accessed May 2024); <https://www.medicines.org.uk/emc/product/7652/smpc>. 25. Janssen-Cilag Ltd. Summary of product characteristics. TREVICTA 175mg, 263mg, 350mg, 525mg prolonged release suspension for injection. 2023 (last accessed August 2024); <https://www.medicines.org.uk/emc/medicine/32050>. 26. Janssen-Cilag Ltd. Summary of product characteristics. Byannli 700mg prolonged-release suspension for injection in pre-filled syringe (paliperidone). 2023 (last accessed August 2024); <https://www.medicines.org.uk/emc/product/13307/smpc>. 27. Janssen-Cilag Ltd. Summary of product characteristics. RISPERDAL CONSTA 25mg powder and solvent for prolonged-release

suspension for intramuscular injection (risperidone). 2022 (last assessed August 2024); <https://www.medicines.org.uk/emc/medicine/9939>. 28. ROVI Biotech Ltd. Summary of product characteristics. Okedi (risperidone) 100mg powder and solvent for prolonged-release suspension for injection pre-filled syringes. 2023 (last accessed August 2024); <https://www.medicines.org.uk/emc/product/13778/smpc>. 29. Shandong Luye Pharmaceutical Co Ltd. Highlights of prescribing information. RYKINDO® (risperidone) for extended-release injectable suspension for intramuscular use. 2023 (last checked June 2024); https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212849s000lbl.pdf. 30. Indivior UK Ltd. Highlights of prescribing information. PERSERIS (risperidone) for extended-release injectable suspension, for subcutaneous use. 2018 (last accessed September 2024); https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210655s000lbl.pdf. 31. Teva Neuroscience Inc. Highlights of prescribing information. UZEDY (risperidone) extended-release injectable suspension for subcutaneous use. 2024 (last checked June 2024); <https://www.uzedy.com/globalassets/uzedy/prescribing-information.pdf>. 32. Otsuka Pharmaceutical (UK) Ltd. Summary of product characteristics. Abilify 7.5mg/ml solution for injection (intramuscular) (aripiprazole). 2023 (last accessed August 2024); <https://www.medicines.org.uk/emc/product/6239/smpc>. 33. ADVANZ Pharma. Summary of product characteristics. Haloperidol injection BP 5mg/ml. 2024 (last accessed August 2024); <https://www.medicines.org.uk/emc/product/514>. 34. Concordia International. Medical Information Department – verbal and written communication, 2017. 35. Macure Pharma UK Ltd. Medical Information Department – written communication, 2024. 36. Lilly UK. Medical Information Department – verbal and written communication, 2017. 37. Eramol (UK) Ltd. Summary of product characteristics. Xyquila 10mg powder for solution for injection (olanzapine). 2023 (last accessed August 2024); <https://www.medicines.org.uk/emc/product/15138/smpc>. 38. Wang M, et al. A retrospective comparison of the effectiveness and safety of intravenous olanzapine versus intravenous haloperidol for agitation in adult intensive care unit patients. *J Intensive Care Med* 2022; 37:222–230. 39. Khorassani F, et al. Intravenous olanzapine for the management of agitation: review of the literature. *Ann Pharmacother* 2019; 53:853–859. 40. Sanofi. Medical Information Department – written communication, 2024. 41. Carpenter S, et al. Clotiapine for acute psychotic illnesses. *Cochrane Database Syst Rev* 2004; 4:CD002304. 42. Henry R, et al. Evaluation of the effectiveness and acceptability of intramuscular clozapine injection: illustrative case series. *BJPsych Bull* 2020; 44:239–243. 43. Casetta C, et al. A retrospective study of intramuscular clozapine prescription for treatment initiation and maintenance in treatment-resistant psychosis. *Br J Psychiatry* 2020; 217:506–513.

The Maudsley® Prescribing Guidelines in Psychiatry, Fifteenth Edition. David M. Taylor, Thomas R. E. Barnes and Allan H. Young. © 2025 David M. Taylor. Published 2025 by John Wiley & Sons Ltd. Note: Page numbers in bold indicate tables and in italics indicate figures, where they fall outside the text range. 5a-reductase inhibitors, psychiatric adverse effects 971 5HT see 5-- hydroxytryptamine 22q11.2 deletion syndrome (22q11.2DS) 820–823 clinical features and risks 820 general prescribing principles 821 managing psychiatric disorders 821–822 Abilify MyCite, adherence monitoring aid 933 Abnormal Involuntary Movement Scale 127 acamprosate, preventing relapse after alcohol detoxification 489–490 ACE see angiotensin-converting enzyme acetaldehyde, metabolism of alcohol 895 acetaminophen see paracetamol acetylcholinesterase inhibitors (AChE--Is) Alzheimer’s disease 630, 632–636, 642, 649 dementia with Lewy bodies 648 management of behavioural and psychological symptoms of dementia 671 mechanism of action 630, 631 mild

cognitive impairment 648 older patients and dementia 654–658, 659, 689 other dementias 647, 648, 649 rare dementias associated with neurological conditions 649 use in Parkinson's disease 842 vascular dementia 647 activated partial thromboplastin time, psychotropic agent effects 965 activation adverse effects, depression in children and adolescents 571 Acuphase see zuclopenthixol acetate acute behavioural disturbance use of term 543 see also drug-induced excited states acutely disturbed/violent behaviour 62–73 oral/inhaled treatment 62 parenteral treatment 62–65 practical measures 65 zuclopenthixol acetate 66–67 acute mania, treatments 310–315 AD see Alzheimer's disease adapted Naranjo adverse drug reaction scale 972, 973 addiction 477–560 see also alcohol dependence; dependence syndrome; drugs of misuse; illicit drugs; new psychoactive substances; nicotine dependence; opioid dependence; smoking; substance misuse and dependence ADH see alcohol dehydrogenase ADHD see attention deficit hyperactivity disorder adherence 927–936 antipsychotics 30, 928–929, 933–934 assessing 929, 930 clinician-patient relationship 939 definitions and terminology 927 enhancing medication adherence 931–934 factors affecting 929 impacts of non-adherence 928–929 intervention 932 intervention research of poor quality 931 lithium 284 monitoring and assessing attitudes 931 object relations 939 rates and degrees 927–928 relational aspects 939–944 relational factors influencing clinicians 939 relational factors influencing patients 940 restarting medications after period of non-compliance 937–938 strategies 931 administration of medicines alternative routes 115–118 covertly in food and drink, older people 629, 694–699 covertly in food and drink for older people 629, 694–699 site of intramuscular injections 954–957 adolescents bulimia nervosa/binge eating disorder 794 see also children and adolescents adrenergic α_2 agonists, tics and Tourette's syndrome 615 ADRs see adverse drug reactions aducanumab, Alzheimer's disease treatment 646 adverse drug reactions adapted Naranjo adverse drug reaction scale 972, 973 Naranjo scale 972, 973 adverse drug reactions (ADRs) anticholinergic effects of antipsychotics 43–44 antipsychotics in menopausal women 859–860 Index

976 Index adverse drug reactions (ADRs) (cont'd) biochemical effects of psychotropics 959, 960–965 discussion with patients 941 haematological effects of psychotropics 959, 965–966 increased incidence and severity in older people 627–628 non-psychotropics with psychiatric effects 969–974 psychiatric adverse effects of non-psychotropic drugs 969–974 psychiatric effects of antiseizure medications 812–813 psychotropic sensitivity in people with learning difficulties 825 see also extrapyramidal side effects AF see atrial fibrillation age effects changes in pharmacodynamics 627–628 depression in children and adolescents 570 see also children and adolescents; older people aggressive behaviours Huntington's disease 832 paradoxical/disinhibitory drug reactions, benzodiazepines 471–473 valproate treatment 290 agitation and irritability, Huntington's disease 832, 833 agomelatine in overdose 913 smokers 892 agonist replacement therapy, limited evidence for stimulant use disorder 532 agranulocytosis 245, 251, 267–268, 275–276, 959, 966 akathisia 43, 44, 127, 128, 131–134 alanine aminotransferase (ALT) 960 albumin hepatic impairment 753, 754 psychotropic agent effects 960 alcohol dehydrogenase (ADH) 895, 896 alcohol dependence 479–497 in children and adolescents 493 clinical assessment 479–480 mild 480, 485 moderate 480, 485 in older people 493 pharmacologically assisted withdrawal 482–487 in pregnancy 492–493 preventing relapse after detoxification 489–492 severe 480, 486 Wernicke's encephalopathy/thiamine deficiency 487–488 withdrawal 480–489 alcohol detoxification benzodiazepines 484–486 carbamazepine 487 community or in-patient 482 fixed dose treatment regimen 485–486 pharmacologically assisted withdrawal 482–487 preventing relapse 489–492 symptom-triggered treatment regimen 486 alcohol use amnesia 898 ataxia 898 bariatric surgery

effects 855 disulfiram reaction 490 driving impairment 922 electrolyte disturbances 898 health guidance 479 metabolism of 895 pharmacodynamic interactions 897–899 pharmacokinetic interactions 895–897 psychotropic drug combination 895–899 sedation 897 alcohol use disorder (AUD) comorbid mental health disorders 494–496 see also alcohol dependence Alcohol Use Disorders Identification Test (AUDIT) 480, 482 alcohol withdrawal 480–489 benzodiazepines 484–487 common interventions 484 community detoxification 482 delirium tremens 480, 481, 482, 486 mild 480, 484 pharmacologically assisted/ detoxification 482–487 seizures 480, 481 severe 481, 484 severity assessment 480, 483 treating somatic symptoms 488–489 treatment interventions 484 aldehyde dehydrogenase 895, 896 alkaline phosphatase in blood, psychotropic agent effects 960 allopurinol 226 α 2A-adrenoceptor agonists, see also guanfacine alpha blockers, older patients with urinary retention, drug safety 658 alpha-lipoic acid, for antipsychotic-induced weight gain 145 ALT see alanine aminotransferase alternative therapies Alzheimer's disease management 641, 643–645 inclusion on MHA forms T2 and T3 950 see also complementary therapies; natural remedies Alzheimer's disease (AD) atrial fibrillation patients 847 cognitive enhancers 630–641 adverse effects 635–637 combination treatment 634 dosing and formulations 633–634 drug interactions 637–640 drug tolerability 634–635 efficacy 632 mechanism of action 630 switching drugs 632–633 differentiating from vascular dementia 647 management with alternative substances 641, 643–645 NICE guidelines 642 novel antibody treatments 646–647 amantadine for antipsychotic-induced weight gain 145 for fatigue in multiple sclerosis 837 for tardive dyskinesia 136 ambivalence about medication, clinicians understanding patients 940–941 amfebutamone see bupropion amfetamines attention deficit hyperactivity disorder in adults 798–800 breastfeeding mothers 747 depression 388 in pregnancy 727 stimulant use disorder 533–534 see also methamphetamine use disorder amino acids, for tardive dyskinesia 137 amisulpride 3, 4 clozapine augmentation 221 efficacy 3 in overdose 915 plasma level monitoring 869–870 target range 868 use in patients with hepatic impairment 754, 756, 761 amitriptyline antidepressant 337 for clozapine-induced hypersalivation 258, 259 post-stroke pain treatment 393 in pregnancy 720 serotonin reuptake inhibition 404 ammonia in blood, psychotropic agent effects 960 amnesia, alcohol effects 898 amylase in blood, psychotropic agent effects 961 AN see anorexia nervosa Anafranil see clomipramine analgesics headache after ECT 384 managing behavioural and psychological symptoms of dementia 668 opioid avoidance for patients on naltrexone 490, 518 opioid substitution treatment combination 518–519

safety in older patients/dementia 660–661 see also non-steroidal anti-inflammatory drugs; opioids; paracetamol angiotensin-converting enzyme (ACE) inhibitors, lithium interaction 284–285 angiotensin II receptor antagonists, lithium interaction 285 anhedonia, stimulant use detoxification 535 ANI see asymptomatic neurocognitive impairment anorexia nervosa (AN) 792–794 antidepressants 793 co-morbid conditions 792, 794 monitoring when on oral electrolyte supplementation 794 NICE guidelines 795 psychological symptom treatment 793 relapse prevention 794 treating physical aspects 793–794 weight restoration 792 Antabuse see disulfiram anti-amyloid therapy, Alzheimer's disease treatment 646–647 antibiotics psychiatric adverse effects 969 safety in older patients/dementia 662 anticholinergic adverse effects of antipsychotics 43–44 anticholinergic burden, cognitive impairment 642 anticoagulants, safety/use in older patients/dementia 662 anticonvulsants benzodiazepine properties 484 borderline personality disorder 789 people with learning difficulties 827 use in alcohol withdrawal management 480, 481 see also antiseizure medications anti-dementia drugs 630–649 use in renal impairment 778 see also cognitive enhancers antidepressants adverse effects, relative and absolute risks 444–445 with

alcohol 899 anorexia nervosa 793 antipsychotic augmentation 35 with antipsychotics for psychotic depression 362 anxiety spectrum disorders 340 arrhythmia induction 411–415 atrial fibrillation patients 846 bariatric surgery patients 850 bipolar depression 321 bleeding risks 432–439 borderline personality disorder 789 breastfeeding mothers 735, 736, 737–740 bulimia nervosa/binge eating disorder 794–795 cardiac effects 406–408, 409–415 choice 338–339 co-prescribed with warfarin leading to non-GI bleeding risk 433 diabetes mellitus 423–425 dosing 626 increasing if insufficient response 345, 346 driving impairment 922 drug interactions 401–405 pharmacodynamic effects 402, 404–405 pharmacokinetic effects 401–402, 403 duration of treatment 340 effectiveness 337 electroconvulsive therapy combination 384 Fatal Toxicity Index 412 glucose homeostasis effects 423–425 hyperbolic tapering 366, 376, 379, 382 hyperprolactinaemia 420–422 hyponatraemia induction 416–419 ketamine 357 managing behavioural and psychological symptoms of dementia 672–673 managing treatment-resistant depression 348–356, 357 minimum effective doses 342, 366 natural 440–443 next-steps if no response 340 onset of action 338 in overdose 913–915 overview 337–341 perioperative bleeding risks with non-SSRI antidepressants 437 pharmacodynamic drug interactions 402, 404–405 pharmacokinetic drug interactions 401–402, 403 post-stroke prophylaxis 393 practical application of tapering 380–381 in pregnancy 719–722 prolactin effects 420 prophylaxis 393, 397–400 relapse risk of discontinuation after medium/long term use 398–399 relative adverse effects 338–339, 412 risks to people with epilepsy 815 St John's wort 440–443 sexual dysfunction 426–431 smokers 893 stopping 378 sudden cardiac death 411, 412 suicidality 339 suicide risks in children and adolescents 570–571 swapping and stopping guide 368–371 switching 345, 366–372 tapering 366, 376, 378–382 Index target ranges 874 use in older people with depression 688–693 use in patients with hepatic impairment 753, 757–758, 761 use in patients with renal impairment 772–775 use in stimulant use disorder 535 antidepressant withdrawal at risk patients 375 avoidance 375–376 clinical relevance 375 incidence and severity of symptoms 373–374 signs and symptoms 373–376 stopping 378 switching 366–367 time course 374 treatment 376 troubleshooting during tapering 381 antiemetics, safety in older patients/ dementia 658–659 antihistamines driving impairment 923 safety in older patients/dementia 661, 674 antihypertensives, safety/use in older patients/dementia 661 anti-inflammatory drugs, Alzheimer's disease management 644–645 antimalarials psychiatric adverse effects 969 QT prolongation 165 antiparkinsonian treatments, psychiatric adverse effects 970 antipsychotic depot, see also long-acting injectable antipsychotics Antipsychotic Non-Neurological Side-Effects Rating Scale 4 antipsychotics adherence to treatment 30, 928–929, 933–934 administration of 115–118 buccal 117 inhalation 115, 116 intranasal 115, 116–117 intravenous 117 rectal 116, 118 sublingual 115, 117 transdermal 116 adverse effects 1, 2, 3–4, 23–24, 30, 43–44, 126–213 acute kidney injury risk 769 agranulocytosis 245, 251, 267–268 akathisia 43, 44, 127, 128, 131–134, 207 atrial fibrillation risk 846 blood pressure changes 182–185 cardiomyopathy 254 cardiovascular adverse effects 253–257 colitis 245

978 Index antipsychotics (cont'd) constipation 241, 263–266 delirium 245 diabetes and impaired glucose tolerance 174–181, 207 dyslipidaemia 207 dystonia 127, 128 ECG changes (QTc prolongation) 161–168, 207 eosinophilia 245 extrapyramidal symptoms 126–130, 207 gastrointestinal hypomotility 241, 263–266 gastrointestinal necrosis 245 haematological adverse effects 251–252 heat stroke 245 hepatic failure/enzyme abnormalities 245 hyperglycaemia 186 hyperlipidaemia 186 hyperprolactinaemia 190–194, 196, 207 hypersalivation 241, 258–262 hypertension 183–184 hyponatraemia 186–189 hypothermia 245 interstitial lung disease 245 interstitial nephritis 245 knee-buckling 245 myocarditis 253–254, 255 neuroleptic malignant

syndrome 150-153 neutropenia 267-272 ocular effects 245 orthostatic hypotension 182-183, 207
in overdose 913-915 pancreatitis 246 parotid gland swelling 246 pericardial effusion 246
pericarditis 246 plasma lipids 169-173 pneumonia 204-206 polyserositis 246 pseudoparkinsonism
127-128 QTc prolongation 161-168, 207 renal injury risk 769 sedation 207 sexual dysfunction
195-203, 207 skin reactions 246 stuttering 246 tardive dyskinesia 120, 127, 128, 135-140, 208
thrombocytopenia 246 thromboembolism 211-213, 246, 253 venous thromboembolism 211-213,
253 weight gain 141-149, 208 with alcohol 895-899 antidepressant augmentation 35 with
antidepressants for psychotic depression 362 augmentation of 58-59 bariatric surgery patients
851-852 bipolar disorder 300-304, 305-307, 310, 311 depression 301, 319 first generation 300
mania 300, 301, 302 second generation 300-302 specific drugs 301-302 borderline personality
disorder 788 breastfeeding mothers 736, 741-743 with caffeine 903 children and adolescents 590,
598, 606, 615-616, 623, 626 choosing 2-3 classification of 1-2 clozapine augmentation 221
combinations of 7, 22-25, 58-59 discontinuation of 7, 28, 29, 30-31, 119-125 pattern of tapering
121-122 reduction of olanzapine 121, 122 tapering in practice 122 when to attempt
discontinuation 123 driving impairment 922 equivalent doses 14-15 first-generation adverse
effects 3-4, 49 classification 2 diabetes, antipsychotic-related 174 equivalent doses 14 long-acting
injectable antipsychotics 75, 76 maximum doses 11, 12 minimum effective doses 8 nomenclature
49 penfluridol 106-107 relative efficacy 3 role of older antipsychotics 49-50 treatment algorithm
46 treatment of negative symptoms 35 hepatic impairment 754-756, 761 high-dose 55-56 adverse
effects 18, 76 efficacy 17-18 prescribing and monitoring 17-19 recommendations 19 Huntington's
chorea 831 increased free plasma levels in hepatic impairment 753-754 long-term treatment 8-84
managing behavioural and psychological symptoms of dementia 668 maximum doses 11-12
menopausal women 858, 859, 860 minimum effective doses 8 monitoring 40-41 monotherapy poor
response to 22 switching to 59 mortality risks in dementia patients 669 neurobiology of withdrawal
120 oestrogen interactions 858, 859, 860 optimal dosage 55 options for menopausal women 860 in
overdose 915-916 people with 22q11.2 deletion syndrome 822 people with epilepsy, risks 816
people with learning difficulties 826 plasma level variations 56-57 polypharmacy 22-25, 59, 95,
226 adverse effects 23-24 long-term treatment 22-23 poor response to antipsychotic monotherapy
22 poor tolerability 207-210 in pregnancy 715-718 first-generation 715-716 neurodevelopment
effects 717-718 second-generation 716-717 preventing sudden cessation by non-compliance 933
principles of prescribing 7 prophylaxis 28-33 alternative views 31 discontinuation of 30-31 dose for
30 reducing 28 relative adverse effects 43-44 relative efficacy 3-4 renal impairment 769-771
response assessment 7 second-generation 49, 50 adverse effects 3-4 classification 2 diabetes,
antipsychotic-related 174-176 equivalent doses 14, 15 long-acting injectable antipsychotics 4, 75
maximum doses 11, 12 minimum effective doses 8 neuroleptic malignant syndrome association
151 optimal dosage 55 relative efficacy 3 treatment algorithm 46 treatment of negative symptoms
35 smokers 892-893 stopping 7, 28, 30-31, 90, 119-125 hyperbolic reduction schedule 121, 122
pattern of tapering 121-122 reduction of olanzapine 121, 122 tapering in practice 122 when to
attempt discontinuation 123 withdrawal effects 119-120, 123 suppositories 118 switching
medication 57-58, 207-210 target ranges 868-873, 873-874 teratogenic potential 715-717

topiramate 221, 228 use in patients with hepatic impairment 754-756, 761 use patients with in
renal impairment 769-771 withdrawal effects 119-120, 123 see also individual drug names
antiretroviral therapy (ART) adverse psychiatric effects 808-809 human immunodeficiency virus
treatment 804 interactions with psychotropic drugs 804, 807-808 pharmacokinetic interactions
with other drugs 545 antiseizure medications 882 driving impairment 922 interactions with

psychotropic drugs 813–814 managing behavioural and psychological symptoms of dementia 673
psychiatric side-effects (adverse and beneficial) 812–813 use in alcohol dependence treatment 492
see also anticonvulsants; valproate antispasmodics, safety in older patients/ dementia 659 anxiety
children and adolescents with autism spectrum disorder 610 comorbid alcohol use disorder 495
drug treatment in anorexia nervosa 793 Huntington's disease 832, 833 menopausal women 858 in
pregnancy 726–727 anxiety spectrum disorders 446–475 atrial fibrillation patients 847
benzodiazepines 446, 460 caffeine effects 905 children and adolescents 582–586 after prescribing
584–585 before prescribing 582–583 clinical guidance 582 diagnostic issues 582 dosages 585 what
to prescribe 583–584 cognitive behavioural therapy 447, 448, 449 multiple sclerosis 836 NICE
guidelines 448–449 and nicotine 909 people living with human immunodeficiency virus 805–806
pre-school children 586 psychological approaches 448 specific drugs used 449–455 SSRIs/SNRIs
446–447 see also generalised anxiety disorder; obsessive-compulsive disorder; panic disorder;
post-traumatic stress disorder; social phobia anxiolytic effect, benzodiazepines 460 anxiolytics
driving impairment 922 use in renal impairment 776–777 see also benzodiazepines apathy,
Huntington's disease 832, 833 apgar scores, medications in pregnancy 720, 723, 724 aripiprazole
8, 11, 15, 24, 43 for antipsychotic-induced weight gain 145 Aristada 12, 88 bipolar disorders 301,
305, 306, 316 borderline personality disorder 788 cardiac safety of 164 clozapine augmentation
221 effects on impulse control disorders 560 hyperprolactinaemia 191 long-acting injections 85–89
bipolar disorder 305, 306 brands 88 delayed doses 86, 87 doses and frequencies 77, 85, 86, 87
switching to 86 in overdose 915 pharmacokinetics 81 plasma level monitoring 870 pneumonia
association 204–205 in pregnancy 717, 718 QTc prolongation 164 rapid-cycling bipolar affective
disorder 316 target range 868 weight restoration in anorexia nervosa 792 Aristada (aripiprazole
lauroxil) 12, 88 arrhythmia cardiovascular risk factors 166 clozapine 240 flumazenil 70 induction by
antidepressants 411–415 physiological risk factors 164 psychotropic drug risks 845 ART see
antiretroviral therapy ascites, risk in hepatic impairment 753, 754 ASD see autism spectrum
disorder asenapine bipolar disorder 301 psychosis 8, 11, 12, 15, 43 sublingual 62, 117 aspartate
aminotransferase (AST), psychotropic agent effects 961 aspirin, valproate interactions 292
assessing adherence 929, 930 AST see aspartate aminotransferase asymptomatic neurocognitive
impairment (ANI), HIV related 806 ataxia, alcohol effects 898 atomoxetine, attention deficit
hyperactivity disorder in adults 799, 801 atrial fibrillation (AF) 845–848 Index psychiatric conditions
increasing risk 846, 847 psychotropic drug prescription 845–847 treatment 845 types 845 atropine
258, 259, 489, 660 attachment style of patients affecting relationship with clinician 941 attention
deficit hyperactivity disorder (ADHD) in adults 798–802 diagnosis 798 NICE guidelines 800 non--
stimulant medication 798, 799, psychostimulants 798, 799, 800 amfetamines 533 borderline
personality disorder relationship 789 caffeine effects 905 children with 22q11.2 deletion syndrome
821 children and adolescents 562, 563, 574, 597–604 bipolar disorder/bipolar affective disorder
relationship 574 diagnostic issues 597 inattention, overactivity and impulsiveness symptoms in
autism spectrum disorder 607–608 melatonin use for insomnia 620–621 prescribing guidelines
597–598, 599–602 drug use in renal impairment 778 medication risks in people with epilepsy 816--
817 and nicotine 909 in pregnancy 727 stimulant use disorder 533 atypical eating disorders 795
atypical/typical antipsychotic classification 1–2 AUD see alcohol use disorder AUDIT see Alcohol Use
Disorders Identification Test autism spectrum disorder (ASD) children and adolescents 605–613,
620–621 inattention, overactivity and impulsiveness symptoms 607–608 melatonin use for
insomnia 620–621 pharmacological treatment of co- occurring disorders and problem behaviours
607–610 pharmacological treatment of core symptoms 605–606 restricted repetitive behaviours
and interests 606 social and communication impairment 606 psychotropic drugs used 826–827

980 Index baclofen, preventing relapse after alcohol detoxification 492 BALANCE study, bipolar disorder 290, 326 bariatric surgery 849–856 drug pharmacokinetic alterations 849 general recommendations for psychotropic prescribing 854 lithium in perioperative phases 853 medication formulation considerations 849 mental health after surgery 855 psychiatric illness risk 849 Barnes Akathisia Rating Scale 127 basophils, psychotropic agent effects 965 Bazett's correction formula 162 BDD see body dysmorphic disorder BED see binge eating disorder behavioural changes, benzodiazepine induced disinhibition 471–473 behavioural disturbance see acutely disturbed/violent behaviour; aggressive behaviours; drug-induced excited states behavioural and psychological symptoms of dementia (BPSD) 667–679 non-drug management measures 667–668 pharmacological measures 668–679 beneficial psychiatric effects, antiseizure medications 812–813 benign ethnic neutropenia (BEN) 268, 269, benperidol 43 benzhexol (trihexyphenidyl), clozapine-induced hypersalivation 259 benzodiazepine, breastfeeding 746 benzodiazepine dependence 464, 540–542 dose reduction recommendations 540 novel illicit drugs 540 overuse of prescribed medication 540 polysubstance use 541, 542 withdrawal management 466–469, 540–542 benzodiazepines 64–65 adverse effects 461–462 adverse effects of long-term use 464, 465 alcohol withdrawal treatment 484–487 anxiolytic effect 460 breastfeeding mothers 746 with caffeine 903 for catatonia 154–155 concentration in normal dosing and UK legal limit 923 dependence/withdrawal/ discontinuation 464–465, 540–542 diazepam equivalent doses 466, 467 direct taper or switch to diazepam 466 disinhibition 471–473 driving impairment 922 drug interactions 462 fixed dose regimen for alcohol withdrawal 485–486 hypnotic effect 460 long-term use effects 464–465 mania treatment in bipolar disorder 310, 311–312 for neuroleptic malignant syndrome 151 not recommended for managing behavioural and psychological symptoms of dementia 671–672 in overdose 917 pregnancy 541 process before tapering 468 psychiatric disorder treatment 460–463 reduction schedules 469 sedatives in hepatic impairment 761 smokers 892 stopping 466 symptom-triggered regimen for alcohol withdrawal 485, 486–487 tapering 466 tapering patterns 467 tapering process 468 for tardive dyskinesia 136 troubleshooting during tapering process 468–469 use in anxiety spectrum disorders 446 use in children and adolescents with autism spectrum disorder 609 use in depression 461 use in pregnancy 726 use in psychosis 461 withdrawal management 466–469, 540–542 symptoms 465 benzotropine, clozapine-induced hypersalivation 259 beta agonists, safety in older patients/ dementia/Parkinsons 659 betahistine, for antipsychotic-induced weight gain 145 bethanechol, for constipation treatment 265 bicarbonate in blood, psychotropic agent effects 961 bilirubin in blood, psychotropic agent effects 961 binge eating disorder (BED) 794–795 comorbid depression 795 NICE guidelines 795 biochemical effects of psychotropics 959, 960–965 bipolar disorder/bipolar affective disorder 279–334 antipsychotic drugs 300–304, 311 long-acting injections 305–307 atrial fibrillation patients 846 carbamazepine 295–299 children and adolescents 573–579 after prescribing 574 attention deficit hyperactivity disorder relationship 574 before prescribing 573 clinical guidance 573–574 depression treatments 577 first--line treatments 577 mania treatments 575–576, 577 specific issues 574–575 what to prescribe 573, 575–577 comorbid alcohol use disorder 495 depression 319–325 antipsychotics 301, 302 lithium 280 meta-analysis of drug studies 319 valproate 290 disruptive mood dysregulation disorder relationship 574 lithium 279–288 maintenance treatment 280 prophylaxis 326, 327, 328 stopping/withdrawal effects 331–332 tapering 332–333 mania acute/hypomania 310–315 antipsychotic treatments 300, 301, 302, 311 benzodiazepines 310, 311–312 lithium treatment 279–280 treatment strategies 310 valproate treatment 289–290 multiple sclerosis 836 other treatments 574–575 people living with human immunodeficiency virus 805 physical monitoring 283, 291, 297, 308–309 postpartum psychosis risk 715 in pregnancy 722, 725–726 prophylaxis

326-330 antipsychotics 301, 302 carbamazepine 295-296 lithium 326, 327, 328 valproate 290 rapid cycling type 290, 316-318 relapse after stopping medication 332 stopping lithium and other mood stabilisers 331-334 tapering lithium 332-333 valproate 289-294 bleeding gastrointestinal irritant drugs 753 SSRI effects 393-394, 404, 409, 432-439 warfarin interactions with SSRIs 846 see also platelets blonanserin 8, 12, 15, 43, 227 blood-brain barrier, increased permeability with old age 628 blood clotting antipsychotics risk of pathological clotting 212 see also bleeding; platelets blood count, antipsychotic medication monitoring 40

blood lipids, antipsychotic medication monitoring 40 blood pressure changes 182-185 antipsychotic medication monitoring 41 hypertension 41, 183-184, 241 orthostatic hypotension 182-183, 207 blood tests biochemical effects of psychotropics 959, 960-965 haematological effects of psychotropics 959, 965-966 blood transfusion in surgery, SSRI risks 436-437 BN see bulimia nervosa body dysmorphic disorder (BDD) 587-592 children and adolescents 587-594 NICE guidelines 588-589 psychological therapies 447, 587 SSRIs/SNRIs 447, 588 treatment duration and follow-up 591 treatment initiation 589 treatment-refractory cases 590 bone loss, anorexia nervosa risk 794 bone marrow suppression, antiretrovirals 807 bone mineral density (BMD), reduction by antiretrovirals 807 borderline personality disorder (BPD) 787-791 antidepressants 789 antipsychotics 788 botulinum toxin 790 co-morbid mental health conditions 787, 788 crisis management 790 drug treatment evidence 788-790 ketamine 790 lack of evidence for drug treatments 787-788 mood stabilisers and anticonvulsants 789 omega-3 fatty acids 790 opioid antagonists 789 sedatives, short term use recommended 788 botulinum toxin borderline personality disorder 790 clozapine-related hypersalivation 259 tardive dyskinesia 137 BPD see borderline personality disorder BPSD see behavioural and psychological symptoms of dementia bradykinesia 35 see also pseudoparkinsonism breast enlargement 196 breastfeeding antidepressants 735, 737-740 antipsychotics 736, 741-743 general prescribing principles 734-735, 736 measuring infant exposure to drugs 734 mood stabilisers 736, 744-745 not permitted with lithium use 736 stimulants 747 use of psychotropic medications 734-747 bremelanotide use in patients with hepatic impairment 761 use in patients with renal impairment 778 brexanolone, in overdose 913 brexpiprazole 8, 12, 15, 43, 915 British Association for Psychopharmacology catatonia 156 dementia recommendations 649 bronchodilators, safety in older patients/ dementia 659-660 buccal administration, antipsychotics 117 bulimia nervosa (BN) 794-795 comorbid depression 795 NICE guidelines 795 buprenorphine analgesia for patients on opioid substitution treatment 519 blocking other opioids 506, 507, 519 cautions 513 conventional induction 508-509 intoxication 513 liver function effects 513 low-dose induction 509 methadone comparison 503 opioid substitution treatment 501, 503, 506-514 overdose 513 prolonged-release injection/ Bupival 509-510 timecourse of withdrawal symptoms 501 transferring back to methadone 512-513 transition from methadone 510-512 treatment methods and doses 508, 509 withdrawal 501, 516--517 buprenorphine with naloxone (Suboxone) 513 bupropion (amfebutamone) 145, 259 adverse effects 527 attention deficit hyperactivity disorder in adults 799, 801 borderline personality disorder 789 clinical effectiveness 527 contraindicated in anorexia nervosa 794 nicotine addiction 527, 529 not recommended in bulimia nervosa/ binge eating disorder 795 in overdose 914 in pregnancy 721, 722 preparations and doses 527, 529 buspirone, in overdose 917 butyrophenones, in overdose 915 caffeine 901-907 anxiety disorders 905 attention deficit hyperactivity disorder 905 Index dose and psychotropic effects of 902-903, 902 drink types 901 energy drinks 901, 904 general effects of 902 interactions 903 intoxication 903-904 mood disorders 905 pharmacokinetics 902-903 schizophrenia 904 withdrawal effects 902 calcium antagonists, for tardive dyskinesia 137

calcium in blood, psychotropic agent effects 961 calcium levels, long-term lithium use 282
cannabis/cannabinoids 36, 546, 550, 558, capacity and consent assessment in older people 694
covert administration of medicines in food and drink 629, 694-699 learning difficulties 824-825
Mental Health Act 629, 694-698, 950, 951 right not to take medication 931 carbamazepine 295--
299 adverse effects 296-297 bipolar disorder 295-299, 310, 311 depression 295 discontinuation
297, 298 drug interactions 297-298 formulations 295 indications 295-296, 298 lithium interactions
286 mania 295 mechanism of action 295 in overdose 916 plasma levels 296 prescribing 298 pre-
treatment tests and monitoring 297, 298 prophylaxis 295-296 smokers 892 target range 868
teratogenicity 297, 714, 723-724 carbohydrate-deficient transferrin (CDT), psychotropic agent
effects 961 cardiac arrhythmia, atrial fibrillation 845-848 cardiac death 161, 166 cardiac drugs,
safety/use in older patients 662 cardiac effects antidepressants 406-408, 409, 411-412 drug-
induced excited states 543, 544 torsades de pointes/QT interval prolongation risk with methadone
506 cardiac malformation in infants, maternal mental health problems and lithium 723

982 Index cardiomyopathy 254 cardiovascular agents, psychiatric adverse effects 970
cardiovascular disease 169 cardiovascular effects, antiretrovirals 807 cardiovascular mortality 176
cardiovascular risks, acetylcholinesterase inhibitors in Alzheimer's disease 637 care homes and
environments, learning difficulties 825 cariprazine 8, 11, 15, 43 bipolar disorder 301, 321 in
overdose 915 catatonia 154-160 algorithm for treatment of catatonic stupor 157 associated
psychiatric and medical conditions 154 ECT treatment 155 in schizophrenia 155 sub-types 154
treatment 154-156, 158 CATIE study 58 CBT see cognitive behavioural therapy CDT see
carbohydrate-deficient transferrin cerebrolysin, Alzheimer's disease management 643-644
cerebrovascular disease see vascular dementia cerebrovascular events anticoagulants reducing
risks 662 antipsychotic risks 212, 669 see also stroke checklist for prescribing clinician factor 942--
943 patient/clinician relationship 943 patient factor 942 checklists, adherence assessment 931
chemotherapeutic agents, psychiatric adverse effects 971 chemotherapy, clozapine
contraindicated 273-274 child neurodevelopment, antipsychotic exposure during pregnancy 717--
718 children, 22q11.2 deletion syndrome 821 children and adolescents 561-626 alcohol misuse
493 antipsychotics use 568, 573, 580, 590, 606, 615-616 augmentation of other drug treatments
590 first-generation antipsychotics 580, 615 rapid tranquillisation 623 second-generation
antipsychotics 568, 573, 580, 590, 608, 615-616, 623 anxiety, with autism spectrum disorder 610
anxiety disorders 582-586 chlorpromazine 1, 8, 11, 14, 28, 43, 118 chlorprothixene, possible
teratogen 716 chocolate, Alzheimer's disease management 644 cholesterol 169, 170, 962
cholinesterase inhibitors see acetylcholinesterase inhibitors chorea, Huntington's disease 830, 831
chronic kidney disease (CKD), psychiatric disorders 769 Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) formula, glomerular filtration rate estimation 766 cigarette smoking see
smoking CIGH see clozapine-induced GI hypomotility cimetidine, psychiatric adverse effects 971
citalopram as antidepressant 337, 338 binge eating disorder 794 switching antidepressants 366
use in patients with hepatic impairment 761 CK see plasma creatine kinase CKD see chronic kidney
disease CKD-EPI see Chronic Kidney Disease Epidemiology Collaboration Clinical Institute
Withdrawal Assessment of Alcohol Scale - Revised (CIWA-Ar) 482, 483, 484, 485, 486, 537 Clinical
Opiate Withdrawal Scale (COWS) 501, 502 clinician-patient relationship attachment style of
patients 941 collaboration enhancing medication adherence 931 importance to outcomes 939
prescribing influences 943 clinicians responsibilities with 'off-label' prescribing 945 seeking support
943 training in compliance therapy and adherence 933-934 clomipramine (Anafranil) in pregnancy
719 serotonin reuptake inhibition 404 clonazepam, concentration in normal dosing and UK legal

limit 923 clonidine, clozapine-induced hypersalivation 259 clotiapine 8, 15, 957 clotting factor synthesis reduction, hepatic impairment 753 clozapine 214–277 adverse effects 239, 241–277 agranulocytosis 245, 251, 267–268 cardiomyopathy 254 cardiovascular adverse effects 240, 253–257 approved psychotropic medications 563–564 attention deficit hyperactivity disorder 597–604 medication continuing into adulthood 799 symptoms 562, 563, 574, 607–608 autism spectrum disorder 605–613, 620–621 bipolar disorder 573–579 body dysmorphic disorder 587–594 bulimia nervosa/binge eating disorder 794 cognitive behavioural therapy 566–567, 574, 587, 590, 595 depression 566–572 with autism spectrum disorder 610 irritability (aggression, self-injurious behaviour, and severe disruptive behaviours) in autism spectrum disorder 608 lack of engagement with psychological therapies 587 lithium plasma levels 281 melatonin use for sleep disturbance/insomnia 575, 609–610, 620–622 obsessive compulsive disorder 587–594 with autism spectrum disorder 610 optimising lithium treatment for prophylaxis in bipolar disorder 327 post-traumatic stress disorder 595–596 pre-school children, anxiety disorders 586 prescribing principles 561–565 psychosis 580–581 psychotropic drug starting doses 626 rapid tranquillisation 623–625 relative infant dose 734 restricted repetitive behaviours and interests, autism spectrum disorder 606 selective serotonin reuptake inhibitors 566–567, 583–584, 585, 588 sleep disturbance in autism spectrum disorder 609–610 social and communication impairment, autism spectrum disorder 606 SSRI use 566–567, 583–584, 585, 588 suicidal ideation risk with SSRIs 588 symptom rating scales 573 tics and Tourette’s syndrome 614–619 adrenergic α_2 agonists 615 antipsychotics 615–616 use of adult treatments 562 depression 568–569 mania 574 obsessive compulsive disorder 592 chlordiazepoxide, alcohol withdrawal treatment 485–486 chloride in blood, psychotropic agent effects 962

colitis 245 common adverse effects 241–242 constipation 241, 263–266, 882 delirium 245 eosinophilia 245 gastrointestinal hypomotility 263–266 gastrointestinal necrosis 245 haematological adverse effects 251–252 heat stroke 245 hepatic failure/enzyme abnormalities 245 hypersalivation 241, 258–262 hypertension association 184, 241 hypothermia 245 interstitial nephritis 245 knee-buckling 245 myocarditis 253–254, 255 neutropenia 267–272 nocturnal enuresis 242 ocular effects 245 pancreatitis 246 parotid gland swelling 246 pericardial effusion 246 pericarditis 246 pneumonia 242 pneumonia association 204, 205 polyserositis 246 sedation 242 seizures 242 skin reactions 246 stuttering 246 tachycardia 184, 234, 242, 253, 255 thrombocytopenia 246 thromboembolism 246, 253 uncommon adverse effects 245–246 venous thromboembolism 253 weight gain 242 augmentation of treatment 220–222 bipolar disorder 301–302 borderline personality disorder 788 with caffeine 903 chemotherapy contraindication 273–274 clozapine/norclozapine ratio 871 combined medications 24 community initiation 236–240 adverse effects 239 dosing 237, 238 essential criteria for 236 initial work-up 236–237 mandatory blood monitoring and registration 237 recommended additional monitoring 239 relative contraindications 236 serious cardiac adverse effects 240 switching from other antipsychotics 239 titration schedules 238 delay/underuse of 57 dosing 214–218, 237, 238 ECT augmentation 108–109 EEG test 41 efficacy 3–4 efficacy for negative symptoms 35 genetic testing for treatment 275–277 agranulocytosis 275–276 benign ethnic neutropenia 276 glucose tolerance impairment association 174–175 hyponatraemia treatment 187 initiation schedules 214–218 interruptions in treatment 234–235 intramuscular clozapine 219 lithium use with 269–270, 271 maximum dose 11 ‘off-label’ prescribing 947 in overdose 915 people with 22q11.2 deletion syndrome 822 people living with human immunodeficiency virus and treatment-resistant schizophrenia 804 plasma level monitoring 870–871, 881–882 plasma lipids, effect on 170 possible risks in pregnancy 717 prescribing of 7

relative efficacy 3 restarting after a break in treatment 234–235 site of administration of intramuscular injections 957 smokers 892 smokers/non-smokers, dosing regimens 216–218 switching from other antipsychotics 239 target range 868 titration schedules 214–215, 216–218, 238 treatment optimisation 220–225 treatment-resistant schizophrenia 214–233 alternatives to clozapine 226–233 dosing regimen 214–218 faster titrations 215 intramuscular clozapine 219 treatment optimisation 220–225 clozapine-induced GI hypomotility (CIGH) 263–266, 882 clozapine rechallenge following severe constipation 265 management of suspected acute CIGH 264 prevention and simple management 264 risk factors 263 clozapine-related life-threatening agranulocytosis (CRLTA) 251 cocaine, stimulant use disorder 533 Cochrane review acute behavioural disturbance 63 benzodiazepines 64–65 Index catatonia treatment 155 long-acting injectable antipsychotics 74 smoking cessation 909 Cockcroft and Gault equation, creatinine clearance calculation 766, 767 COCP see combined oral contraceptive pill cognitive behavioural therapy (CBT) anxiety spectrum disorders 447, 448, 449 benzodiazepine withdrawal 541, 542 children and adolescents 566–567, 574, 587, 590, 595 psychosis 929 cognitive decline, anticholinergic drugs 654, 658 cognitive disturbances and decline, Huntington’s disease 834 cognitive enhancers adverse effects 631, 635–637 Alzheimer’s disease 630–641 combination treatment 634 discontinuation 640–641 dose tolerability 634–635 dosing and formulations 633–634 drug interactions 637–640 efficacy 632 managing behavioural and psychological symptoms of dementia 671 mechanism of action 630, 631 switching drugs 632–633 see also acetylcholinesterase inhibitors; memantine cognitive impairment anticholinergic burden 642 multiple sclerosis 837 people living with human immunodeficiency virus 806 see also Alzheimer’s disease; dementia; mild cognitive impairment; vascular dementia collaboration between the patient and the prescriber, enhancing medication adherence 931 combination nicotine replacement therapy 524, 529–530 combination therapies bipolar depression 319, 322 prophylaxis in bipolar disorder 327, 328 psychotic depression 362, 364 combined oral contraceptive pill (COCP), premenstrual syndrome 474–475 communication, patient factor in prescribing 942 communication with patients, adherence relationship 933–934 community detoxification, alcohol withdrawal 482 Community Treatment Order (CTO), Mental Health Act 953 complementary therapies, Parkinson’s disease 842

984 Index compliance use of term 927 see also adherence ‘compliance therapy’ 933 compulsion, dependence syndrome 477–478 concurrent illnesses, drug interactions in older people 627 consent see capacity and consent constipation causing drugs, avoid in hepatic impairment 754 constipation, clozapine-induced 263–266, clozapine rechallenge following severe constipation 265 prevention and management 241, 264 risk factors 263 controlled drugs psychostimulants used for attention deficit hyperactivity disorder in adults 798, 799 see also illicit drugs corticosteroids agents, psychiatric adverse effects 971 countertherapeutic use of medication 942 countertransference, clinicians 939, 942 covert administration of medicines in food and drink, older people 629, 694–699 COVID-19 pandemic 268 valproate preventative effects 290 COWS see Clinical Opiate Withdrawal Scale COX-2 inhibitors, lithium interactions 285–286 CrCl see creatinine clearance C-reactive protein in blood, psychotropic agent effects 961 creatine kinase, psychotropic agent effects 962 creatine kinase (CK) elevations, antiretrovirals 807 creatinine in blood, psychotropic agent effects 962 creatinine clearance (CrCl), renal function assessment 766, 767 creatinine phosphokinase, antipsychotic medication monitoring 41 CRLTA see clozapine-related life-threatening agranulocytosis Crocus sativus (saffron), Alzheimer’s disease management 643 cross-tapering, switching antidepressants 366 CTO see Community Treatment Order cultural

beliefs, influencing adherence 940 CYP see cytochrome function cyproheptadine, 'off-label' prescribing 947 cytosine adverse effects 526 clinical effectiveness for smoking cessation 526 nicotine addiction 526, 529 preparations and doses 526, 529 cytochrome (CYP) function 883–891 alcohol and substrates for enzymes 896, 897, 898 antidepressant interactions with enzymes 339, 401, 401–402, 403 caffeine metabolism/clearance 903 enzyme phenotype frequency by ancestry 889–890 genetics 888–891 nicotine/smoking effects 903, 910 environmental lithium effects 279 Huntington's disease 834 inappropriate sexual behaviour 680–687 Lewy bodies 630, 642, 648, 649, 842 management of behavioural and psychological symptoms of dementia 667–679 mild cognitive impairment/pre-clinical dementia 648 other kinds 648–649 Parkinson's disease 842 people living with human immunodeficiency virus 806 safer prescribing 654–666 vascular 647 dementia with Lewy bodies (DLB) 630, 642, 648, 649, 842 dependence definition/diagnosis 477–478 see also addiction; substance misuse and dependence dependence syndrome, definition 477–478 depot antipsychotic medications 4, 29, 74–80, 95 comparison of types 76 doses and frequencies 77–78 improving adherence and outcomes 4, 29, 928–929, 932–933 pharmacokinetics 81 prescribing advice 75–76 reduction of 123 restarting after period of non-compliance 937 schizophrenia 29, 53 site of administration of intramuscular injections 954–957 depression 335–445 atrial fibrillation patients 846 basic prescribing principles 335–336 children and adolescents 566–572 acute phase 569–570 after prescribing 569–570 with autism spectrum disorder 610 before prescribing 567 clinical guidance 566–571 diagnostic issues 566 discontinuation phase 570 maintenance phase 570 specific issues 570 what to prescribe 567–569 chronic kidney disease 769 comorbid alcohol use disorder 494 comorbid with eating disorders 794, 795 diabetes mellitus association 423 drug treatment summary chart 344, 345–347 Huntington's disease 832, 833 ketamine as treatment 351, 357–361 lithium DAI see Drug Attitude Inventory DAOAs see direct-acting oral anticoagulants daridorexant in overdose 917 use in patients with hepatic impairment 761 use in patients with renal impairment 777 database studies, antidepressant associated hyponatraemia 416, 417 DBM see dibenzoylmethane DBS see deep brain stimulation DBT see dialectical behaviour therapy decision making, relational aspects 939–943 deep brain stimulation (DBS) 137, 227, 230, 592 delirium 245 analgesics causing 660 antibiotics association 662, 663 anticholinergic drug effects 654, 658 antipsychotics used to manage 117, 118 benzodiazepine reactions similar to 471 caffeine at high doses 902 clozapine adverse effects 245 constipation effects in dementia patients 658 ECT/lithium effects 384, 385 excited delirium see drug-induced excited states gamma--butyrolactone withdrawal 534, 537 GHB/GBL withdrawal 534, 537 haloperidol treating in older people 706 hyperthermia and drug-induced excited states 543 opioid effects 660 people living with human immunodeficiency virus 806 post-injection delirium sedation syndrome 76, 77, 91 delirium tremens, severe alcohol withdrawal 480, 481, 482, 486 demeclocycline 187, 188 dementia 630--653 Alzheimer's disease 630–647 antipsychotic prescriptions 119 drug recommendations and drugs to avoid 663–664

augmentation of antidepressants in unipolar depression 280 prophylaxis of unipolar depression 281 managing behavioural and psychological symptoms of dementia 672–673 menopausal women 858 multiple sclerosis 835 natural remedies St John's wort 440–443 taken without doctor's knowledge 442 NICE guidelines 336 nicotine effects 909 older people 688–693 Parkinson's disease 840 people living with human immunodeficiency virus 804–805 post stroke 393–396 in pregnancy 719–726 psychostimulants 388–392 psychotic symptoms 362–365 St John's wort 440–443 sexual dysfunction 426 stimulant use association 535 treatment resistant 348–356 use of benzodiazepines 461 see also antidepressants; bipolar disorder designer drugs see new psychoactive substances;

synthetic cannabinoids detoxification opioid substitution treatment 500 see also alcohol detoxification deutetrabenazine hepatic impairment 761 renal impairment 778 for tardive dyskinesia 136 dexamfetamine, attention deficit hyperactivity disorder in adults 798, 800 dextromethorphan, in overdose 914 DHA see docosahexanoic acid diabetes mellitus antidepressants 423–425 antipsychotic-related 174–181 comorbid depression 423 see also glucose homeostasis dialectical behaviour therapy (DBT), borderline personality disorder 787 diazepam 68 with alcohol 898 benzodiazepine withdrawal 540, 541 concentration in normal dosing and UK legal limit 923 switching from benzodiazepines 466 diazepam equivalent doses, benzodiazepines 466, 467 dibenzoylmethane (DBM), Alzheimer's disease management 645 DiGeorge syndrome (22q11.2 deletion syndrome) 820–823 diphenhydramine, clozapine-induced hypersalivation 259 direct-acting oral anticoagulants (DOACs) atrial fibrillation patients 845, 846 citalopram/escitalopram not affecting 394 possible SSRI interactions 394 renal function assessment 766 discontinuation symptoms when switching antidepressants 366–367 see also withdrawal discontinuation syndrome, donepezil 632 disinhibition benzodiazepines 471–473 clinical implications 472 incident rates 471 mechanism 472 risk factors 471–472 subjective reports 472 see also paradoxical/disinhibitory/aggressive drug reactions disruptive mood dysregulation disorder (DMDD), bipolar disorder relationship 574 distribution of drugs, changes with old age 628 disulfiram (Antabuse), preventing relapse after alcohol detoxification 491–492 diuretics, lithium interaction 285 diversion and misuse of prescribed drugs opioids 503, 512, 513, 514 stimulants for ADHD in adults 798, 799 DLB see dementia with Lewy bodies DOACs see direct-acting oral anticoagulants docosahexanoic acid (DHA) see omega-3 fatty acids doctor see clinician donanemab, Alzheimer's disease treatment 646 donepezil Alzheimer's disease treatment 630–637, 638, 640, 642 for tardive dyskinesia 137 dopamine and norepinephrine-reuptake inhibitors see bupropion dopaminergic agents and dopamine partial agonists, possible effects on impulse control disorders 560 dosage reduction see tapering dose-related adverse drug effects, increased in hepatic impairment 753 Driver and Vehicle Licensing Agency (DVLA), UK 923–924 driving and psychotropic medicines 921–926 duty of driver 923 duty of prescriber 924 effects of mental illness 921 medication-induced sedation 923 Index psychotropic drug groups causing impairments 922 UK General Medical Council guidelines for prescribers 924 UK law 921–923 driving restrictions, people with epilepsy 817 dronabinol, weight restoration in anorexia nervosa 792 droperidol 64, 65 drug administration see administration of medicines Drug Attitude Inventory (DAI) 931 drug half-life 866 see also pharmacokinetics drug-induced excited states 543–544 hyperthermia risk 543, 544 identification 543 illicit drugs 543–544 illicit and misused drugs 543–544 management 543–544 outcomes 544 pathophysiology 543 restraint risks 543 drug-induced parkinsonism see pseudoparkinsonism drug interactions acetylcholinesterase inhibitors 637–638, 638–639 alternative treatments used by menopausal women 858 antidepressants 339, 401–405 pharmacodynamic interactions 402, 404–405 pharmacokinetic interactions 401–402 atrial fibrillation patients 847 carbamazepine 297–298 changes with old age 627, 628–629 illicit drugs with prescribed psychotropic drugs 545, 546–548 lithium 284–286, 286 ACE inhibitors 284–285 sodium levels 284–285 memantine 637–638, 640 post stroke depression 393 valproate 292 drugs of misuse summary 549–553 see also diversion and misuse of prescribed drugs; illicit drugs; substance misuse and dependence dual diagnosis, substance misuse with mental illness 477 dual reuptake inhibitors adverse effects relative to other antidepressants 338 see also duloxetine; venlafaxine duloxetine borderline personality disorder 789 in overdose 914 in pregnancy 721 smokers 892

986 Index duty of managers of hospitals to give information to detained patients, S132 of the Mental Health Act
dyslipidaemia 169 clinical management 170–171 switching antipsychotics 207
dystonia extrapyramidal effects 127, 128 Huntington's disease 830, 831 see also
pseudoparkinsonism early-onset schizophrenia spectrum (EOSS) disorder 580 eating disorders
792–797 anorexia nervosa 792–794 atypical/eating disorders not otherwise specified 795 bulimia
nervosa/binge eating disorder 794–795 comorbid depression 794, 795 NICE guidelines 795
Ebstein's anomaly (cardiac malformation), lithium in pregnancy 723, 725 ECG changes,
antiretrovirals 807 ECT see electroconvulsive therapy efavirenz, psychiatric adverse reactions 808
eGFR see estimated glomerular filtration rate eicosapentaenoic acid (EPA) see omega-3 fatty acids
elderly people atrial fibrillation 845–848 genitourinary symptoms of menopause 861 optimising
lithium treatment for prophylaxis in bipolar disorder 327 electrocardiogram (ECG) monitoring
antipsychotic medication users 41, 165 methadone users with QT prolongation risk factors 506 see
also QTc prolongation electroconvulsive therapy (ECT) 108–110, 227 adverse effects 109 for
catatonia 155 children and adolescents 568, 569 drug resistant depression treatment 351
managing behavioural and psychological symptoms of dementia 675 in pregnancy 722 psychotic
depression treatment 363 psychotropic drug combination 384–386 S58a of the Mental Health Act
952–953 for treatment-resistant schizophrenia 108–109 electrolytes alcohol effects 898 anorexia
nervosa 793–794 antipsychotic medication monitoring 40 see also sodium levels electronic nicotine
vaping devices see nicotine vaping devices embolic events, SSRIs decreasing risk 433 emergency
situations, rapid tranquilisation 68–69 energy drinks, caffeine content 901, 904 environmental
lithium, high levels inversely related to suicide and dementia at a population level 279 eosinophilia
245 eosinophils, psychotropic agent effects 965 EOSS see early-onset schizophrenia spectrum
disorder EPA see eicosapentaenoic acid epilepsy 811–819 learning difficulties comorbidity 825
psychiatric comorbidities 811–812 see also people with epilepsy EPSEs see extrapyramidal side
effects EPS (extrapyramidal symptoms) see extrapyramidal side effects erectile dysfunction 199,
200 erythrocyte sedimentation rate, psychotropic agent effects 966 escitalopram smokers 893 use
in patients with hepatic impairment 761 esketamine, enantiomer of ketamine 357 esketamine
(intranasal) treatment resistant depression 336, 351, 357, 359 see also ketamine Espranor
orodispersible buprenorphine brand 507, 508 estimated glomerular filtration rate (eGFR), renal
impairment assessment 766 ethanol see alcohol excited delirium use of term 543 see also drug--
induced excited states excretion of drugs, changes with old age 628 excretory capacity of the
kidney, estimation in renal impairment assessment 766 expectations of treatment, placebo and
nocebo effects 941 extended release (ER) preparations intramuscular injections 955, 956
memantine for older adults 633 extended release preparations, see also long-acting injectable
antipsychotics; modified-release preparations; prolonged release injections; slow-release oral
morphine extrapyramidal side effects (EPSEs) 1–2, 3, 126–130 amisulpride 869 children 623
features of most common symptoms 127–128 first generation antipsychotics 580 high-dose
antipsychotics 56 methamphetamine use plus antipsychotics 534 patient sensitivity 75 people with
learning difficulties 825 people living with human immunodeficiency virus 804, 806 smoking
alleviating symptoms 909 switching antipsychotics 207 treatment 128 see also
pseudoparkinsonism family, improving medication adherence 932, 933 fasting plasma glucose
(FPG) test 176, 177 Fatal Toxicity Index (FTI), antidepressants 412 fatigue multiple sclerosis 837
psychostimulants to reduce in depression 388, 389 fentanyl dependence, buprenorphine low-dose
induction 509 ferritin in blood, psychotropic agent effects 962 FGAs see first-generation
antipsychotics financial incentives, improving adherence 933 first-generation antipsychotics (FGAs)
adverse effects 3–4, 49 bipolar disorder 300 children and adolescents 580 classification of 2

equivalent doses 14 impaired glucose tolerance and diabetes 174 long-acting injectable antipsychotics 75, 76 maximum doses 11, 12 minimum effective doses 8 nomenclature 49 penfluridol 106–107 people with learning difficulties 826 in pregnancy 715–716 relative efficacy 3 role of older antipsychotics 49–50 site of administration of intramuscular injections 954–955 treatment algorithm 46 treatment of negative symptoms 35 fish oils dyslipidaemia treatment 171 mild/moderate depressions in older adults 689 schizophrenia treatment/ prevention 111–114 for tardive dyskinesia 137 see also omega-3 fatty acids fixed-dose regimens, benzodiazepines for alcohol withdrawal management 485

fluid restriction, hyponatraemia treatment 187, 188 flumazenil, guidelines for use of 70 flunitrazepam, concentration in normal dosing and UK legal limit 923 fluoxetine bipolar depression 322 borderline personality disorder 789 bulimia nervosa 794 children and adolescents autism spectrum disorder 610 depression/bipolar disorder 566–568, 569, 570–571, 574 'off-label' prescribing 947 in pregnancy 720 suicidality in children and adolescents 566, 570–571, 588, 610 flupentixol bipolar disorder 305, 306 borderline personality disorder 789 long-acting injection doses and frequencies 77 pharmacokinetics 81 fluphenazine, smokers 893 fluvoxamine for antipsychotic--induced weight gain 145 smokers 893 for tardive dyskinesia 137 folic acid, Alzheimer's disease management 643 forms T2 and T3, Mental Health Act 950 forms T4/T5/T6, Mental Health Act 952--953 formulations of drugs impaired absorption following bariatric surgery 849 problems with tablets when tapering 382 FPG see fasting plasma glucose test FRAMES principles (feedback, responsibility, advice, menu, empathy, self-efficacy), NICE public health guidance on harmful drinking 479 frontotemporal dementias 648–649 FTI see Fatal Toxicity Index full blood count, antipsychotic medication monitoring 40 galantamine Alzheimer's disease 630–636, 639, 642 mild cognitive impairment 636 gambling disorder 560 gamma-aminobutyric acid A (GABA-A) 897 gamma-butyrolactone (GBL; pro-drug of GHB) 537–539 see also gamma-hydroxybutyrate and gamma-butyrolactone gamma-glutamyl transferase (GGT), psychotropic agent effects 963 gamma-hydroxybutyrate (GHB) and gamma-butyrolactone dependence 537–539 planned elective withdrawal 538–539 unplanned withdrawal 538 withdrawal management 537–539 withdrawal syndrome 534, 537 GASS see Glasgow Antipsychotic Side-effect Scale gastro-esophageal reflux disease (GERD) 22q11.2 deletion syndrome 820 clozapine 241 gastrointestinal bleeding, SSRI risks 433–434 gastrointestinal disorders, drug safety in older patients/dementia 658–659 gastrointestinal disturbances, antiretrovirals 807 gastrointestinal hypomotility, clozapine-induced 263–266 gastrointestinal irritant drugs, increased risk of bleeding in hepatic impairment 753 gastrointestinal necrosis 245 GBL see gamma-butyrolactone G-CSF see granulocyte-colony stimulating factor generalised anxiety disorder (GAD) NICE guidelines 448 pregabalin 447–448 specific drugs used 449–450 SSRIs/SNRIs 446 valproate treatment 290 generalised seizures, severe alcohol withdrawal 480, 481 General Medical Council, UK, guidelines for prescribers, medical conditions and safe driving 924 genetics of cytochrome function 888–891 genetic testing, for clozapine treatment 275--277 genitourinary symptoms of menopause (GSM) 857, 861, 862 gestational diabetes, antipsychotics risk 716–717 GFR see glomerular filtration rate GGT see gamma-glutamyl transferase GHB see gamma-hydroxybutyrate Ginkgo biloba 136, 222, 227, 641, 643 G see gamma-hydroxybutyrate and gamma-butyrolactone GABA-A see gamma-aminobutyric acid A gabapentin borderline personality disorder 789 tardive dyskinesia 137 use in patients with hepatic impairment 761 gabapentinoids (GABA analogues), addiction/physical dependence and withdrawal 464, 465, 469 GAD see generalised anxiety disorder galactorrhoea 196 Index ginseng, Alzheimer's disease management 643 Glasgow Antipsychotic Side-effect Scale (GASS) 4 glomerular filtration

rate (GFR), estimation for renal impairment assessment 766 glucocorticoid receptor blocking, psychotic depression treatment 364 glucose in blood, psychotropic agent effects 963 glucose homeostasis antidepressant effects 423-425 SSRIs improving control 423 see also diabetes mellitus glucose tolerance impairment, antipsychotic-related 174-181, 207 glutamate, role in cognitive function/ dementia 630, 631, 672 glycated haemoglobin (HbA1c) 53, 175, 176, 177, 424, 432, 963 glycopyrrolate, clozapine-induced hypersalivation 259 gonadotrophin-releasing hormone agonists, medical menopause induction test 475 granulocyte-colony stimulating factor (G-CSF) 270-271 GSM see genitourinary symptoms of menopause guanfacine attention deficit hyperactivity disorder in adults 799, 801 clozapine-induced hypersalivation 259 gynaecological and obstetric haemorrhage, SSRI risks 435-436 H2 see histamine-2 HAD see HIV-associated dementia haematological effects of psychotropics 959, 965-966 haemodialysis, depression treatment 769 haemoglobin, psychotropic agent effects 966 half-life of drugs 866 see also pharmacokinetics haloperidol 8, 11, 14, 43, 49, 50 acute behavioural disturbance 62, 63, 65 clozapine augmentation 221 intravenous administration 117 long-acting injections, doses and frequencies 77 pharmacokinetics 81 possible teratogen 716 smokers 893 haloperidol decanoate 11, 14 Hamilton Depression Rating Scale (HAM-D), drug effect assessment 337, 345 HAND see HIV-associated neurocognitive disorders HbA1c see glycated haemoglobin

988 Index HD see Huntington's disease HDL see high-density lipoprotein cholesterol heat stroke 245 hepatic CYP enzymes antidepressant interactions 401-402, 403 see also cytochrome function hepatic damage clozapine induced 245 hepatitis B and C infection effects 545 toxicity assessment in new drugs 762 valproate induced 291 hepatic encephalopathy, from reduced drug metabolism in hepatic impairment 753, 754 hepatic impairment in patients 753-767 antidepressants 753, 757--758, 761 antipsychotics 754-756, 761 lower starting doses recommended 753-754 mood stabilisers 759, 761 sedatives 754, 760, 761 stimulants 760 hepatitis B and C infections, drug metabolism effects 545 hepatotoxicity assessment in new drugs 762 avoiding known drugs in hepatically impaired patients 754 herbal medicine see natural remedies high-density lipoprotein (HDL) cholesterol 169 high-dose antipsychotics 17 adverse effects 18 efficacy 17-18 recommendations 19 highly protein-bound drugs, increased toxicity in hepatic impairment 753-754 hirudin, Alzheimer's disease management 643 histamine-2 (H2) antagonists, safety in older patients/dementia 662 HIV, see also human immunodeficiency virus; people living with human immunodeficiency virus HIV-associated dementia (HAD) 806 HIV-associated neurocognitive disorders (HAND) 806 HIV mania, secondary mania in people living with human immunodeficiency virus 805 hormonal treatments, premenstrual syndrome 474-475 hormone replacement therapy (HRT) 861-863 adverse effect management 863 depression/anxiety treatment for menopausal women 858 local treatments for GSM 861, 862 products and regimens 861, 862, 863 risks 861 starting treatment 863 versus raloxifene for psychosis treatment in menopausal women 860 hospital managers, duty to give information to detained patients under S132 of the Mental Health Act 952 HRT see hormone replacement therapy 5HT6 receptor antagonist, Alzheimer's disease management 644 human immunodeficiency virus (HIV) 803-810 treatment advances 804 see also people living with human immunodeficiency virus Huntington's disease (HD) 830-834 cognitive symptoms 834 general principles of pharmacological symptom management 830-831 mental and behavioural symptoms 831-833 motor symptoms 830-831 huperzine A, Alzheimer's disease management 643 hyperbolic tapering antidepressants 366, 376, 379, 382 benzodiazepine 467 lithium for bipolar disorder 333 hypercalcaemia, lithium 282 hypercholesterolaemia 170 hyperglycaemia 174, 186 hyperlipidaemia 170, 171, 186 hyperparathyroidism, lithium 282

hyperprolactinaemia 2, 24, 41, 50, 190–194, 196 antidepressants 420–422 contraindications 191 effects of antipsychotic medication on prolactin concentration 190 management 191, 192 switching antipsychotics 207 hypersalivation 258–262 clozapine 241 oral anticholinergic agents, safety in older patients/dementia 660 treatment 258, 259–260 hypersensitivity reactions, drug-induced hepatic damage 762 hypertension 41, 183–184, 241 hyperthermia, drug-induced excited states 543, 544 hypertriglyceridemia 169, 171 hypnotic effect, benzodiazepines 460 hypnotics breastfeeding mothers 736, 746 driving impairment 922 in pregnancy 727 use in renal impairment 776–777 hypoalbuminaemia, hepatic impairment 753, 754 hypoglycaemia 898 hypokalaemia, anorexia nervosa 793–794 hypokinetic phase/rigidity, Huntington’s disease 830, 831 hypomania, treatments 310–315 hyponatraemia 186–189 antidepressants 416–419 lithium retention and toxicity 286 other psychoactive prescribed drugs 418 and syndrome of inappropriate antidiuretic hormone 186, 188 treatment 187–188 and water intoxication 186 hypo-oestrogenic states, high prolactin levels in menopausal women 860 hypophosphataemia, anorexia nervosa 794 hypotension 41, 43, 44 clozapine 241 orthostatic 182–183, 207 hypothermia 245 hypothyroidism, lithium risk 282 Hy’s rule, assessment of hepatotoxicity of new drugs 762 iatrogenic dependence, benzodiazepines/ z-drugs/gabapentinoids 464, 540 idalopirdine (5HT₆ receptor antagonist), Alzheimer’s disease management 644 ideational perseveration, Huntington’s disease 832 illicit drugs drug-induced excited state 543–544 drugs of misuse summary 549–553 interactions with prescribed psychotropic drugs 545–548, 546–548 see also new psychoactive substances; substance misuse and dependence iloperidone 8, 12, 15, 43, 915 IM see intramuscular... immediate-release (IR) preparations attention deficit hyperactivity disorder treatments 600, 620, 799, 800 medication doses for older adults 633, 700 modified release stimulant preparations preferred in adults 799 impulsive behaviour, disinhibitory drug reactions, benzodiazepines 471–473 inappropriate sexual behaviour in older people 680–687 incongruence of affect, multiple sclerosis 836 infant exposure relative infant dose 734 see also breastfeeding inhaled administration acutely disturbed/violent patients 62 antipsychotics 62, 115, 116 injectable diamorphine, prescribing guidelines for opioid dependency 514

injections site of administration of intramuscular injections 954–958 see also long-acting injectable antipsychotics in-patient detoxification, alcohol withdrawal 482 INR see international normalised ratio in situ microparticle technology see risperidone ISM insomnia melatonin use in children and adolescents 575, 609–610, 620–622 menopausal women 858 people living with human immunodeficiency virus 805, 808, in pregnancy 726–727 see also sleep disturbance integrase strand transfer inhibitors, psychiatric adverse reactions 809 intentional non-adherence 932 interferons- α and - β , psychiatric adverse effects 971 international normalised ratio (INR), psychotropic agent effects 967 interstitial lung disease 245 interstitial nephritis 245 intracranial/intracerebral haemorrhage, SSRI risks 434–435 intramuscular (IM) injections, acute behavioural disturbance 62–66 intranasal antipsychotics 115, 116–117 intranasal esketamine, treatment resistant depression 336, 351, 357, 359 intranasal ipratropium, clozapine-induced hypersalivation 259 intranasal naloxone 499 involuntary movements, abnormal see tardive dyskinesia ipratropium nasal spray, clozapine-induced hypersalivation 259 IR see immediate-release preparations irritability (aggression, self-injurious behaviour, and severe disruptive behaviours), children and adolescents with autism spectrum disorder 608 irritability and agitation, Huntington’s disease 832, 833 isotretinoin, psychiatric adverse effects 971 racemic mixture 357 route of administration 357–358 treatment resistant depression 351, 357–361 see also esketamine ketoacidosis, diabetic 174, 175 kidneys see chronic kidney disease; renal... knee-buckling 245

lactate in blood, psychotropic agent effects 963 LAI see long-acting injectable antipsychotics
lamotrigine borderline personality disorder 789 clozapine augmentation 221 life-threatening
cutaneous reactions 937 in overdose 916 restarting after period of non-compliance 937, 938
target range 868 laxative misuse/abuse 792, 961, 962 laxatives 239, 241, 264-265, 658, 882 LDL
see low-density lipoprotein cholesterol learning difficulties 824-829 capacity and consent 824-825
epilepsy comorbidity 825 general considerations 824 prescribing practice 824-825 lecanemab,
Alzheimer's disease treatment 646 legal issues Mental Health Act England and Wales (1983) 949--
953 'off label' prescribing 945-946 UK drug-driving law 921-923 see also capacity and consent
lemborexant managing sleep disturbance in dementia 674 in overdose 917 use in patients with
hepatic impairment 761 leukopenia, psychotropic agent effects 966 levetiracetam, for tardive
dyskinesia 137 Levodopa, hypokinetic rigidity in Huntington's disease 831 levomepromazine 11, 43
Lewy body dementia 630, 642, 648, 649, LFTs see liver function tests libido 196, 199 linaclotide,
for constipation treatment 265 lipids see plasma lipids lipoproteins in blood, psychotropic agent
effects 963 liraglutide, for antipsychotic-induced weight gain 145 lisdexamfetamine attention
deficit hyperactivity disorder in adults 798-800 borderline personality disorder 789 bulimia
nervosa/binge eating disorder 795 KarXT (xanomeline-trospium), Alzheimer's disease management
645 ketamine 65, 68, 357-361 anti-suicidal effects 339 bipolar depression 321 borderline
personality disorder 790 dosing recommendations 358 mechanism of antidepressant action 357
'off-label' prescribing 947 in overdose 914 psychotic depression treatment 363 Index lithium 279--
288 adherence/non-compliance limiting effectiveness 284 adverse effects 282-283 with alcohol
899 augmentation of antidepressants in unipolar depression 280 bariatric surgery patients 852,
853 bipolar disorder 279-288 depression 280 mania 279-280, 310, 311 stopping treatment 331--
334 suicide risk 281 borderline personality disorder 789 with caffeine 903 clinical indications 279--
281, 284 clozapine use with 269-270, 271 depression treatment 280-281 discontinuation 283-284
driving impairment 922 drug interactions 283, 284-286 environmental concentration inversely
related to suicide and dementia at a population level 279 formulations 282 mania, acute treatment
279-280, 310, 311 mechanism of action 279 on-treatment monitoring 283, 284 optimising
treatment for different ages 327 in overdose 916 patients on long-term lithium 280 people with
learning difficulties people living with human immunodeficiency virus 805 plasma levels 281
postpartum 736 in pregnancy 723, 725 pre-treatment tests 283 prophylaxis for unipolar depression
281, 399 renal effects 282, 285 renal function assessment 766 target range 868 teratogenicity 283
thyroid effects 282 toxicity 282-283 use in patients with hepatic impairment 754, 759, 761
withdrawal effects 331-332 liver function tests (LFTs) interpretation 753, 762 monitoring to assess
drug effects 41, 754, 762 see also hepatic damage lofepramine, in overdose 914 lofexidine,
clozapine-induced hypersalivation 259 lone atrial fibrillation 845

990 Index long-acting injectable (LAI) antipsychotics 4, 7, 23, 29, 74-80 advice on prescribing 75--
76 aripiprazole 85-89 for bipolar disorder 83-84, 300, 301, 302, 305-306, 326-327 clozapine
augmentation 221 differences between 76 doses and frequencies 77-78 equivalent doses 14, 15
management of patients 83-84 maximum doses 11, 12 for menopausal women 859 olanzapine
90-92 paliperidone palmitate 93-98 risperidone 94, 99-105 test doses 75 long-acting oral
antipsychotics improving adherence 933 preventing sudden cessation 932-933 restarting after
period of non-compliance 937 loop diuretics, lithium interaction 285 loperamides, safety in older
patients/ dementia 658 lorazepam 68, 155 catatonia treatment 155 concentration in normal dosing
and UK legal limit 923 rapid tranquillisation of children and adolescents 623 use in patients with
hepatic impairment 761 low-density lipoprotein (LDL) cholesterol 169 low-dose aspirin co--

prescribed with SSRIs, GI bleeding risk 433, 434 loxapine 43, 893 lumateperone 8, 12, 15, 43, 208, 915 lung disease, interstitial 245 lurasidone 8, 11, 15, 43 bipolar depression 302 cardiac safety of 164 clozapine augmentation 221 in overdose 916 QTc prolongation 164 lymphocytes, psychotropic agent effects 966 MADRS see Montgomery-Asberg Depression Rating Scale maintenance for drug dependence, opioid substitution treatment 500, 501-504 maintenance phase, children and adolescents with depression 570 maintenance treatment bipolar disorder 326-330 psychotic depression 363-364 schizophrenia 29, 53 major depressive disorder (MDD) 335-361 bipolar depression comparison 319 older people 688 see also depression malabsorptive surgical procedures, bariatric surgery 849 mania people living with human immunodeficiency virus 805 treatment in children and adolescents 575-576 mania (bipolar disorder) antipsychotics 300, 301, 302, 311 benzodiazepines 310, 311-312 carbamazepine 295 lithium treatment 279-280 treatment options 310-315 valproate treatment 289-290 manic switch, depression in children and adolescents 571 MAOIs see monoamine oxidase inhibitors MARS see Medication Adherence Rating Scale MCI see mild cognitive impairment MDD see major depressive disorder MDRD see Modification of Diet in Renal Disease mean cell haemoglobin concentration, psychotropic agent effects 966 medical foods, Alzheimer's disease management 644 medical menopause, assessing premenstrual syndrome/premenstrual dysphoric disorder 475 Medication Adherence Rating Scale (MARS) 931 medication-taking aids 932 melatonin adverse effects, children and adolescents 621 for antipsychotic-induced weight gain 146 children and adolescents 620, 621, 626 description 620 efficacy 620 managing behavioural and psychological symptoms of dementia 674 'off-label' prescribing 947 sleep disturbance/insomnia treatment, children and adolescents 575, 609-610, 620-622, 626 for tardive dyskinesia 137 melperone 15 memantine 222, 227 Alzheimer's disease 630-634, 636-637, 640, 641 borderline personality disorder 789 immediate release versus extended release 633 managing behavioural and psychological symptoms of dementia 671 methods of action in AD treatment 630, 631 vascular dementia 647 memory, clinicians' procedural memory and unconscious influences 939 menopause 857-864 depression/anxiety 858 diagnosis 857 elderly care 861 genitourinary symptoms and treatments 857, 861, 862 hormone replacement therapy 861-863 increased adiposity effects 859-860 psychological symptoms 857, 858-860 psychosis 858-860 mental capacity see capacity and consent Mental Health Act (MHA), England and Wales (1983) 629, 682, 694-698, 949-953 mephedrone, misuse and dependence 533, 537, 543 metabolic abnormalities, antiretrovirals 808 metformin for antipsychotic-induced weight gain 146 possible mood improvement in type II diabetes 424 methadone buprenorphine comparison 503 cautions 505-506 general hospital settings 504, 505 hepatic/renal dysfunction 505 initiation of treatment 504 intoxication 505 opioid substitution treatment 501, 503-506 in overdose 506, 917 psychiatric hospital settings 504-505 titration schedules 504, 505 transferring back from buprenorphine 512-513 transition to buprenorphine 510-512 withdrawal 516 methamphetamine use disorder 533-534 detoxification 534 psychotic symptoms 534-535 methylphenidate attention deficit hyperactivity disorder in adults 798-800 borderline personality disorder 789 driving impairment 922 people with learning difficulties 827 in pregnancy 727 psychotic depression treatment 364 metreleptin, weight restoration in anorexia nervosa 792 MHA see Mental Health Act (MHA) MI see myocardial infarction mianserin, in overdose 914 microdeletion syndrome, 22q11.2 deletion syndrome 820-823

midazolam 64, 65 mild alcohol withdrawal 480 mild cognitive impairment (MCI), treatments 636, 643, 646, 648 mild neurocognitive disorder (MND), HIV related 806 mineral supplements anorexia nervosa 793 see also nutritional supplements minimum effective doses antidepressants 342, 366

antipsychotics 8 determining for patient 84 minocycline 226, 227 mirtazapine in overdose 914 in pregnancy 721–722 smokers 893 weight restoration in anorexia nervosa 792 missed doses of psychotropic medication 937 MND see mild neurocognitive disorder moclobemide 914 modafinil for antipsychotic-induced weight gain 146 depression 388 fatigue in multiple sclerosis 837 not recommended in pregnancy 727 in overdose 917 Modification of Diet in Renal Disease (MDRD) formula, glomerular filtration rate estimation 766 modified-release (MR) preparations methylphenidate 600 stimulants for attention deficit hyperactivity disorder in adults 798, 799, 800 see also extended release preparations; slow-release oral morphine molindone 12, 15 monoamine oxidase inhibitors (MAOIs) adverse effects, relative to other antidepressants 338 with alcohol 899 with caffeine 903 electroconvulsive therapy combination 385 glucose homeostasis 423, 424 hyponatraemia 416, 417, 418 interaction with tyramine-containing foods 338–339 not recommended for people living with human immunodeficiency virus 805 not recommended in pregnancy 722 in overdose 914 pharmacodynamic drug interactions 404–405 serotonin syndrome 367 swapping and stopping antidepressants 368 monoclonal antibodies, Alzheimer's disease treatment 646 monocytes, psychotropic agent effects 966 montelukast, psychiatric adverse effects 971 Montgomery-Asberg Depression Rating Scale (MADRS), drug effect assessment 345 Montgomery vs Lanarkshire Health Board appeal case decision, 'off-label' prescribing 945 mood disorders caffeine effects 905 see also bipolar disorder; depression mood elevation, psychostimulants use in depression 388 mood stabilisers adverse effects, rationale for reducing/ stopping 331 with alcohol 899 bariatric surgery patients 852 bipolar depression 319 bipolar disorder 279–299, 310–311 stopping treatment 331–334 borderline personality disorder 789 breastfeeding mothers 736, 744–745 combinations for rapid-cycling bipolar affective disorder 316 managing behavioural and psychological symptoms of dementia 673 non-antipsychotic agents for bipolar illness in pregnancy 723–725 in overdose 916–917 use in patients with hepatic impairment 759, 761 use in renal impairment 775–776 withdrawal effects 331–332 see also carbamazepine; lithium; valproate mood-stabilising anticonvulsants, chronic kidney disease risk 769 mortality antipsychotic polypharmacy versus monotherapy 22, 23 antipsychotics versus other risk factors 166 cardiovascular with antipsychotics 18, 166, 176 diabetes-related with antipsychotics 174 drug-induced hyperthermia 544 neuroleptic malignant syndrome 151 motivation of patients adherence 929, 932, 933 readiness to change 940 movement disorders, and nicotine 910 MR see modified--release MS see multiple sclerosis multiple sclerosis (MS) 835–839 anxiety 836 bipolar disorder 836 cognitive impairment 837 depression 835 fatigue 837 Index pseudobulbar affect 836 psychosis 836–837 multisubstance misuse see polysubstance abuse muscle rigidity see pseudoparkinsonism muscular spasm, uncontrolled see dystonia mutual aid and peer support, stimulant abstinence 532 myasthenia gravis, acetylcholinesterase inhibitors use in older patients/ dementia 660 myocardial function effects, drug-induced excited states 543 myocardial infarction (MI), SSRI protective effects 433 myocarditis 253–254, 255 myoclonus clozapine 241, 871 Huntington's disease 831 lithium 269 nalmefene, alcohol dependence 490–491 naloxone buprenorphine combination (Suboxone) 513 injection or intranasal treatment 499 opioid overdose treatment 499 naltrexone for antipsychotic--induced weight gain 146 borderline personality disorder 789 gambling disorder 560 'off-label' prescribing 947 people with learning difficulties 827 preventing relapse after alcohol detoxification 490 preventing relapse after opioid detoxification 517–518 for tardive dyskinesia 137 NAPLS see North American Prodromal Longitudinal Studies Naranjo adverse drug reaction scale (adapted) 972, 973 National Confidential Inquiry into Suicide and Homicide by People with Mental Illness 928 National Institute for Health and Care Excellence (NICE) guidelines anxiety spectrum disorders 448–449 attention deficit hyperactivity disorder in adults 800 attention deficit hyperactivity

disorder in children and adolescents 599 borderline personality disorder 788 dementia 642
depression 336 eating disorders 795 generalised anxiety disorder 448 hypercholesterolaemia 170
obsessive compulsive disorder 449 panic disorder 448 prophylaxis in bipolar disorder 327

992 Index National Institute for Health and Care Excellence (NICE) guidelines (cont'd) psychotic
disorder monitoring 176 relapse prevention after alcohol detoxification 489, 490, 492 schizophrenia
2, 52-54 National Poisons Information Service (NPIS) 538 natural remedies Alzheimer's disease
management 641, 643 drug interactions in menopausal women 858 Ginkgo biloba 136, 222, 227,
641, 643 non-standardised preparations 440, 441 potential risks 442 St John's wort 440-443 taken
without doctor's knowledge 442 nausea, clozapine 241 NbN see Neuroscience-based Nomenclature
NE see norepinephrine negative predictive value (NPV) 275 neonatal problems first-generation
antipsychotics risk 716 tricyclic antidepressant withdrawal 720 nephritis, interstitial 245
nephrotoxic drugs, renal function assessment 766 Netherlands Clozapine Collaboration Group 267
NEURAPRO trial 111-112 neurocognitive disorders HIV related 806 inappropriate sexual behaviour
in older people 680-687 see also dementia neurodevelopment, antipsychotic exposure during
pregnancy 717-718 neuroleptic malignant syndrome (NMS) 150-153 catatonic stupor in 155, 156
renal impairment 769 restarting antipsychotics 150 risk factors 150, 151 signs and symptoms 150
treatment 150, 151 neurological conditions, rare dementias 649 neuromodulation stimulant use
disorder 533 see also transcranial magnetic stimulation Neuroscience-based Nomenclature (NbN)
2, 49 neurotoxicity, lithium 283 neutropenia agranulocytosis 267-268 benign ethnic neutropenia
268, 269 clozapine-related 251, 267-272 granulocyte-colony stimulating factor 270-271 lithium
269-270 neutrophils, psychotropic agent effects 966 new psychoactive substances (NPSs/designer
drugs) 477, 540, 543, 544 NICE see National Institute for Health and Care Excellence nicotine 908--
911 attention deficit hyperactivity disorder 909 depression and anxiety 909 drug interactions 910
movement disorders 910 Parkinson's disease 910 psychotropic effects 908 schizophrenia 908-909
smoking cessation and withdrawal symptoms 910 see also smoking nicotine dependence 523-531,
910 bupropion 527, 529 cytisine 526, 529 electronic vaping devices 527-528, 530 nicotine
replacement therapy 523-524, treatment algorithms 528-530 varenicline 524-526 withdrawal
symptoms 910 nicotine replacement therapy (NRT) 523-524 adverse effects 524 clinical
effectiveness 524 combination of formulations 524, 529-530 preparations and doses 525, 529-530
nicotine vaping devices (vaping) 527-528, 530 adverse effects 528 clinical effectiveness 528
preparations and doses 528, 530 N-methyl-D-aspartate (NMDA) receptor antagonists Alzheimer's
disease 630 see also ketamine NMS see neuroleptic malignant syndrome placebo effects, patient
expectations of treatment 941 nocturnal enuresis, management 242 non-adherence impacts 928--
929 lithium 284 rates and degrees of adherence 927-928 restarting psychotropic medications after
period of non-compliance 937-938 non-competitive N-methyl-D-aspartate receptor antagonists 630
non-compliance see non-adherence non-iatrogenic benzodiazepine dependence 540 non--
nucleoside reverse transcriptase inhibitors 808-809 non-steroidal anti-inflammatory drugs (NSAIDs)
Alzheimer's disease management 644-645 co-prescribed with SSRIs, GI bleeding risk 433, 434
lithium interactions 285-286 safety in older patients/dementia 660 norclozapine 871
norepinephrine (NE)-modulating agents see viloxazine norepinephrine (NE)-reuptake inhibitors see
atomoxetine; bupropion North American Prodromal Longitudinal Studies (NAPLS) 112 NPIS see
National Poisons Information Service NPSs see new psychoactive substances NPV see negative
predictive value NRT see nicotine replacement therapy NSAIDs see non-steroidal anti-inflammatory
drugs nucleoside reverse transcriptase inhibitors, psychiatric adverse reactions 808 nutritional
supplements Alzheimer's disease management 643, 644 anorexia nervosa 793-794 fatigue in

multiple sclerosis 837 obesity 145, 145–146, 166, 169, 176, 580, see also weight gain Objective Opiate Withdrawal Scale (OOWS) 501 object relations 939 obsessive compulsive behaviours, Huntington's disease 832, 833 obsessive compulsive disorder (OCD) alternative and experimental treatments 591 children and adolescents 587–594 with autism spectrum disorder 610 clinical guidance 587, 588–589 need for drug treatment 587 psychological therapies 587 SSRI use 588 NICE guidelines 449, 588–589 specific drugs used 453–454 SSRIs/SNRIs 447 treatment duration and follow-up 591 treatment initiation 589 treatment-refractory cases 590 use of adult treatments 592 obstetric and gynaecological haemorrhage, SSRI risks 435–436 OCD see obsessive compulsive disorder ocular effects, and antipsychotics 245 oesophageal varices, consequences of reduced hepatic blood flow 753 oestrogen antipsychotics effects 858 decline in menopausal women 857, 858, 860 selective oestrogen receptor modulators 860

oestrogen augmentation psychosis treatment adjunct for menopausal women 860 see also hormone replacement therapy 'off-label' prescribing (outside a drug's licensed indications) 945–948 legal issues 945–946 recommendations 946–947 OGTT see oral glucose tolerance tests Okedi see risperidone ISM olanzapine acute behavioural disturbance 62, 63 acute kidney injury risk 769 bipolar depression 322 bipolar disorder 302, 310 borderline personality disorder 788 children and adolescents, adverse effects 573, 574 dose reductions 121, 122 doses and frequencies 77, 90 efficacy 3 glucose tolerance impairment association 175 linear dose reductions 121 long-acting injections 90–92 in overdose 916 pharmacokinetics 81 plasma level monitoring 871–872 plasma lipids, effect on 169–170 post-injection delirium sedation syndrome 91 rapid-cycling bipolar affective disorder 316 risks in pregnancy 716, 717 smokers 893 stopping 90 suppositories 118 target range 869 weight restoration in anorexia nervosa 792 olanzapine/fluoxetine combination, children and adolescents with bipolar depression 574, 577 olanzapine pamoate 11, 15 olanzapine/samidorphan combination, bipolar disorder 302 older people 627–712 Alzheimer's disease 630–647 behavioural and psychological symptoms of dementia management 667–679 covert administration of medicines in food and drink 629, 694–699 dementia 630–687 depression 688–693 dose recommendations for common psychotropics 700–712 general prescribing principles 627–629 inappropriate sexual behaviour 680–687 safer prescribing/cognitive risks 654–666 omega-3 (polyunsaturated) fatty acids (fish oils or supplements) Alzheimer's disease management 643 borderline personality disorder 790 dyslipidaemia treatment 171 mild/moderate depressions in older adults 689 schizophrenia treatment and prevention 111–114, 221 tardive dyskinesia 137 ondansetron 137, 226, 228 OOWS see Objective Opiate Withdrawal Scale opioid antagonists, borderline personality disorder 789 opioid dependence 498–522 changes in prescribing practice 498 overdoes 498–499 prescribing psychotropic medications 515 timecourse of withdrawal symptoms 501 opioid receptor agonists, buprenorphine blocking other opioids 506, 507 opioids detoxification and reduction regimens 516–518 diversion potential of prescribed substances 503, 512, 513, 514 driving impairment 922 misuse 498–522 overdose risk after detoxification 518 overdose symptoms and treatment 498–499 psychiatric adverse effects 969 relapse prevention with naltrexone 517–518 safe storage importance 505 safety in older patients/ dementia 660–661 transferring from prescription drugs to buprenorphine 512 opioid substitution treatment (OST) 500–519 alternative oral preparations 514 induction and stabilisation of maintenance treatment 501 injectable diamorphine 514 pain control in patients 518–519 relapse prevention with naltrexone 517–518 safe prescribing 501 slow-release oral morphine 514 see also buprenorphine; methadone opioid withdrawal buprenorphine 516–517 community settings 516–517 methadone 516 specialist addiction in-patient settings 517 timecourse of symptoms 501 treatment of

symptoms 515 validated scales 501 Index oral glucose tolerance tests (OGTT) 176, 177 oral nicotine products see nicotine replacement therapy orexin antagonists see lemborexant; suvorexant orlistat for antipsychotic-induced weight gain 146 for constipation treatment 265 orodispersible drug administration, Espranor/buprenorphine 507–508 orthostatic hypotension 182–183, 207 OST see opioid substitution treatment osteoporosis, anorexia nervosa risk 794 overdose, psychotropics in 913–920 oxazepam catatonia treatment 155 concentration in normal dosing and UK legal limit 923 use in patients with hepatic impairment 761 oxcarbazepine, risks in pregnancy 724 P450 (CYP) pathways inhibition by different SSRIs 339 see also cytochrome function packed cell volume, psychotropic agent effects 966 paediatric autoimmune neuropsychiatric disorder associated with Streptococcus (PANDAS) 617 pain control for patients on opioid substitution treatment 518–519 see also analgesics paliperidone pharmacokinetics 81 target range 869 use in patients with hepatic impairment 761 paliperidone palmitate long-acting injections 29, 31, 93–98 dose and administration 11, 77, 93 pancreatitis 246 panic disorder NICE guidelines 448 specific drugs used 450–451 SSRIs/SNRIs 446–447 use of benzodiazepines 446 paracetamol (acetaminophen) for behavioural and psychological symptoms of dementia 668 hepatotoxicity 762 pain in alcohol withdrawal 489 safety in older patients/dementia 660 paradoxical disinhibitory/aggressive drug reactions, benzodiazepines 471–473 parenteral thiamine, prophylaxis against Wernicke's encephalopathy in alcohol dependency 484–485

994 Index parenteral treatment, for acutely disturbed/ violent patients 62–65 parkinsonian symptoms dementia with Lewy bodies 648 see also pseudoparkinsonism Parkinson's disease (PD) 840–844 cholinesterase inhibitors 842 complementary therapies 842 depression 840 and nicotine 910 pimavanserin use 842 psychiatric adverse effects of treatments 970 psychosis 841–842 parotid gland swelling 246 paroxetine in pregnancy 720 use in patients with hepatic impairment 761 paroxysmal atrial fibrillation 845 pathological laughing or crying (pseudobulbar affect), multiple sclerosis 836 patient factors, affecting adherence 940–942 patient monitoring bipolar disorder 283, 291, 297, 308–309 mitigating serious consequences of non-adherence 928 plasma level monitoring of psychotropic drugs 865–878 PD see Parkinson's disease PDSS see post-injection delirium sedation syndrome penfluridol 43, 106–107 people with epilepsy (PWE) 811–819 driving restrictions 817 drug interactions between antiseizure medications and psychotropics 813–814 possible causes of psychiatric symptoms 811–812 prescribing principles 811 psychiatric comorbidities 811–812 psychiatric side effects of antiseizure medications 812–813 seizure risk from psychotropic drugs 814–817 people living with human immunodeficiency virus (PLWH) 803–810 bipolar affective disorder 805 depression 804–805 factors contributing to psychiatric symptoms 803 prescribing principles 803–804 psychosis 804 secondary mania 805 see also human immunodeficiency virus pericardial effusion 246 pericarditis 246 pericyazine 11, 14 perimenopause 857, 861 perioperative blood loss, SSRI risks 436–437 permanent atrial fibrillation 845 perospirone 12 perphenazine 11, 14, 43 Perseris (RBP-7000) 101–102 persistent atrial fibrillation 845 personal and cultural beliefs, influencing adherence 940 personality disorders antipsychotic prescriptions 119, 331 benzodiazepines causing disinhibition 472 substance misuse 477 see also borderline personality disorder P-glycoprotein (P-gp) 883 pharmacodynamic drug interactions with alcohol 897–898 antidepressants 339, 402, 404–405 antiretroviral drugs and psychotropics 807–808 antiseizure medications and psychotropics 814 pharmacodynamics changes in older people 627–628 menopause effects 858 pharmacokinetic drug interactions antidepressants 401–402, 403 antiretroviral drugs and psychotropics 807 antiseizure medications and psychotropics 813 pharmacokinetics 865–899 caffeine 902–903 changes in older people 627, 628 cytochrome

function 883–891 depot antipsychotics 81 drug interactions with alcohol 895–899 half-life increased in hepatic impairment 754 impaired drug absorption following bariatric surgery 849 menopause effects 858 plasma level monitoring of psychotropic drugs 865–878 postmortem blood concentrations 879–880 smoking and psychotropic drugs 892–894 phenothiazines, in overdose 916 phenytoin, target range 869 phosphate in blood, psychotropic agent effects 964 pimavanserin 8, 12, 15, 208 managing behavioural and psychological symptoms of dementia 675 use in Parkinson's disease 842 pitolisant 761, 778, 917 placebo and nocebo effects, patient expectations of treatment 941 plasma creatine kinase (CK) 150 plasma drug levels, elevated due to reduced hepatic blood flow 753 plasma glucose levels, antipsychotic medication monitoring 40 plasma level monitoring of psychotropic drugs 865–878 amisulpride 869–870 aripiprazole 870 clozapine 870–871, 881–882 first-order pharmacokinetics 865 interpretation of results 867 olanzapine 871–872 quetiapine 872–873 risperidone 873 sampling time 866, 868–869 steady state 865–866, 868–869 target ranges 867–869 plasma levels risperidone long-acting injections 99 variations in 56–57 plasma lipids 169–173 screening and monitoring 170, 171 see also dyslipidaemia plasma protein synthesis reduction, hepatic impairment 753 platelets agents associated with aggregation 967 psychotropic agent effects 967 SSRI effects bleeding 393–394, 404, 409, 432–437 decreasing embolic events/MI risk 433 plecanatide, for constipation treatment 265 PMDD see premenstrual dysphoric disorder PMR see postmortem redistribution PMS see premenstrual syndrome pneumonia, antipsychotic-induced 204–206, 242 polypharmacy, menopausal women 858 polyserositis 246 polysubstance abuse benzodiazepine dependence 541, 542 opioids and cocaine, substitution therapy reducing both 534 polyunsaturated fatty acids (PUFAs) see omega-3 fatty acids PORT see Program of Rehabilitation and Therapy study positive predictive value (PPV) 275 post-injection delirium sedation syndrome (PDSS) 76, 77, 91 post menopause, continuous combined HRT 861 postmortem blood concentrations 879–880 postmortem redistribution (PMR) 879 postpartum depression 719 postpartum haemorrhage, antidepressant use in pregnancy 435–436, 720, 721, 722 postpartum medication, breastfeeding mothers 734–737

postpartum psychosis 715 post-SSRI sexual dysfunction (PSSD) 428–429 post stroke depression 393–396 prophylaxis 393 SSRI risks 393–394 post-traumatic stress disorder (PTSD) benzodiazepine use 446 children and adolescents 595–596 specific drugs used 452 SSRIs/SNRIs 447 postural hypotension see orthostatic hypotension potassium levels, psychotropic agent effects 964 power to treat, under S58 of the Mental Health Act 949–950 PPH see postpartum haemorrhage PPIs see proton pump inhibitors PPV see positive predictive value pramipexole, bipolar depression 321 pregabalin generalised anxiety disorder 447–448 in overdose 917 in pregnancy 724–725 use in opiate misusers 519 use in patients with hepatic impairment 761 pregnancy 713–733 alcohol use 492–493 benzodiazepines 541 depression/antidepressants 719–726 evidence of psychotropic drug effects 713 gynaecological and obstetric haemorrhage risk 435–436 newly diagnosed mental illness 714 planning when taking psychotropic drugs 714 psychiatric illness as risk factor 713 psychosis 715–718 selective serotonin reuptake inhibitors 435–436, 720–721 substance misuse 492–493, 554–559 tricyclic antidepressants 719–720 in women taking psychotropic drugs 714 premature ejaculation, antidepressants as treatment 426, 428 premenstrual dysphoric disorder (PMDD) 474 medical menopause using gonadotrophin- prescribers, duty of, medical conditions and safe driving 924 prescribing checklists, relational aspects 942–943 prescribing drugs outside their licensed indications (off-label) 945–948 legal issues 945–946 recommendations 946–948 preterm delivery risk antidepressants 720 antipsychotics 716, 717 lithium 723 tricyclic antidepressants 720 primavanserin 43, 916 procedural memory, clinicians' unconscious influences 939 prochlorperazine

117, 118 pro-drugs, not recommended in hepatic impairment 754 Product Licences 945 Program of Rehabilitation and Therapy (PORT) study 112 prolactin levels antidepressant effects 420–422 antipsychotic medication monitoring 41 elevation 43, 44 menopausal women 860 psychotropic agent effects 190, 964 prolonged QT interval see QTc prolongation prolonged-release injection, buprenorphine/ Buvidal 509–510 prolonged release preparations, see also extended release preparations; long-acting injectable antipsychotics; modified-release preparations; slow-release oral morphine promazine 43 promethazine acutely disturbed or violent behaviour in schizophrenia 63, 64, 68 breastfeeding 746 not recommended for managing behavioural and psychological symptoms of dementia 674 in pregnancy 726 prophylaxis antidepressants 397–400 after first episode of depression 397 dosing 399 post stroke 393 for recurrent depression 397–398 bipolar disorder 281, 290, 326–330 lithium for depression/mood disorders 281 post stroke depression 393 thiamine for Wernicke's encephalopathy in alcohol dependency 487–488 propranolol, for tardive dyskinesia 137 protein in blood, psychotropic agent effects 964 proteinuria, renal impairment assessment 766 releasing hormone agonists 475 premenstrual syndrome (PMS) 474–475 hormonal treatment 474–475 medical menopause using gonadotrophin-releasing hormone agonists 475 non-hormonal treatment 474 pharmacological management chart 474 prenatal exposure to medications see pregnancy pre-school children, anxiety disorders 586 Index prothrombin time (PT), psychotropic agent effects 967 proton pump inhibitors (PPIs), safety in older patients/dementia 662 prucalopride, for constipation treatment 265 pseudobulbar affect, multiple sclerosis 836 pseudoparkinsonism (drug-induced parkinsonism) 34, 35, 43, 44, 50, 126, 127, 128, 291, 804 PSSD see post-SSRI sexual dysfunction psychiatric adverse effects of non-psychotropic drugs 969–974 antiretroviral therapy 808–809 differential diagnosis 972–973 drugs and effects 969–972 Naranjo scale 972, 973 psychiatric symptoms in the context of other disorders 803–864 psychodynamic interventions adherence 929 depression 336 psychoeducation 932 psychological/psychosocial interventions anorexia nervosa 795 anxiety spectrum disorders 448 behavioural disturbance in people with learning difficulties 825 benzodiazepine withdrawal 466, 468, 541, 542 borderline personality disorder 787 children and adolescents 566, 568, 587, 597 depression 336, 337, 566, 568 improving medication adherence 932, 933–934 learning disabilities 825 schizophrenia 29, 52, 53, 54, 230 see also cognitive behavioural therapy; dialectical behaviour therapy psychosis acute behavioural disturbance 62–73 atrial fibrillation patients 846 cannabis 36 catatonic stupor in 155 children and adolescents 580–581 during pregnancy 715–718 electroconvulsive therapy 108–110 first episode 28–29, 31 duration of treatment 54 negative symptoms 34 NICE guidelines 52–53 treatment algorithm 45 gamma-butyrolactone withdrawal 534, 537 Huntington's disease 832, 833 menopausal women 858–860 methamphetamine use disorder 534–535 multi-episode 29–30 multiple sclerosis 836–837 and nicotine 908–909

996 Index psychosis (cont'd) oestrogen augmentation in menopausal women 860 oestrogen decline reducing antipsychotic activity in menopausal women 858 people living with human immunodeficiency virus 804 postpartum 715, 736 prevention with polyunsaturated fatty acids 111–114 relapse, withdrawal-associated 119 and sexual dysfunction 195–196 'super-sensitivity psychosis' 31 use of benzodiazepines 461 see also schizophrenia and related psychoses psychosocial interventions see psychological/ psychosocial interventions psychostimulants attention deficit hyperactivity disorder in adults 798, 799, 800 depression 388–392 psychotherapies, post-traumatic stress disorder 595 psychotic depression 362–365 acute treatment 362 combination therapies 362, 364 ECT treatment 363 ketamine 363 maintenance treatment 363–364 psychotropic drugs with alcohol 895–899 driving impairment 921–926

interactions with illicit drugs 545, 546–548 in overdose 913–920 plasma level monitoring 865–878 steady state 865–866, 868–869 target ranges 867–869 smokers 892–894 target ranges 867–869 use in renal impairment 769–778, 779 PT see prothrombin time PTSD see post-traumatic stress disorder PUFAs see polyunsaturated fatty acids PUFAs (polyunsaturated fatty acids) see omega-3 fatty acids pure red cell aplasia, psychotropic agent effects 967 PWE see people with epilepsy pyridoxine, for tardive dyskinesia 136 QTc prolongation antipsychotic-related 43, 44, 161–168 cardiovascular risk factors 166 ECG monitoring 165 management 166 metabolic inhibition 165 non-psychotropic association 165 physiological risk factors 164 QT interval 161–162 risk factors 164–165 risk quantification 162–164 switching antipsychotics 207 methadone risk 506 prescribing in atrial fibrillation patients 845 quercetin Alzheimer’s disease management 645 for tardive dyskinesia 137 questionnaires adherence assessment 930, 931 severity of alcohol dependence 480, 482, 485 quetiapine acute kidney injury risk 769 bipolar disorder 302 borderline personality disorder 788 glucose tolerance impairment association 175 in overdose 916 plasma level monitoring 872–873 rapid-cycling bipolar affective disorder 316 risks in pregnancy 717 target range 869 thyroid function tests 41 weight restoration in anorexia nervosa 792 patient factors 940–942 prescribing checklist 942–943 relational aspects of prescribing practice 939–944 relative infant dose (RID), medication in breastfeeding mothers 734 renal adverse effects antiretrovirals 807 lithium 282 renal function, NSAIDs affecting sodium/ lithium reabsorption 285 renal impairment in patients 766–785 anti-dementia drugs 778 antidepressants 772–775 antipsychotics 769–771 anxiolytics and hypnotics 776–777 classification of stages 767 clinical guidance 768 lithium 282 methadone 505 monitoring 768 mood-stabilisers 775–776 other psychotropic drugs 768 recommended psychotropic drugs 779 repetitive transcranial magnetic stimulation (rTMS) for catatonia 155–156 for negative symptoms in schizophrenia 36 for tardive dyskinesia 137 restarting psychotropic medications after a break in treatment 234–235 after neuroleptic malignant syndrome 150 after period of non-compliance 937–938 restlessness (akathisia) 43, 44, 127, 128, 131–134 restraint, exacerbating risks in drug-induced excited states 543 restricted repetitive behaviours and interests (RRBIs), core symptom of autism spectrum disorder 606 reticulocyte count, psychotropic agent effects 967 re-titration, after period of non-adherence to medication regime 937, 938 RID see relative infant dose rilpivirine, psychiatric adverse reactions 809 risk awareness, clinician responsibilities to patients 945 Risperdal Consta 99–101, 103 risperidone 2, 3, 8, 29, 58, 228 bipolar disorder 302, 305–306 clozapine augmentation 221 efficacy 3, 17 equivalent dose 15 glucose tolerance impairment association 175 maximum dose 11 maximum doses 12 in overdose 916 raloxifene 228, 860 see also selective oestrogen receptor modulators rapid-cycling bipolar affective disorder 290, 316–318 rapid tranquilisation (RT) 62, 68–70 children and adolescents 623–625 physical monitoring 69 remedial measures 70 site of administration of intramuscular injections 956–957 Rating of Medication Influences (ROMI) scale 931 RBP-7000 (Perseris) 101–102 readiness to change, influencing adherence 940 recommendations to patients, adherence 927 rectal administration, antipsychotics 116, 118 recurrent depression, prophylaxis 397–398 red blood count/red cell distribution width, psychotropic agent effects 967 reduced hepatic blood flow, consequences of hepatic impairment 753 reduced metabolism of drugs changes with old age 628 hepatic impairment 753 refractory schizophrenia see treatment-resistant schizophrenia refusal of treatment, older people’s mental health and capacity 629, 694–699 relational aspects of adherence clinician factors 939

pharmacokinetics 81 plasma level monitoring 873 possible teratogen 716 relative adverse effects 43 target range 869 use in children and adolescents with autism spectrum disorder 609, 610

weight restoration in anorexia nervosa 792 risperidone intramuscular injection (Rykindo) 100, 103 risperidone ISM (in situ microparticles) 81, 100, 101, 103, 873, 956 risperidone long-acting injections (RLAs) 12, 15, 81, 99–105, 103 approximate dose equivalence 94 bipolar disorder 305–306 blood levels following discontinuation 99 doses and frequencies 78 equivalent doses 103 intramuscular injections 99–101 plasma concentrations timescale 99 Rykindo 100, 103 subcutaneous injections 101–102 switching from 100 RISQ-PATH study 163 Risvan see risperidone ISM rivastigmine, Alzheimer's disease 630–636, 639, 642 RLAs see risperidone long-acting injections road traffic accidents (RTAs), psychotropic drugs and driving impairment 922 ROMI see Rating of Medication Influences scale routine monitoring, mitigating serious consequences of non-adherence 928 Roux-en-Y gastric bypass (RYGB) 849 RRBI see restricted repetitive behaviours and interests RT see rapid tranquilisation RTAs see road traffic accidents rTMS see repetitive transcranial magnetic stimulation RYGB see Roux-en-Y gastric bypass Rykindo see risperidone intramuscular injection antipsychotic response 55–61 atrial fibrillation patients 846 caffeine effects 904 cardiometabolic risk factors 169 catatonia 155 comorbid alcohol use disorder 495–496 diabetes association 174 electroconvulsive therapy 108–109 first episode 28–29, 31 duration of treatment 54 negative symptoms 34 treatment algorithm 45 maintenance treatment 29, 53 multi-episode 29–30 negative symptoms 34–39 NICE guidelines 2, 53–54 and nicotine 908–909 people with 22q11.2 deletion syndrome 822 people living with human immunodeficiency virus 804 poorly responsive to standard antipsychotic treatment 57–59 prescribing practice for 17 QTc prolongation 161 relapse 28, 29, 30, 31 withdrawal-associated 120 relapse/acute exacerbation, treatment algorithms 46–47 suicide risk 29 'super-sensitivity psychosis' 31 treatment adherence 30, 928–929, 933–934 algorithms 45–48 NICE guidelines 2, 52–54 polyunsaturated fatty acids 111–114 for poorly responsive schizophrenia 57–59 treatment-resistant 18, 53–54, 108–109, 214–233 see also antipsychotics second-generation antidepressants anorexia nervosa 794 see also bupropion; monoamine oxidase inhibitors; tricyclic antidepressants second-generation antipsychotics (SGAs) 49, 50 adverse effects 3–4 bipolar disorder 300–302 borderline personality disorder 788 children and adolescents 568, 573, 580, 590, 608, 615, 623 classification 2 diabetes, antipsychotic-related 174–176 equivalent doses 14, 15 long-acting injectable antipsychotics 4, 75 maximum doses 11, 12 minimum effective doses 8 neuroleptic malignant syndrome association 151 'off-label' prescribing 947 SADQ see Severity of Alcohol Dependence Questionnaire safer prescribing, older people/ dementia 654–666 saffron see *Crocus sativus* St John's wort (SJW) (*Hypericum perforatum*), treating depression 440–443 SAWS see Short Alcohol Withdrawal Scale schizoaffective disorder, atrial fibrillation patients 846 schizophrenia and related psychoses 1–277 acute behavioural disturbance 62–73 adherence to treatment 30 Index optimal dosage 55 people with learning difficulties 826 people living with human immunodeficiency virus 804 in pregnancy 716–717 relative efficacy 3 site of administration of intramuscular injections 955–956 treatment algorithm 46 treatment of negative symptoms 35 Second Opinion Appointed Doctor (SOAD), the Mental Health Act 950–951, 953 sedation 43, 44 alcohol effects 897 management 242 medication-induced 923 over-sedation 64 switching antipsychotics 207 sedatives antihistamines not recommended for behavioural and psychological symptoms of dementia 674 'high-dose sedation' 64 in pregnancy 726–727 respiratory depression role in death from opioid agonists overdose 545 use in patients with hepatic impairment 754, 760, 761 see also benzodiazepines; promethazine seizures antiretrovirals 808 drug risks for people with 22q11.2 deletion syndrome 820, 821–822 management 242, 882 psychotropic drug risks in people with epilepsy 814–817 severe alcohol withdrawal 480, 481 selective oestrogen receptor modulators (SERMs) psychosis treatment adjunct for menopausal women 860 see also raloxifene selective serotonin reuptake inhibitors (SSRIs)

adverse effects relative to other antidepressants 338 anxiety spectrum disorders 446–447
arrhythmia risk 411 atrial fibrillation patients 845, 846 bipolar depression 322 bleeding risks 432–
439 gastrointestinal 433–434 gynaecological and obstetric haemorrhage 435–436
intracranial/intracerebral haemorrhage 434–435 mechanisms 432 post stroke depression 393–394
risk factors 432–433 surgical and postoperative 436–437

998 Index selective serotonin reuptake inhibitors (SSRIs) (cont'd) body dysmorphic disorder 447
with caffeine 903 cardiac effects 406–408, 409, 411–412 co-prescribed with low-dose aspirin/
NSAIDs, GI bleeding risk 433, 434 co-prescribed with warfarin, non-GI bleeding risk 433, 434 driving
impairment 922 gastric acid secretion effects 432 gastrointestinal effects 432, 433–434
generalised anxiety disorder 446 hyperprolactinaemia induction 420 hyponatraemia induction 416,
417, 418 increased free plasma levels in hepatic impairment 753–754 increased risk of bleeding in
hepatic impairment 753 interactions with anticoagulants 846 lithium interactions 286 obsessive
compulsive disorder 447 in overdose 914 panic disorder 446–447 people with learning difficulties
826 people living with human immunodeficiency virus 805, 806 pharmacodynamic drug
interactions 404 pharmacokinetic drug interactions 401 platelet effects 393–394, 404, 409,
432, 433 bleeding 432–439 decreasing embolic events/MI risk 433 post stroke depression 393–394
post-traumatic stress disorder 447 in pregnancy 720–721 premenstrual syndrome treatment 474
sexual dysfunction 199, 427, 428–429 social phobia 447 type II diabetes improvement 423 use in
children and adolescents 566–567, 583–584, 585, 588 withdrawal symptoms 373 semaglutide, for
antipsychotic-induced weight gain 146 SERMs see selective oestrogen receptor modulators
serotonergic antidepressants, treatment of sexual dysfunction 426, 428 serotonin-noradrenaline
reuptake inhibitors (SNRIs) anxiety spectrum disorders 446–447 hyperprolactinaemia induction 420
hyponatraemia induction 416, 417 pharmacokinetic drug interactions 401, 404 in pregnancy 720
use in children and adolescents 583, 584, 585, 592, 598 serotonin reuptake inhibition see selective
serotonin reuptake inhibitors serotonin syndrome renal impairment 769 switching antidepressants
367 sertindole 11, 15, 43, 228 sertraline bulimia nervosa/binge eating disorder 794 'off-label'
prescribing 947 in pregnancy 720 use in patients with hepatic impairment 761 severe alcohol
dependence 480, 486 severe alcohol withdrawal 481, 484 Severity of Alcohol Dependence
Questionnaire (SADQ) 480, 482, 485 sexual behaviour (inappropriate) in older people 680–687
sexual drive reduction by hormone implants 682 sexual dysfunction antidepressants 426–431
effects of antipsychotics 195–203, 196–197, 207 effects of psychosis 195–196 management of
antidepressant effects 428–429 selective serotonin reuptake inhibitors 199, 427, 428–429
treatment 198, 199 SGAs see second-generation antipsychotics Short Alcohol Withdrawal Scale
(SAWS) 482, 484, 485, 486 SIADH see syndrome of inappropriate antidiuretic hormone sialorrhoea
see hypersalivation site of administration of intramuscular injections 954–958 SJW see St John's
wort skin diseases, and antipsychotics 246 sleep disturbance children and adolescents autism
spectrum disorder 609–610 use of melatonin 575, 609–610, 620–622 managing behavioural and
psychological symptoms of dementia 674 see also insomnia slow-release oral morphine (SROM)
514 smokers/non-smokers, clozapine dosing regimens 216–218 smoking with caffeine 903
cessation 523–531, 909 pregnant women with mental illness 714 and psychotropic drugs 892–894
see also nicotine SNRIs see serotonin-noradrenaline reuptake inhibitors SOAD see Second Opinion
Appointed Doctor social and communication impairment, core symptom of autism spectrum
disorder in children and adolescents 606 social phobia (social anxiety disorder) 447, 454–455
sodium levels lithium toxicity 283, 284–286 psychotropic agent effects 964 sodium oxybate, for
tardive dyskinesia 137 sodium valproate clozapine augmentation 221 'off-label' prescribing 947

solriamfetol in overdose 917 use in patients with hepatic impairment 761 use in renal impairment 778 Souvenaid (dietary supplement), Alzheimer's disease management 644 special educational needs see learning difficulties SROM see slow-release oral morphine SSRIs see selective serotonin reuptake inhibitors statins no evidence for benefit in vascular dementia 647 preventing cardiovascular events 170, 171 safety/use in older patients 661 vascular dementia 647 stimulants attention deficit hyperactivity disorder in adults 798, 799, 800 breastfeeding mothers 747 definition 532 depression 388–392 use in patients with hepatic impairment 760 see also psychostimulants stimulant use disorder (SUD) 532–536 amfetamines/ methamphetamine 533–534 cocaine 533 depression/anhedonia from abstinence 535 polysubstance abuse, opioids plus cocaine 534 psychotic symptoms 534–535 stopping medication abrupt cessation by non-compliant patients 928 antidepressants 339, 378 antipsychotics 119–125 benzodiazepines 466 lithium 331–334 long-acting antipsychotics reducing impacts of non-adherence 932–933 see also withdrawal

sulpiride 8, 11, 14, 43 clozapine augmentation 221 clozapine-induced hypersalivation treatment 260 typical or atypical classification 2 use in patients with hepatic impairment 754, 756, 761 see also amisulpride suppositories, antipsychotics 116, 118 surgical and postoperative bleeding, SSRI risks 436–437 surgical procedures, bariatric surgery 849–856 suvorexant managing sleep disturbance in dementia 674 in overdose 917 use in patients with hepatic impairment 761 switching between drugs antidepressants 366–372 general guidelines 366–377 swapping and stopping guide 368–370 timing 345–346 within and between drug classes 345 symptom-triggered regimen, benzodiazepines for alcohol withdrawal management 485 syndrome of inappropriate antidiuretic hormone (SIADH) 186, 188 synthetic cannabinoids 543 stroke antipsychotic risks 212–213, 669 dyslipidaemia 171 post stroke depression 393–396 stupor see catatonia stuttering, and antipsychotics 246 sublingual administration antipsychotics 115, 117 buprenorphine 503, 507–508 Suboxone (buprenorphine with naloxone) 513 substance misuse and dependence alcohol 479–497 benzodiazepine misuse 540–542 concurrent alcohol and other substance use disorders 493–494 drugs of misuse summary 549–553 dual diagnosis with mental illness 477 illicit drug interactions with prescribed psychotropic drugs 545–548 mixed substance use 532 mutual aid and peer support for stimulant abstinence 532 nicotine dependence 523–531 opioid dependence 498–522 people living with human immunodeficiency virus 806 personality disorders 477 pregnancy 554–559 stimulant use disorder 532–536 SUD see stimulant use disorder sudden cardiac death, antidepressants 411, 412 suicidality antidepressant cessation 339 antidepressant use in adolescents and young adults 339 antidepressant use balance 339 body dysmorphic disorder in children and adolescents 587, 588 cognitive behavioural therapy decreasing effects of fluoxetine 566 depression in children and adolescents 570–571 environmental lithium effects 279 fluoxetine use in children and adolescents 566, 570–571, 588, 610 Huntington's disease 832, 833 lithium reducing risk in bipolar and unipolar depression 281, 284 non-adherence impacts 928 obsessive compulsive disorder in children and adolescents 587, 588 overdose of psychotropics 913 peri-natal risks from psychotropic medication withdrawal 713 psychotic depression 362 PTSD in children and adolescents 595 schizophrenia 29 SSRI use in children and adolescents 566, 570–571, 584, 588, 610 valproate risk 291 tachycardia, clozapine effects 184, 234, 242, 253, 255 tapering antidepressants 366, 376, 378–382 benzodiazepines 466–469 drug formulation problems 382 z-drugs/gabapentinoids 469 tardive dyskinesia (TD) 3, 29, 50, 120, 127, 128 switching antipsychotics 208 treatment 135–140 tDCS see transcranial direct current stimulation temazepam concentration in normal dosing and UK legal limit 923 use in patients with hepatic impairment 761 use in patients with renal impairment 777 teratogenic potential antidepressants 721, 722 carbamazepine 297,

714, 723-724 first generation antipsychotics 715-716 mood stabilisers (eg valproate) 714, 723-724 second generation antipsychotics 716-717 valproate 292 Index test doses, long-acting injectable antipsychotics 75 testosterone in blood, psychotropic agent effects 964 tetrabenazine Huntington's chorea 831 tardive dyskinesia 136 theophylline, safety in older patients/ dementia 659 therapeutic threshold 867 thiamine deficiency (Wernicke's encephalopathy), alcohol dependency 487-488 thiamine (vitamin B1) injections, alcohol withdrawal adjunctive treatment 484-485 thiazide diuretics, lithium interaction 285 thrombocytopenia 246, 291, 745, 820 thromboembolism 211-213, 246, 253, 860 thyroid adverse effects, lithium 282 thyroid function tests, antipsychotic medication monitoring 41 thyroid-stimulating hormone, psychotropic agent effects 964 thyroxine in blood, psychotropic agent effects 964 tics and Tourette's syndrome children and adolescents 614-619 adrenergic α_2 agonists 615 antipsychotics 615-616 comorbid conditions 614 education and behavioural treatments 614 pharmacological treatments 614-615 recommended treatments 617 TMS see transcranial magnetic stimulation tobacco see nicotine; smoking tolerance, dependence syndrome 477-478 topical vaginal oestrogen 862 topiramate 35, 228 for antipsychotic-induced weight gain 146 borderline personality disorder 789 clozapine augmentation 221 teratogenic risk 714, 724 torsades de pointes, methadone risk 506 Tourette's syndrome (TS) children and adolescents 614-619 see also tics training of practitioners, compliance therapy and adherence 933-934 tranquilisation see rapid tranquilisation transaminases, drug induced increase in hepatic impairment 754 transcranial direct current stimulation (tDCS) 36, 156 transcranial magnetic stimulation (TMS) stimulant use disorder 533 see also repetitive transcranial magnetic stimulation

1000 Index transdermal patches antipsychotics 116 equivalent doses 15 maximum doses 12 nicotine 494, 524, 616 trazodone Alzheimer's disease management 645 driving impairment 922 increased free plasma levels in hepatic impairment 753-754 in overdose 915 in pregnancy 721 smokers 893 TRBD see treatment-resistant bipolar disorder TRD see treatment resistant depression treatment framework, clinicians using knowledge of their normal practices to avoid psychological factors influencing decision-making 939 treatment preferences of patients, affecting outcomes 941-942 treatment-resistant bipolar disorder (TRBD), clozapine 301-302 treatment resistant depression (TRD) 348-356 addition of extra drugs 348-349, 351 commonly used treatments 348-350 ketamine 351, 357-361 less commonly used treatments 351-352 potential therapies 353-356 treatment-resistant schizophrenia (TRS) 18 and clozapine 214-233 alternatives to clozapine 226-233 dosing regime 214-218 intramuscular clozapine 219 treatment optimisation 220-225 NICE guidelines 53-54 tremor see pseudoparkinsonism tricyclic antidepressants (TCAs) adverse effects relative to other antidepressants 338 with alcohol 899 arrhythmogenic activity 411 driving impairment 922 hyperprolactinaemia 420, 420 increased free plasma levels in hepatic impairment 753-754 not recommended for managing behavioural and psychological symptoms of dementia 673 in overdose 915 people living with human immunodeficiency virus 805 pharmacodynamic drug interactions 404 pharmacokinetic drug interactions 402 in pregnancy 719--720 psychotic depression 362 smokers 893 target range 869 trifluoperazine 8, 11, 14, 44 triglycerides in blood, psychotropic agent effects 965 triiodothyronine in blood, psychotropic agent effects 965 TRS see treatment-resistant schizophrenia TS see Tourette's syndrome TV-46000 see Uzedy typical/atypical antipsychotic classification 1-2 tyramine-containing foods, monoamine oxidase inhibitor interactions 338-339 adverse effects 526 clinical effectiveness 525 nicotine addiction 524-526 preparations and doses 526, 529 vascular dementia (VaD) 647 velocardiocardial syndrome (22q11.2 deletion syndrome) 820-823 venlafaxine in overdose 915 possible teratogen 721 venous thromboembolism (VTE) antipsychotic risks 211-213 clozapine adverse effects 253

oestrogen augmentation risk in menopausal women 860 risk of pathological blood clotting 212
Vienna High Risk (VHR) study 111 viloxazine, attention deficit hyperactivity disorder in adults 799,
801 violent behaviour see acutely disturbed/ violent behaviour vitamin B1 (thiamine), alcohol
withdrawal adjunctive treatment 484–485 vitamin B6 akathisia adjunctive treatment 131
hyperprolactinaemia 191 vitamin D3 intake, hyperprolactinaemia 191 vitamin D supplementation
anorexia nervosa 793 fatigue in multiple sclerosis 837 vitamin E for tardive dyskinesia 136 vitamin
K, prophylactic if caprbamazepine given in pregnancy 724, 726 vitamin K-dependent clotting factor
synthesis reduction, hepatic impairment 753 vitamin and mineral supplements, anorexia nervosa
793 vitamin replacement, alcohol withdrawal adjunctive treatment 484–485 vitamin supplements
Alzheimer’s disease management 643 hyperprolactinaemia 191, 192 VMAT2 inhibitors,
Huntington’s chorea 831 vortioxetine in overdose 915 use in patients with hepatic impairment 761
VTE see venous thromboembolism UGIB see upper gastro-intestinal bleeding UGT see uridine
diphosphate glucuronosyltransferase unintentional non-adherence 932 upper gastro-intestinal
bleeding (UGIB), antidepressants 433 urate (uric acid) in blood, psychotropic agent effects 965
urea in blood, psychotropic agent effects 40, 965 urgent treatment, S62 of the Mental Health Act
952, 953 uridine diphosphate glucuronosyltransferase (UGT) 883 urinary incontinence,
anticholinergic drugs 658 urine testing for illicit drugs, in psychiatric care settings 549 Uzedy (TV--
46000) risperidone injections 12, 15, 81, 101–102, 103 VaD see vascular dementia vaginal bleeding
abnormalities, SSRI risks 435 valbenazine for tardive dyskinesia 136 use in patients with hepatic
impairment 761 use in renal impairment 778 valproate 229, 883 adverse effects 291 bipolar
disorder 289–294, 310, 311 borderline personality disorder 789 discontinuation 291, 292 drug
interactions 292 formulations 289, 292 indications 289–290, 292 mechanism of action 289 not
recommended for dementia patients 673 in overdose 916 pharmacokinetics 290 plasma levels 290
prescribing 292 pre-treatment tests and monitoring 291, 292 restricted use 311 target range 869
teratogenic risk 292, 714, 723–726 use in pregnancy 714, 723–726 vaping see nicotine vaping
devices varenicline warfarin atrial fibrillation patients 845, 846 co-prescribed with SSRIs, non-GI
bleeding risk 433, 434 water intoxication 186 WCC see white cell count weight changes after
bariatric surgery 854 antipsychotic medication monitoring 40

weight gain 43, 44, 141–149 after bariatric surgery 854 dose-response 142 drugs to aid weight
restoration in anorexia nervosa 792 management 242 risk/extent of 141–142 switching
antipsychotics 208 time course 142 treatment 144–149 Wernicke-Korsakoff syndrome 485
Wernicke’s encephalopathy (thiamine deficiency), alcohol dependence 487–488 white cell count
(WCC) 267, 268, 269, 271 withdrawal antipsychotics 119–120, 123 benzodiazepines 464–465,
540–542 buprenorphine 501, 516–517 caffeine 902 gabapentinoids 464, 469 gamma--
hydroxybutyrate or gamma- butyrolactone 534, 537–539 lithium and other mood stabilisers,
bipolar disorder 331 methadone 516 non-adherence impacts 937 role of hyperbolic tapering 379 z--
drugs 464, 469 see also alcohol withdrawal; antidepressant withdrawal; opioid withdrawal women
of child-bearing potential avoid contra-indicated drugs even if not planning pregnancy 714 see also
teratogenic potential xanomeline 8, 12, 15, 44 xanomeline-trospium (KarXT), Alzheimer’s disease
management 645 Index ZA see zuclopenthixol acetate z-drugs (zolpidem/zopiclone/zaleplon)
breastfeeding 746 dependence and withdrawal 464, 469 insomnia in dementia patients 674 in
overdose 917 in pregnancy 727 for tardive dyskinesia 137 use in patients with hepatic impairment
761 ziprasidone 8, 12, 15, 17, 44, 229 clozapine augmentation 221 in overdose 916 zonisamide, for
antipsychotic-induced weight gain 146 zotepine 229 zuclopenthixol 11, 14, 44, 893 zuclopenthixol
acetate (ZA) 66–67 zuclopenthixol decanoate 12, 14, 81